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Abstract 
The ultimate aim of periodontal treatment is to regenerate the tissue lost during 
the disease process, thereby restoring the aesthetics and function of the 
periodontium. Guided tissue regeneration (GTR) is one technique that is used 
clinically to promote tissue regeneration.  The technique employs a membrane to 
create space in the appropriate surgical site to produce periodontal regeneration.  
However there may be considerable potential to improve the outcomes of this 
technique by development of novel membrane materials.  
The aim of the studies described in this thesis was to investigate the potential of 
polylactic acid-calcium phosphate (PLA-Ca P) composite materials to be developed 
into a GTR membrane with increased potential for producing periodontal 
regeneration.  Ca P materials included nano-hydroxyapatite (n-HA) and ß tri-
calcium phosphate (ß-TCP).  PLA-Ca P composite films were produced by the 
solvent casting method. The Ca P powders and the PLA-Ca P composite films were 
characterized.  The degradation of PLA-Ca P composites was analysed in phosphate 
buffer saline (PBS).  The bioactive potential of the composite films was determined 
in simulated body fluid (SBF).  The growth and differentiation of PDL cells and 
osteoblasts were assessed on PLA-nHA composite films and the ability of these films 
to carry platelet derived growth factor (PDGF) and its effect on osteoblast growth 
was investigated.  Further, fibre reinforced PLA-HA composite membranes were 
fabricated and their mechanical strength and kinetics of protein interactions were 
investigated. Finally mandibular alveolar bone profiles were analyzed to define the 
possible shapes required for manufacture of GTR membranes.  
Results showed that Ca P decreased the degradation and increased the bioactivity 
of the PLA-Ca P composite films.  The cell proliferation on composite films 
containing 10 wt % nHA was high when compared to PLA films. However, cell 
proliferation decreased with increase in nHA concentration. The highest alkaline 
phosphate activity (ALP) was shown by cells on composite films containing 70 wt % 
nHA. The PDGF added to the PLA-nHA composite films retained its activity and 
increased the proliferation of osteoblasts. The flexural strength was high for the 
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fibre reinforced PLA-HA composite membranes, containing maximum number of PLA 
fibres laid at 0°. The fibre reinforced membranes containing HA showed gradual 
and sustained protein release compared to fibre reinforced membranes without HA. 
The analysis of alveolar bone profiles of different patients showed marked 
similarities between each other, suggesting that only a few membrane shapes may 
be required to fit most patients in clinical use.     
These studies demonstrate the potential of fibre reinforced PLA-HA composite 
material to be used for the production of preshaped GTR membranes with 
favourable properties to increase periodontal regeneration. 
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 Glossary 
Osteoinduction: “This term means that primitive, undifferentiated and pluripotent 
cells are somehow stimulated to develop into the bone-forming cell lineage” 
[Albrektsson and Johansson, 2001]. 
 
Osteoconduction: “This term means that bone grows on a surface. An 
osteoconductive surface is one that permits bone growth on its surface” 
[Albrektsson and Johansson, 2001]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 1: LITERATURE REVIEW 
  
1.1 INTRODUCTION 
Periodontal diseases are common and in their advanced stages can lead to 
severe periodontal tissue loss, ultimately resulting in tooth loss. Different modes 
of treatments ranging from scaling the teeth to the use of advanced techniques 
such as bone grafts and guided tissue regeneration (GTR) have been employed 
for treatment of periodontal diseases depending on the severity of disease and 
amount of tissue loss. In the last two decades GTR has evolved as an effective 
mode of treatment for regeneration of periodontal tissues lost during the disease 
process. GTR has helped to overcome the limitations and disadvantages 
associated with other regeneration techniques. However there is still a need for 
research to optimise and improve the results possible with the use of GTR. GTR 
works on the principle of blocking the invasion of competing non-osteogenic soft 
tissue cells into the wound defect area by placement of a membrane over the 
bone defect. The membrane maintains a space between the defect and soft 
tissue and allows periodontal ligament and bone cells to repopulate the space.  
Both resorbable and nonresorbable membranes have been used for GTR 
procedures, however the membranes used have limitations and the results with 
these membranes have been modest. Thus there is a need to develop a 
membrane with better mechanical properties with the ability to deliver growth 
factors and to facilitate tissue regeneration.  
This study aims towards making a composite membrane for GTR procedures, 
with better mechanical and physical properties, and with the ability to release 
bioactive proteins at the defect site to facilitate and accelerate the 
regeneration process. 
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1.2 PERIODONTIUM  
The periodontium consists of tissues that surround and anchor the tooth in the 
alveolar processes of maxilla and mandible. The periodontium includes: (a) 
Gingiva, (b) Periodontal ligament, (c) Cementum and (d) Alveolar bone (Figure 
1.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic presentation of periodontium [adapted from Suchanek et al., 2002]. 
 
The characteristics of a healthy periodontium are shown in Figure 1.2.The 
functions of the periodontium include: 
 a) To provide a tissue seal at the cervical portion of the tooth.  
 b) To provide support to the teeth during mastication 
 c) To hold the tooth in the socket 
 d) To protect the dentine 
Chapter 1 
 26 
  e) Mechanoresponsive regulation of mastication  
 
Figure 1.2 Schematic drawing of a healthy periodontium [from Rose, 2004]. 
 
1.2.1 Gingiva    
Gingival tissue covers the alveolar processes of the jaws and cervical portions of 
the teeth and provides a seal around the cervical portions of the teeth. It is 
composed of an outer layer of epithelium and an inner core of connective tissue 
called the lamina propria. The healthy gingiva is pale pink, however, the colour 
may vary depending on epithelial thickness, keratinisation, vascularity and 
pigmentation. The gingiva consists of free and attached gingiva (Figure 1.3). 
The free gingiva is also called the marginal or unattached gingiva. It surrounds 
the tooth at the region of the cemento-enamel junction (CEJ). It consists of the 
gingival tissue from the gingival margin to the free gingival groove. The space 
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Free gingiva 
 
Attached gingiva 
between the free gingiva and tooth surface is called the gingival sulcus. It meets 
the tooth in a thin rounded margin called the gingival margin.   
The attached gingiva is located between the free gingiva and the alveolar 
mucosa and is tightly attached to the cementum of the cervical third of the 
tooth and to the periosteum of the alveolar bone. Healthy attached gingiva is 
pink and has stippling which is caused by the presence of connective fibres that 
attach the gingival tissue to the cementum and the bone. Attached gingiva 
provides support to the gingival tissue during mastication, talking and tooth 
brushing [Rose, 2004].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic presentation of free and attached gingiva [dapted from Eley and 
Manson, 2004]  
 
The epithelium of gingiva, which is a keratinized stratified squamous epithelium, 
is divided into four cell layers depending on the degree of keratin-producing cell 
differentiation. These layers are the basal cell layer, prickle cell layer, granular 
cell layer and keratinized cell layer. Keratin producing cells comprise 90% of the 
total cell population of the oral epithelium; other cells present in the oral 
epithelium are melanocytes, Langerhan’s cells, Merkel’s cells and inflammatory 
cells.      
The connective tissue of gingiva consists of collagen fibres (60%), vessels and 
nerves (35%), fibroblasts and other cells (5%).  The collagen fibres of gingival 
connective tissue are produced by fibroblasts, which are the main cells of 
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connective tissue and comprise 65% of total cell population. Other cells present 
are mast cells, macrophages and inflammatory cells. The cells, nerves and 
vessels are embedded in a matrix which is mainly produced by fibroblasts [Nanci 
and Ten Cate, 2003].  
1.2.2 Periodontal Ligament 
The periodontal ligament (PDL) is a soft connective tissue which is highly 
vascular and cellular. It covers the tooth root and attaches it to the bone of the 
tooth socket. The periodontal ligament is composed of fibre bundles which are 
attached to the cementum on one side and to the alveolar bone of the tooth 
socket on the other side. The length of periodontal ligament fibres is in the 
range of 0.2 - 0.4mm depending on their position around the tooth root.  
PDL contains osteoblasts, osteoclasts, cementoblasts, fibroblasts and 
undifferentiated mesenchymal cells. Undifferentiated mesenchymal cells 
present in the PDL can differentiate into osteoblasts, cementoblasts and 
fibroblasts when a suitable trigger is applied. PDL cells can play an important 
role during alveolar bone regeneration and during normal alveolar bone 
formation [Hosoya et al., 2008; Zhou et al., 2008]. Studies have shown that 
regeneration of periodontal tissue can be achieved when epithelial and gingival 
connective tissue cells are blocked and cells from periodontal ligament are 
allowed to repopulate the healing area [Gottlow et al., 1984]. Progenitor PDL 
cells differentiate into cementoblasts on direct contact with root dentin 
[Hasegawa et al., 2005]. It is still not clear whether a single progenitor cell gives 
rise to daughter cells which then differentiate into different cell types, or 
whether separate progenitor cells are present for each cell type [Nanci and Ten 
Cate, 2003].  
The fibres of periodontal ligament are divided into five groups depending on 
their location (Figure 1.4): 
Alveolar crest:  Extend from the cervical cementum to the alveolar crest. They 
resist lateral forces and retain the tooth in the alveolus.  
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Horizontal: Present just below the alveolar crest fibres and their orientation is 
perpendicular to the long axis of the tooth. 
Oblique: Extend from the cementum and run diagonally towards the crown of 
the tooth inserting in the alveolus. These fibres provide resistance against 
axially directed forces. 
Interradicular:  Present between the roots of multi rooted teeth, they prevent 
tipping and extrusion of the teeth. 
Apical:  Present at the apex of the root. They prevent the extrusion of teeth 
and provide protection to the blood vessels and nerve supply of teeth.  
 
 
 
 
 
 
 
Figure 1.4: Schematic presentation of PDL fibres [adapted from Nanci and Ten Cate, 2003] 
 
The PDL has the following functions: 
Supportive function: PDL attaches and maintains the teeth in the alveolar 
sockets. PDL allows the transfer of forces generated during mastication and 
tooth contact to be transferred to and absorbed by the alveolar bone.  
Nutritive function: It provides nutrition to the bone and the cementum. 
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Sensory function: Sensory feelings such as pain and pressure are provided to the 
tooth by the PDL. 
Formative function: It builds up and maintains cementum and alveolar bone of 
the tooth socket.  
Resorptive function: In response to the pressure the PDL can remodel the 
alveolar bone, as occur during orthodontic procedures.  
1.2.3 Alveolar Bone 
Alveolar bone surrounds and supports the tooth root. The development of 
alveolar bone is dependent on the presence of teeth. Alveolar bone resorbs after 
the extraction of teeth and does not develop if teeth do not erupt. Alveolar 
bone constantly undergoes remodelling depending on its functional stimuli. The 
outer surfaces of alveolar processes consist of compact bone which overlies a 
trabecular bone structure. There are numerous small canals in the alveolar walls 
through which vessels and nerves enter the periodontal ligament space. The 
layer of the bone into which the fibres are inserted is sometimes referred to as 
“bundle bone” and it has many features similar to root cementum in respect of 
function and structure. The compact bone on the superficial/outer aspects of 
the alveolar processes varies in thickness. In the maxilla, the buccal cortical 
bone in the incisor, canine and premolar regions is thin, but thicker at the 
buccal and palatal aspect of the molars. In the mandible the cortical bone is 
thinner on the buccal aspect of the incisors and premolar, whereas in the molar 
region it is thinner on the lingual aspect than on the buccal aspect. Alveolar 
bone like other bones consists of bone matrix and bone cells [Rose, 2004].  
1.2.3.1 Bone Matrix 
Bone matrix consists of organic collagen fibres, ground substance and inorganic 
bone minerals (Table 1.1). Toughness and stiffness of bone is provided by its 
mineral content whereas collagen provides bone with tensile strength and 
flexibility [Murugan and Ramakrishna, 2005]. The organic matter consists of type 
I collagen and amorphous ground substance containing proteoglycans, 
glycoproteins, glycosaminoglycans, lipids and peptides [Triffitt and Owen, 1973]. 
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The organic matter of bone is produced by osteogenic cells which are then 
surrounded by this organic matter. 90% of the organic matrix is collagenous and 
these collagen fibres in association with hydroxyapatite gives bone its stiffness 
and strength. Noncollagenous protein and ground substance act as a cementing 
agent for collagen fibres and crystals. They also play a role in mineralisation of 
the bone.     
The inorganic matter makes up 50% of the dry weight of bone matrix and mainly 
consists of calcium and phosphorus in addition to bicarbonate, citrate, 
magnesium, potassium and sodium ions [Damien and Parsons, 1991]. Calcium and 
phosphorus form substituted hydroxyapatite crystals having the composition Ca10 
(PO4)6(OH) 2 with the substances also including CO3, Si and Fl. 
Table 1.1: Composition of bone matrix [adapted from  Murugan and Ramakrishna, 2005] 
Inorganic components Organic components 
                                                Wt% 
Hydroxyapatite                           60 
Carbonate                                   4 
Citrate                                        0.9 
Sodium                                        0.7 
Magnesium                                  0.5 
Others: Cl-, F-, K+, Sr2+, Pb2+, Zn2+, 
Cu2+, Fe2+ 
                                                   Wt% 
Collagen               20 
Water                9 
Non-collagenous proteins               3 
                                                          
 
Others: Polysaccharides, lipids, 
cytokines                                       
 
1.2.3.2 Bone Cells 
The three main cells of bone are osteoblasts, osteocytes and osteoclasts. These 
cells are responsible for the production, maintenance and resorption of bone 
respectively. In addition to these cells, bone also contains mesenchymal stem 
cells which are present in the bone marrow and which act as a cell reservoir 
[Weiss, 1988]. These stem cells can differentiate into different cell types which 
include osteoblasts, chondrocytes, myocytes and adipocytes (Figure 1.5) [Aubin, 
1998; Spagnoli et al., 2009].  
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Figure 1.5: Schematic presentation of bone mesenchymal stem cells differentiation into 
different cells types showing the three major cell lines they can form [adapted from Aubin, 
1998]. 
 
Osteoblasts:  Osteoblasts are the bone producing cells which are derived from 
multipotent mesenchymal stem cells, and are present at the surface of the bone 
tissue. They synthesize and secrete the organic component of bone matrix 
including type I collagen, proteoglycans and glycoproteins between the cell and 
the mineralized matrix [Gorski, 1998]. During active production of bone matrix 
osteoblasts have cuboidal or columnar shape (Figure 1.6) and have high alkaline 
phosphatase activity, however as their activity declines they become flattened 
[Barrere et al., 2006]. Active osteoblasts produce a new layers of uncalcified 
matrix (osteoid), calcium salts are subsequently deposited into this newly 
formed matrix thus completing the process of bone apposition. When entrapped 
in newly formed matrix osteoblasts become osteocytes. As matrix is formed 
around the cell and cytoplasmic process, lacunae and canaliculi appear 
[Junqueira and Carneiro, 2005].   
Chapter 1 
 33 
 
 
 
 
Figure 1.6: Bone forming osteoblasts depositing new bone [adapted from Junqueira and 
Carneiro, 2005]. 
 
Osteoblasts also play a part in the calcification of the bone by regulating the 
flow of calcium and phosphate through bone. It is believed that in bone 
remodelling the growth factors released during the bone matrix resorption by 
osteoclasts causes the preosteoblast cells to differentiate into osteoblasts 
[Martin, 2009]. Plasma membranes of active osteoblasts contain high amounts of 
alkaline phosphatase which is a marker for the osteoinductive nature of the cell. 
Alkaline phosphatase from osteoblasts tends to cause cleavage of organically 
bound phosphatase which in turn contributes to the initiation and growth of 
mineral crystal of bone. Osteoblasts also produce certain cytokines and growth 
factors in addition to matrix protein. These growth factors, which include bone 
morphogenic proteins-2 (BMP-2) and 7 (BMP-7), insulin-like growth factors (IGF), 
fibroblast growth factors (FGF) and platelet derived growth factors (PDGF) 
increase the process of bone formation and repair. Parathyroid hormone (PTH), 
which is the most important hormone affecting bone (high concentration=>bone 
resorption, low concentration= >bone formation), works by controlling the 
secretion of growth factors and cytokines. When bone is not being formed the 
inactive osteoblasts become flat and extend along the bone surface, these cells 
are termed as bone lining cells. These cells control the mineral homeostasis by 
forming the gap junctions with osteocytes [Weiss, 1988; Nanci and Ten Cate, 
2003].     
 
 
Osteoblasts 
 
Newly formed 
bone matrix 
Osteocyte 
Chapter 1 
 34 
Osteocytes:  During the process of bone deposition some of the osteoblasts 
become trapped inside the matrix. These osteoblasts are then called osteocytes. 
The number of osteoblasts being surrounded by matrix and converted into 
osteocytes is directly proportional to the speed of bone formation. Initially 
osteocytes resemble osteoblasts, however with time their size reduces and they 
become flat, almond shaped with reduced Golgi complex and rough endoplasmic 
reticulum. The spaces occupied by osteocytes inside the matrix are called 
lacunae. Lacunae for younger osteocytes are round, however as the osteocytes 
mature and their size reduces, the lacunae also become oval or lenticular. 
Lacunae have narrow extensions called canaliculi which house the cytoplasmic 
processes of osteocytes and are formed by deposition of matrix around these 
processes (Figure 1.7). The cells make contact and exchange of molecules takes 
place with the adjacent osteocytes and with the bone lining cells through these 
processes. Osteocytes are responsible for the maintenance of bone matrix and 
the matrix is resorbed following the death of these cells [Weiss, 1988; Nanci and 
Ten Cate, 2003].  
Osteocytes play an important role in maintaining the integrity and vitality of the 
bone, especially in repairing micro fractures. Osteocytes detect the biochemical 
and mechanical changes and transmitting the signal through their processes to 
osteoblasts and osteoclasts or to bone lining cells [Lanyon, 1987].  
 
 
 
 
 
 
Figure 1.7: Schematic drawing of osteocytes present in lacunae arranged between lamellae 
[adapted from Junqueira and Carneiro, 2005].  
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   Lamellae     Lacuna 
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Osteoclasts: Osteoclasts are bone resorbing cells and are of hematopoietic 
origin. They are large cells ranging from 20 µm to more than 100 µm in diameter 
and are multinucleated, containing from 5 to 50 nuclei. Osteoclasts contain 
abundant mitochondria which are scattered throughout the cytoplasm and Golgi 
complexes which are present around multiple nuclei. Osteoclasts can be 
cytochemically distinguished from the multinucleated giant cells by the presence 
of tartrate resistant acid phosphatase in their cytoplasmic vesicles and vacuoles. 
Acid, collagenase and other proteolytic enzymes secreted by osteoclasts attack 
the bone matrix thus liberating the calcified ground substance and also 
eliminate the debris produced during bone resorption.  In the areas where active 
bone resorption is taking place they sit in enzymatically etched depressions in 
the matrix which are known as Howship’s lacunae. When osteoclasts are active 
their bone facing surface is folded into irregular, subdivided projections, which 
are known as the ruffled borders. The importance of this ruffled border is seen 
in osteopetrosis, a genetic disease in which osteoclasts lack ruffled border 
formation, which renders them incapable of bone resorption. A cytoplasmic zone 
which is devoid of organelles and rich in actin, vinculin and talin surrounds the 
ruffled border. This zone creates a microenvironment between the cell and the 
bone matrix and provides cell adhesion to the site. Lysosomal enzymes which are 
synthesized in the rough endoplasmic reticulum are transported to Golgi 
complex from where these enzymes are transported to the ruffled border. A 
proton pump, which is associated with the ruffled border creates an acidic 
microenvironment and causes demineralisation of the bone thus exposing the 
organic matrix (Figure 1.8). The exposed organic matrix is then degraded by the 
released enzymes [Barrere et al., 2006].  
The activity of osteoclasts is regulated by cytokines which are local proteins 
mediators and calcitonin which is a thyroid hormone. Although osteoclasts do 
not have receptors for parathyroid hormone, when osteoblasts are activated by 
parathyroid hormone they produce cytokines which in turn activate osteoclasts 
[Junqueira and Carneiro, 2005].  Osteoblasts play an important role in the 
regulation of osteoclasts as they produce M-CSF and RANKL which affect the 
proliferation and differentiation of osteoclast precursor cells. M-CSF stimulate 
the proliferation of osteoclast precursors cells by binding to c-Fms which is 
present on the cells surface.  Whereas RANKL produced by osteoblasts triggers 
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osteoclast precursors differentiation into mature osteoclasts [Hughes et al., 
2006].   
 
 
 
 
 
 
 
 
Figure 1.8: Schematic presentation of bone resorption process by an osteoclast [adapted 
from Junqueira and Carneiro, 2005].   
 
In bone remodelling, osteoclasts resorb a certain amount of bone and die, 
leaving the space to be filled by mesenchymal cells that differentiate into 
osteoblasts and form bone [Martin, 2009].  
1.2.4 Cementum 
Cementum is a thin layer of hard and mineralized tissue which covers the root of 
the tooth, it is yellow in colour and covers the dentine. The matrix of cementum 
consists of calcified collagenous fibrils, mucopolysaccharides and glycoproteins, 
the mineral content is apatite. The main collagen fibres of cementum are of 
type I, however it also contains <5% of type III collagen fibres [Christner et al., 
1977]. There are two main types of cementum, acellular which covers the upper 
portion of the root and cellular which covers the lower portion of the root. 
Cellular cementum plays an adaptive role in response to tooth movement and 
wear. Cementum is produced by cells called cementoblasts which do not have a 
regular shape and are differentiated from PDL fibroblasts by their close 
proximity to cementum. Cementoblasts, like osteoblasts, have receptors for PTH 
[Zhang et al., 1992]. The origin of cementoblasts is considered to be from 
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Hertwig’s epithelial root sheath (HERS) [Hammarstrom et al., 1996; Bosshardt, 
2005]. Recent studies have shown that enamel matrix proteins (EMPs) can cause 
porcine bone marrow-derived stromal cells (BMSCs) to differentiate into 
cementoblasts [Song et al., 2007]. Cementum is more resistant to resorption 
than bone which makes it possible for teeth to be moved by orthodontic forces 
as they cause the resorption of alveolar bone for tooth movement without the 
resorption of the root. It is suggested that cementoblasts are generally 
nonresponsive to mechanical stimulation. Cementum does not resorb or remodel 
extensively. However it is deposited throughout life. Cementum lacks its own 
blood or nutrient supply and receives its nutrients from the PDL [Nanci and Ten 
Cate, 2003].  
Cementum plays an important part of holding the tooth in the socket by 
providing anchorage to the ends of the PDL. PDL fibres are present between 
cementoblasts and are inserted into the cementum produced by these. 
Cementum protects the dentine and provides a seal for the open dentinal 
tubules. Toothwear at the occlusal or incisal surface of the teeth is compensated 
by the formation of cementum at the apical area of the tooth [Weiss, 1988].   
1.3 DISEASES OF THE PERIODONTIUM 
The primary aetiological factor associated with periodontal disease is the 
accumulation of dental plaque around the gingival margin and interdental 
gingiva on the tooth. The accumulation of plaque changes the microbial flora to 
pathogenic leading to mild to moderate gingivitis or severe periodontitis. 
1.3.1 Gingivitis 
Gingivitis is inflammation of the gingiva. It is characterised by changes in the 
color, contour and consistency of the gingival tissue (Figure 1.9). Gingivitis can 
be divided into plaque induced and nonplaque induced gingival inflammation. 
Plaque induced gingivitis can be further subdivided into plaque induced gingivitis 
with and without other local or systemic aggravating factors. These factors 
include pregnancy, diabetes mellitus and certain medications [Seymour et al., 
2000]. In pregnancy the fluctuation of hormones causes enhanced growth of 
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certain plaque flora, whereas some drugs such as phenytoin and cyclosporin can 
cause the enlargement of gingiva in plaque induced gingivitis [de Oliveira Costa 
et al., 2006]. In diabetes mellitus the gingival inflammatory condition is 
aggravated as antibacterial host response is compromised. Nonplaque induced 
gingivitis can be caused by fungal, bacterial and viral infections [Scully et al., 
1998]. Hypersensitivity to certain restorative materials and other oral care 
products can also produce gingival inflammation resembling plaque induced 
gingivitis [Holmstrup, 1999].   
 
Figure 1.9: Schematic drawing of gingivitis [from Rose, 2004]. 
 
Gingivitis is a reversible condition with no permanent tissue damage and resolves 
when its aetiology is removed [Mariotti, 1999]. Blood flow to the gingiva 
increases, which gives the gingiva a red appearance. The gingiva becomes 
swollen as a result of the leaking of leukocytes and plasma proteins from the 
capillaries into the connective tissue. Gingival pockets are formed in gingivitis 
Chapter 1 
 39 
due to gingival enlargement caused by swelling or fibrosis. At this stage there is 
no damage to PDL and alveolar bone. In most cases the body’s immune system is 
adequate to counter bacterial infection and with patient self care and treatment 
gingivitis is resolved and the tissue returns to a healthy state.  
In many untreated cases gingivitis may persist for years without ever progressing 
to the next stage of the disease. However in some cases (10-15% of population) 
it may aggravate to periodontitis.  
1.3.2 Periodontitis  
Initiation and sustainability of periodontitis is related to the accumulation of 
dental plaque. However the destruction of periodontal tissues depends on the 
host response to the plaque bacteria and the characteristics of the disease may 
also be affected by the individual’s immune system [Kinane, 1999; Rose, 2004; 
Honda et al., 2006].  Periodontitis can be divided into chronic and aggressive 
periodontitis.  Both forms of periodontitis can be further subdivided into 
localised and generalized periodontitis. However, in chronic periodontitis the 
two forms have the same aetiology and pathogenesis [Armitage, 2004], whereas 
in aggressive periodontitis the two forms may have differences in aetiology and 
pathogenesis [Lang et al., 1999]. In chronic periodontitis the tissue destruction 
process is not continuous. Short periods of tissue destruction are followed by 
extended periods of disease inactivity and the rate of tissue destruction may 
vary throughout the mouth [Socransky et al., 1984].   
The severity of periodontal disease is judged by the amount of clinical 
attachment loss. 1-2mm attachment loss is described as slight, 3-4mm 
attachment loss is referred to as moderate and more than 5mm attachment loss 
is considered to be severe periodontal disease [Armitage, 1999]. Clinical 
attachment loss is measured by measuring the distance from cementoenamel 
junction to the base of the probable crevice. Periodontitis causes irreversible 
damage to the tissues and affects all parts of the peridontium including the 
gingiva, PDL, cementum and alveolar bone (Figure 1.10). Clinical characteristics 
of chronic and aggressive periodontitis are shown in Figure 1.11 and are listed in 
Table 1.2. 
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Figure 1.10: Schematic drawing of a periodontally involved tooth [from www.drfudge.com 
;Rose, 2004]. 
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Table 1.2:  Clinical characteristics of chronic and aggresive periodontitis [from Lang et al., 
1999; Lindhe et al., 1999; Armitage, 2004] 
 
Chronic periodontitis 
Mostly in adults, however can also occur in children and adolescents 
Subgingival calculus 
Apical migration of junctional epithelium and pocketing 
Connective tissue attachment loss 
Alveolar bone loss 
Tooth mobility   
Slow to moderate progression rate with periods of rapid progression 
Can be associated and aggravated with systemic diseases 
Local predisposing factors can be associated 
Smoking and emotional stress can effect the disease characteristics 
Aggressive periodontitis 
Except for periodontitis the patient is healthy 
Attachment loss and bone destruction is rapid 
                                           Localized                 Generalized 
Onset:                                Circumpubertal          Usually under 30 years 
Subgingival calculus:          Usually absent           May or may not be present 
Serum antibody response     
to infecting agents:            Robust                      Poor 
 
Involvement: First molar/incisor presentation   Interproximal loss is generalized 
                     Interproximal attachment loss      affecting at least three  
                    on two permanent teeth one of     permanent teeth other than 
                    which is first molar.                     first molar and incisor. 
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Figure 1.11 (a) Chronic periodontitis, gingival recession and bone loss is visible. (b) 
Localized periodontitis, bone loss of mandibular anterior teeth. (c) Generalized 
periodontitis, bone loss involving all teeth [from Armitage, 2004]. 
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1.4 TREATMENT OF PERIODONTAL DISEASES 
Treatment of periodontitis involves two components, elimination of bacterial 
plaque and correction of anatomical deformities produced by the periodontitis. 
There are two approaches to correct the anatomical defects: resective and 
regenerative. In resective treatment periodontal defects are eliminated by 
removal of gingival and bony walls; this includes gingivectomy, apically 
positioned flaps and apically positioned flaps with osseous resection. 
Regenerative treatment involves elimination of periodontal defects by the 
production of new bone and periodontal ligament and coronal displacement of 
gingival attachment. 
1.4.1 Plaque removal and root planing 
Elimination of bacterial plaque is essential for the treatment of periodontal 
diseases. Removal of supragingival and subgingival plaque and calculus using 
conventional methods of scaling and root planing with or without flap surgery is 
useful. With scaling a reduction in the probing depth can be gained and it can be 
effective in treating periodontal disease [Becker et al., 2001]. However studies 
have shown that nonsurgical subgingival root planing does not always produce 
good results in terms of complete removal of calculus deposits as produced with 
surgical subgingival root planing [Eaton et al., 1985; Sherman et al., 1990]. In 
root planing the cementum is removed along with calculus deposits and the root 
surface is made smooth and hard. These procedures improve gingival conditions 
and reduce gingivitis and bleeding.  
1.4.2  Resective surgical procedures 
Resective surgical procedures are done to eliminate the disease and to correct 
anatomical deformities. These procedures create the conditions which stop the 
recurrence of the disease and eliminate or reduce gingival pockets:  
1.4.2.1 Gingivectomy  
Gingivectomy involves removal of the soft tissue wall of pathological periodontal 
pocket. The development of flap techniques has limited the use of gingivectomy 
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to removal of enlarged gingiva and minor reshaping.  Gingivectomy is indicated 
in cases where there is a need to eliminate the persistent gingival pockets after 
completion of scaling or root planing or to eliminate gingival enlargements due 
to any medication or genetic factors (Figure 1.12). Studies have shown that the 
regenerated gingiva following gingivectomy contains smaller lesions with lower 
densities of immunocompetent cells when compared to gingiva following non-
resective open-flap debridement [Zitzmann et al., 2005].  For drug induced 
gingival overgrowth, gingivectomy remains the treatment of choice 
[Mavrogiannis et al., 2006]. However gingivectomy is contraindicated in cases of 
acutely inflamed gingiva and where there are infrabony defects and large 
exostoses [Rose, 2004].  
 
 
 
 
 
 
 
 
Figure 1.12(a) Gingival enlargement, a candidate for gingivectomy. (b) Gingival incision at 
the pocket depth(c) A sharp pointed periodontal knife to relieve interproximal area. (d) A 
normal gingiva after treatment [from Rose, 2004].  
 
1.4.2.2 Apically repositioned flaps 
This procedure eliminates the periodontal pocketing and increases the zone of 
attached gingiva by moving the flap in an apical direction [Carnio and Miller, 
1999]. Carnio et al. [2007] described a modification of the apically repositioned 
flap which produced better results than the conventional method. After 
(d
(a) (b) 
(d) (c) 
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repositioning the flap the alveolar crest is covered thus eliminating the pocket. 
A mucoperiosteal attached gingival zone is created on merging of connective 
tissue on the inner surface of the flap with the bone.  
1.4.2.3 Apically positioned flap with osseous resection 
This procedure is also used to reduce or eliminate periodontal pockets.  This 
procedure involves (a) periodontal flap elevation, (b) granulation tissue removal 
(c) tooth root treatment and (d) bone contour correction. This results in 
positioning of the flap more apically than its original position. This procedure 
gives a stable dentogingival junction and is ideal for reducing periodontal 
pockets in patients with moderate periodontitis. However the main disadvantage 
associated with this technique is the root surface exposure which can result in 
hypersensivity and aesthetic problems [Rose, 2004].   
1.4.3 Regenerative procedures 
The resective procedures described above only arrest the disease process, but 
do not reverse or replace the tissue lost during the disease [Needleman et al., 
2002]. Procedures such as bone grafting and guided tissue regeneration (GTR) 
are used to produce regeneration of tissues destroyed by periodontal disease. 
Architecture and function of the lost tissue can be restored by regeneration to a 
limited extent. 
1.4.3.1 Bone grafts  
Tissue loss in severe periodontal disease has been treated with bone grafts for 
many years. Bone grafts can play a part in the correction of the osseous aspects 
of periodontal defects either by the process of osteoinduction or 
osteoconduction [McAllister and Haghighat, 2007]. An osteoinductive material 
can induce bone formation by recruiting undifferentiated mesenchymal cells and 
causing them to differentiate into osteoblastic cells, whereas an 
osteoconductive material acts as a scaffolding material for new bone formation 
from existing bone. 
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Graft materials can be divided into following four general types; 
Autograft: Autografts are obtained from the same individual. The bone is 
harvested from the patient’s own jaw (intraoral) or from any other part of the 
patient’s body (extraoral). Figure 1.13 shows a block autograft obtained from 
the patient’s own ramus. Autograft bone eliminates the possibility of graft 
rejection and transfer of disease. In one study iliac autografts were shown to 
successfully fill 87% of Class II furcation defects and a bone fill from 2.6mm to 
4.16mm was achieved [Schallhorn et al., 1970]. In another study where intraoral 
bone autografts were used, a bone gain of 2.88 to 3.44mm was achieved [Hiatt 
and Schallhorn, 1973]. However there are some studies in which autografts is 
shown not to produce good results [Carraro et al., 1976]. The factors on which 
the outcome of the treatment can depend include the morphology of the defect 
and the type of the bone used. In addition the availability of bone is limited and 
the patient has to undergo surgical procedures at two sites, which can increase 
pain and the potential for complications.  
 
 
Figure 1.13 A block autograft fixed with screws [from McAllister and Haghighat, 2007].  
 
Allograft: Allograft is the bone from another donor of the same species and 
provides a substitute for autograft (Figure 1.14). Allografts have the advantages 
of high availability as these are obtained from cadavers and eliminate need of a 
second surgical procedure on the patients. Iliac allografts were shown to 
produce bone gain of up to 3.6mm in periodontal defects [Hiatt et al., 1978]. 
Allografts used in periodontal regeneration are available in two forms: freeze-
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dried bone allografts (FDBA) and demineralised freeze-dried bone allografts 
(DFDBA) [Rose, 2004]. FDBA and DFDBA both can be effective in correcting 
periodontal bone defects [Mellonig, 1992]. The osteogenic potential of DFDBA 
may depend on the age of the bone donor and recipient. Rat studies have shown 
that DFDBA obtained from middle age animals had more bone forming potential 
than younger animals and bone formation is better in younger recipients than 
older recipients [Jergesen et al., 1991]. Disease transfer, including HIV/AIDs and 
hepatitis, is one of the drawbacks of allografts.    
 
 
Figure 1.14 A block allograft fixed with screws [from McAllister and Haghighat, 2007]. 
 
Xenograft:  Xenograft is bone obtained from different species. These bones are 
obtained from bovine or porcine sources and are thought to be osteoconductive 
and resorbed to be replaced by the host bone over time [McAllister and 
Haghighat, 2007]. A xenograft grafted at the defect site is shown in Figure 1.15. 
Bovine bone is treated with ethylene diamine which removes its organic and 
antigenic fractions, but retains its inorganic structure.  In comparative studies 
anorganic bone showed better restoration of bone defects than bioactive glass 
ceramics [Schmitt et al., 1997], whereas there was no significant difference in 
the results produced by DFDBA and bovine derived xenograft [Richardson et al., 
1999].  However risk of bovine or porcine virus or other infective agent 
transmission is associated with these grafts [Sogal and Tofe, 1999]. 
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Figure 1.15 A bovine xenograft placed at the defect site [from Richardson et al., 1999]. 
 
 
Grafts of bone substitutes and synthetic materials (Alloplast): Alloplasts 
eliminate the problem of limited supply of autograft bone and risk of disease 
transmission from allograft or xenografts. However these materials only act as 
biocompatible space fillers. The following types of alloplastic synthetic grafts 
are available: 
a) Porous hydroxyapatite 
b) Non-porous hydroxyapatite 
c) Beta tricalcium phosphate 
d) HTR polymer 
e) Bioactive glasses and ceramics 
Bioactive glass produced similar clinical results and gain in attachment levels in 
comparison with expanded polytetrafluoroethylene (ePTFE) membranes for the 
treatment of mandibular Class II furcation [Yukna et al., 2001].    
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1.5 GUIDED TISSUE REGENERATION (GTR) 
In modern periodontal disease treatment the aim is not only to stop the disease 
but also to regenerate lost periodontal and supporting bone tissues [Needleman 
et al., 2002]. Guided tissue regeneration (GTR) technique uses a membrane to 
cover the periodontal defect which isolates the defective area from overlying 
soft tissue, thus blocking fast growing soft tissue cells from invading the area 
and allowing mesenchymal cells from PDL or bone to repopulate the area.   
It was proposed by Melcher [1976] that the nature of periodontal tissue healing 
depends on the type of cells which repopulate the root surface. Regeneration at 
the periodontal defect occurs if the root surface is populated by the 
undifferentiated mesenchymal cells from PDL or perivascular region of the bone 
which then differentiate into specific tissue forming cells, whereas if the 
surrounding tissues replace the lost periodontal tissues the healing of the 
periodontal defect occurs by repair.  In repair, if the root surface is populated 
by the cells from gingival epithelium it results in formation of a long junctional 
epithelium and a connective tissue attachment is formed when the root surface 
is populated by the cells from gingival connective tissue which can also cause 
root resorption. If the cells from surrounding bone repopulate the root surface, 
then they will cause root resorption and ankylosis, which is fusion of the tooth to 
the bone.   
The predictability of regenerating bone destroyed by periodontal diseases has 
been increased by use of guided tissue regeneration (GTR) techniques. For more 
than a decade GTR has been considered an effective method to regenerate the 
lost periodontal tissue [Caffesse et al., 1997]. Superiority of GTR over traditional 
techniques has been reported in a number of clinical studies [Nyman et al., 
1982; Murphy and Gunsolley, 2003].  
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1.5.1 Principles of GTR 
GTR is based on the three principles of wound healing.  
First principle is that if the fast growing gingival epithelium and connective 
tissue are blocked from invading the periodontal wound, periodontal tissue can 
regenerate from multipotent cells of PDL and bone. Studies have shown that the 
gingival epithelium cells migrate more rapidly to the periodontal defect than the 
cells from PDL or bone [Caton et al., 1980]. GTR membranes are used to block 
the invasion of competing non-osteogenic soft tissue cells to the periodontal 
defect [Bunyaratavej and Wang, 2001; Ueyama et al., 2002]. 
Second principle is that if a GTR membrane maintains a space between the 
mucoperiosteal flap and the periodontal defect, which allows migrating and 
proliferating cells to reconstruct the defect. 
Third principle is that GTR membranes stabilize and mechanically protect the 
newly formed clot in the wound [Koyama et al., 2003]. Protection of blood clot 
is important for the successful outcome. This clot acts as a scaffold for the 
regenerating osteogenic cells which regenerate bone [Koyama et al., 2003; 
McAllister and Haghighat, 2007].   
1.5.2 Ideal requirements of GTR membranes 
A GTR membrane should have the following properties to obtain the best results: 
• Biocompatibility  
• Mechanical stability   
• Biodegradability 
• Resorbability 
• Adaptability 
• Ability to release bioactive proteins  
• Clinical manageability  
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1.5.3 Types of GTR membranes  
GTR membranes can be divided into two types, resorbable and nonresorbable 
membranes. Nonresorbable membranes require a second surgical procedure for 
their removal. Resorbable membranes have the advantage over nonresorbable 
membranes as they do not require removal and are eliminated from the body by 
metabolic processes [Zellin et al., 1995; Mayfield et al., 1997].  
1.5.3.1 Nonresorbable membranes 
These membranes require a second surgical procedure for their removal which 
not only increase the cost and discomfort for the patient but the removal can 
also damage the newly formed tissue.   
Expanded Polytetrafluoroethylene (ePTFE): These were the first commercially 
available membranes used for GTR. These membranes are removed 
approximately 1 to 3 months after placement [Pontoriero et al., 1988]. This 
membrane has two parts, a collar portion which has open pores which prevent 
migration of epithelium and allow ingrowth of connective tissue, and an 
occlusive portion which prevents the contact of flap tissue to the root surface 
[Scantlebury, 1993]. For larger defects ePTFE membranes are used with titanium 
reinforcement to improve space maintenance ability of the membrane (Figure 
1.16). 
 
Figure 1.16 A titanium reinforced ePTFE membrane fixed with screws [from McAllister and 
Haghighat, 2007]. 
  
Although the use of ePTFE membranes in treatment of periodontal defects like 
class II furcation have shown improved clinical results, the regenerated tissue 
did not completely fill the defects [Pontoriero et al., 1988]. A comparative study 
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showed no significant difference between the results obtained from the defects 
treated by ePTFE and DFDBA [Guillemin et al., 1993]. Imbronito et al. [2002] 
have shown that the membranes made of ePTFE showed similar amounts of bone 
regeneration as compared to polylactic acid (PLA) membranes. In addition these 
membranes have the problem of exposure due to tissue dehiscence which may 
lead to their bacterial contamination which can negatively affect the outcome of 
GTR procedures [Tempro and Nalbandian, 1993; Nowzari et al., 1996; Machtei, 
2001]. In a study carried out by Zitzmann et al. [1997], 44% of the ePTFE 
membranes had to be removed prematurely due to exposure. The use of ePTFE 
has now mostly been replaced by resorbable membranes [Dupoirieux et al., 
2001].    
1.5.3.2 Resorbable membranes 
Due to the limitations associated with nonresorbable membranes, their use is 
mostly replaced by resorbable membranes which eliminate some of the 
drawbacks of nonresorbable membranes [McAllister and Haghighat, 2007]. These 
materials are resorbed and by products are eliminated by the body so do not 
require a second surgical removal procedure. Resorbable materials (Figure 1.17) 
have the advantage of less patient discomfort, cost and less chances of damage 
to newly formed tissues [Scantlebury, 1993; Caffesse et al., 1997]. The 
mechanical properties of resorbable membranes are generally not as good as 
those of nonresorbable membranes, however they can be equally 
osteopromotive and improve GTR if they can be designed to maintain the space 
for an adequate time [Zellin et al., 1995].  
 
Figure 1.17: A PLA/PGA composite resorbable membrane placed over a periodontal defect 
[from Cortellini and Tonetti, 2000].  
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Resorbable membranes are divided into two groups: synthetic and natural 
[McAllister and Haghighat, 2007]. Synthetic and natural membranes have 
different degradation mechanisms. A study in which a synthetic membrane 
consisting of PLA/PGA copolymer and a natural type I collagen membrane was 
used showed equal clinical improvements from the use of either membrane 
[Jepsen et al., 2000].  
Synthetic polymers: These polymers are eliminated out of the body through 
metabolic processes. Degradable polymers used for the production of GTR 
membranes include: (a) Polylactic acid (b) Co-polymers of polylactic (PLA) and 
polyglycolic acid (PGA) (c) Polyurethane. 
Commercially available membranes made up of synthetic polymers includes 
Resolute®, Atrisorb®, Vicryl Periodontal Mesh®, Epi-Guide® and Mempol®.  
Resolute®, which is a composite of PLA and PGA retains its structure for four 
weeks and then completely resorbs within 5 to 6 months [Hurzeler et al., 1997]. 
PLA and PGA copolymer membranes can promote regeneration when used for the 
treatment of intrabony defects and were easier to suture than collagen 
membranes, which tended to tear when tension is applied at the suture [Mattson 
et al., 1999]. Mayfield et al. [1997] used Resolute® in their clinical study and 
showed bone regeneration and complete bone coverage of implant threads in 14 
cases out of 17 and partial coverage in 3 cases. Zellin et al. [1995] showed that 
polylactic/polyglycolic copolymer membranes produced a very low inflammatory 
response in the surrounding tissue and most of it was degraded after 6 weeks of 
healing. Resolute® produced equally good clinical improvements in a 
comparative study with ePTFE [Caffesse et al., 1997].  
Atrisorb® consists of polylactic acid and is prepared at the chair side, is reported 
to be completely resorbed in six to twelve months after implantation [Bogle et 
al., 1997]. A study carried out by Stoller et al. [2001] showed regeneration of 
cementum, alveolar bone and periodontal ligament when they used polylactic 
acid membranes for the treatment of class II furcation defects.   
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Natural biomaterials:  Natural biomaterials used for GTR include: 
1). Collagen: These membranes are of porcine or bovine origin consisting of 
either type I or a combination of type I and type III collagen. A commercially 
available collagen membrane, Bio-Gide®, is produced from collagen of porcine 
origin. Studies have shown the ability of collagen membranes to promote 
regeneration in periodontal defects. Collagen membranes have been used in 
combination with other materials which include bone grafting material, 
fibronectin and heparan sulfate to enhance their regeneration potential [Mattson 
et al., 1999; Bunyaratavej and Wang, 2001]. When using these collagen 
membranes a space filling bone substitute should be used to avoid the collapse 
of these membranes into the defect and to improve GTR results [Strietzel et al., 
2006]. Collagen membranes have a fast degradation rate which can affect their 
ability to act as a barrier, however studies have shown the ability of these 
membranes to inhibit apical migration of epithelium during early wound healing 
when epithelium actively migrates apically. It is reported that regenerative cells 
from bone and PDL reach the wound area in 3 to 4 weeks [Bunyaratavej and 
Wang, 2001]. On the whole, collagen membranes have limited potential to be 
used as GTR membranes because of their lack of ability to maintain space over 
the wound area [Tatakis et al., 1999a]. 
2). Dura mater: These are obtained from cadavers and consist of an irregular 
network of collagen fibres.  They are processed and sterilized, but still pose a 
risk of transferring Creutzfeldt-Jakob disease to the patient and the operator as 
well [Martinez-Lage et al., 1994]. Their use as GTR membranes is limited [Yukna, 
1992].   
1.5.4 Limitations of GTR  
The limitation with the currently used GTR membranes is that the nonresorbable 
materials need to be removed via a second surgical procedure which can 
adversely affect the newly formed periodontal tissues but they generally have 
suitable mechanical properties. Resorbable membranes on the other hand do not 
require removal but currently have too low mechanical properties. Resorbable 
membranes have shown variable results in term of their ability to produce GTR 
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mainly depending on their ability to maintain space and resist collapse. These 
membranes are prone to collapse because of their low mechanical properties. 
Furthermore although GTR techniques have been shown to increase the 
regeneration of periodontal tissues, the increase has been modest [Needleman 
et al., 2002]. To improve the effectiveness of GTR, new research is focused on 
using the combination of different materials which can compliment each other 
to produce increased regeneration. One such combination can be the use of a 
bioactive composite membrane with the ability to deliver growth factors.      
1.5.5 Growth factors and tissue regeneration 
There is considerable interest in the potential therapeutic application of 
bioactive molecules such as growth factors to enhance healing outcomes, and 
GTR membrane materials might also be suitable as carriers for the sustained 
delivery of bioactive molecules [King, 2001; Hughes et al., 2006]. 
Different studies have shown the potential of growth factors to induce the 
regeneration of periodontal tissues [Cho et al., 1995; Park et al., 1995]. Growth 
factors are proteins or polypeptides which have the ability to initiate the 
proliferation or activity of cells. High concentrations of growth factors are 
present in bone and cementum which are released following an injury which 
effect the repair and regeneration of periodontal tissue [Giannobile, 1996]. 
Growth factors bind to specific receptors on target cells, generating a cascade of 
intracellular molecular signals, thus causing cells to proliferate and differentiate 
[Davidson et al., 1985; Giannobile, 1996; Rose, 2004].  Growth factors found in 
bone, cementum and other healing tissues include Platelet Derived Growth 
Factors (PDGF), Bone Morphogenic Proteins (BMPs), Enamel Matrix Derivatives 
(EMDs), Fibroblast Growth Factors (FGFs) and Insulin like Growth Factors (IGFs) 
[Giannobile, 1996].  These growth factors have the ability to induce and promote 
periodontal regeneration [King and Cochrant, 2002].  
1.5.5.1 Platelet derived growth factors (PDGF) 
PDGF is a heparin-binding polypeptide having a molecular weight of approx 
30,000 Da [Antoniades, 1981]. Human platelet derived PDGF is a heterodimer of 
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A and B chains [Ross et al., 1986]. In addition to these chains, C and D chains 
have been recently discovered (AA, BB, AB, CC, DD). The principal source of 
PDGF is α-granules of platelets, however macrophages and fibroblasts when 
activated also produce PDGF. PDGF binds to the α and ß receptors on the 
surfaces of the cells. Both A and B chains bind to α receptors on the cell surface, 
however only the B chain of PDGF binds to the ß receptors of cells [Chong et al., 
2006]. Each PDGF receptor contains five immunoglobulin-like domains 
extracellulary, and there is a tyrosine kinase domain intracellulrly. 
Autophosphorylation of PDGF receptors produce two affects; first, 
phosphorylation of tyrosine residue inside the kinase domains results in an 
increase in the catalytic efficiencies of the kinases. Secondly, phosphorylation of 
tyrosine residues located outside the kinase domain produce docking sites for  
SH2 domain protein such as phosphatidylinositol 3'-kinase (PI 3-kinase), 
phospholipase C (PLC)- . PI 3-kinase binds to and is activated by tyrosine kinase 
receptors, it plays a central role in the transduction of intracellular signals, 
many different cellular responses are mediated by it which includes, actin 
reorganization, chemotaxis and cell growth. PLC-  acts on the same substrate as 
PI 3-kinase.  On binding to PDGF receptor it phosphorylate on specific tyrosine 
residues and its catalytic activity increases. PLC-  stimulates cell growth and 
motility in certain cell types [Heldin and Westermark, 1999]. 
PDGF is considered to play an important role in defining the activity of 
mesenchymal cells and an in vitro study showed that the proliferation of PDL 
was enhanced on addition of PDGF [Mumford et al., 2001]. Interestingly, Hsieh 
and Graves [1998] showed that although PDGF increases the proliferation and 
differentiation of bone forming cells, prolonged exposure of differentiated bone 
cells to PDGF inhibits their bone forming function. PDGF has been reported to 
have mitogenic and chemotactic effects on osteoblasts and it enhances the 
production of type I collagen by osteoblasts [Bolander, 1992]. 
During fracture healing PDGF is produced at the fracture site and PDGF receptors 
on the surfaces of cells also increase which suggests that it has a role during 
bone repair [Andrew et al., 1995; Fujii et al., 1999]. In a human clinical study 
enhanced periodontal regeneration was achieved when PDGF was used in 
combination with bone allografts for the treatment of Class II furcations and 
interproximal intrabony defects [Nevins et al., 2003]. In another clinical study 
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PDGF was shown to stimulate the cells involved in periodontal regeneration 
resulting in enhanced periodontal bone regeneration [Cooke et al., 2006]. An 
increased number of cell receptors for growth factors are found in regenerated 
tissues compared to normal gingival and periodontal ligament tissues [Parkar et 
al., 2001]. In a rat study PDGF loaded chitosan sponge produced enhanced bone 
regeneration in calvarial defects [Lee et al., 2000; Park et al., 2000b]. Sant'Ana 
et al. [2007a] showed increased proliferation of PDL cells in response to PDGF in 
an in vitro study. Howell et al. [1997] reported increased alveolar bone 
formation in human osseous defects with the use of PDGF as compared to bone 
formed by conventional flap surgery.  PDGF absorbed to ß-TCP alloplast material 
produced increased proliferation of osteoblastic cells in vitro [Bateman et al., 
2005].  
1.5.5.2 Bone morphogenic proteins (BMPs) 
Bone morphogenic proteins (BMPs) belong to the transforming growth factor ß 
(TGF-ß) family and their activity was first identified by Urist in 1965 when he 
showed that demineralised bone extracts contains substances which can induce 
bone formation at ectopic sites in rodents [Urist, 1965; Sigurdsson et al., 1997; 
Massague, 1998]. Later these substances were recognized as BMPs and BMP 1,2, 
3 and 4 were successfully purified and cloned [Wozney et al., 1988]. BMPs can be 
isolated and purified from dentine, bone and osteosarcoma tissues, however 
demineralized bone matrix still is used extensively as their source [Urist et al., 
1984; Granjeiro et al., 2005].  
Since then more than 20 different types of BMPs have been identified with each 
having a different biological activity. BMPs play important roles both during 
embryonic growth and later throughout life in repair [Boden, 2005]. BMPs act by 
binding to transmembrane serine-threonine kinase receptors which are present 
on the cell membranes. BMPs form a complex by binding to type II receptors on 
the cell surface and then recruiting a type I receptor. The receptors 
phosphorylate after the formation of the BMP-receptor II-receptor-I complex and 
then phosphorylate SMAD proteins. These phosphorylated SMAD proteins then 
enter the nucleus of the cell and cause the transcription regulation of target 
genes [Massague, 1996; Sakou, 1998]. A schematic description of the possible 
mechanism of action of BMPs on a cell is shown in Figure 1.18.   
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BMPs regulate the processes of cell proliferation, differentiation and apoptosis 
and can induce different tissue formation [Granjeiro et al., 2005]. BMPs 
stimulate the differentiation of mesenchymal stem cells into osteoblasts and can 
induce the production of new bone, among BMPs differentiation of osteoblasts is 
specially regulated by BMP-2, BMP-4 and BMP-7 [Hughes et al., 2006] [Rose, 
2004].  
 
Figure 1.18: A schematic description of BMP action on cell. BMPs bind to the receptors in 
the cell and signals are transduced through Smad 1/4/5 to the cell nuclei [Adapted from 
Yamaguchi et al., 2000].  
 
Interestingly, it was found in vitro that when mesenchymal cells were exposed 
to low concentrations of BMPs they differentiate into adipocytes, however, on 
exposure to high concentrations these mesenchymal cells differentiate into 
osteoblasts. This finding lays emphasis on the importance of specifying the dose 
for their clinical use [Granjeiro et al., 2005]. In different animal studies BMP-2 
has been shown to induce bone formation [Murakami et al., 2002]. An animal 
study has shown that BMP-2 can also be used for the treatment of osteoporosis 
as it increases the activity of mesenchymal cells and can reverse the age related 
bone loss when administered systemically [Gadi et al., 2002].  Although BMPs 
can induce regeneration even without a carrier, a delivery system is needed to 
get a better and more localized effect. BMPs play a considerable role in 
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periodontal healing and have osteoinductive activity. Application of rhBMPs 
enclosed in collagen membrane sponges in Wistar rats has been shown to 
stimulate early cell proliferation and migration towards the periodontal wound 
area and subsequent differentiation occurs more rapidly than in a normal wound 
[Boyne et al., 1997; King et al., 1998; King and Hughes, 2001]. 
In a human clinical study recombinant human (rh) BMP-2 was used for maxillary 
floor sinus augmentation incorporated in an absorbable collagen sponge, the 
results showed significant increased bone growth with a mean gain of 8.51 mm. 
No serious adverse effects were observed in the patients, however facial edema, 
oral erythema and rhinitis were reported [Boyne et al., 1997].  In another human 
clinical trial, Howell et al. [1997] also used rhBMP-2 in a resorbable collagen 
sponge for the treatment of localised osseous defects and prevention of alveolar 
ridge after tooth extraction.  They also found out that the rhBMP-2 was effective 
in regenerating bone after tooth extraction and rhBMP-2 was well tolerated by 
the patients with no serious side effects.  
1.5.5.3 Enamel matrix derivatives (EMD) 
Enamel matrix derivatives consist of proteins which are derived from Hertwig’s 
root sheath of porcine origin. EMD contains different low molecular weight 
proteins which include amelogenins (90%), ameloblastins and enamelin. EMD can 
induce acellular cementum regeneration which is an important part of 
periodontal regeneration, based on the theory that a protein preparation 
present in the EMD resembles the matrix proteins which induce cementogenesis 
[Hammarstrom, 1997; Rose, 2004].  
In vitro studies have shown that EMD enhances the proliferation, proteins and 
collagen production, differentiation and osteoprotegerin production of PDL cells 
and when myoblast cells were exposed to EDM they differentiated into 
osteoblasts or chondroblasts. EMD did not show a significant effect on the 
proliferation of epithelial cells in vitro [Gestrelius et al., 1997; Ohyama et al., 
2002; Lossdorfer et al., 2007].  In another study, Lyngstadaas et al. [2001] 
showed that when PDL cells were exposed to EMD the attachment rate, growth 
rate and metabolism of these cells was increased and they subsequently 
produced more growth factors.  
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In a monkey study, buccal alveolar bone, periodontal ligament and 
corresponding cementum were removed and the defects were then treated with 
porcine enamel matrix with and without a carrier system, the results obtained 
showed that application of EMD produced complete regeneration of cementum 
and collagenous fibres which were embedded in newly formed alveolar bone 
[Hammarström, 1997].  
In a clinical trial intrabony defects were treated with the application of EMD. 
The treatment with EMD produces regeneration of periodontium which was 
comparable with the regeneration produced using a GTR membrane. In addition 
no systemic adverse effects with the application of EMD were observed [Sculean 
et al., 1999].  In another human study EDM was used with xenografts for the 
treatment of osseous periodontal defects with favourable results [Scheyer et al., 
2002].       
1.5.5.4 Fibroblast growth factor (FGFs) 
FGFs belong to heparin binding growth factor family. Basic FGF is found in 
gingiva, periodontal ligament and bone.  
In an in vitro study FGF was shown to have a mitogenic effect on PDL cells, when 
used with allografts as carrier, which can be beneficial for periodontal 
regeneration [Dereka et al., 2006]. In an animal study FGF in a gelatin carrier 
was topically applied to the created class II bone defects. The application of FGF 
produced more periodontal ligament formation and cementum along with new 
bone formation as compared to controls, without producing any ankylosis or root 
resorption. FGF inhibits the differentiation of PDL cells and inhibit their ability 
to produce calcified nodules, however, it enhances the proliferation of PDL cells 
in the early stages of healing. These undifferentiated cells in the later stages of 
healing differentiate into osteoblasts and cementoblasts which increase 
periodontal regeneration [Murakami et al., 2003]. A schematic description of 
FGF effect on PDL cells is shown in Figure 1.19.  
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Figure 1.19:  A schematic description of FGF effect on PDL cells. FGF has the positive effect  
on the mitosis of multipotent immature cells, whereas it downregulates the collagen 
synthesis and formation of calcified nodules by PDL cells [adapted from Takayama et al., 
1997] 
 
The proliferation effect of FGF on PDL proliferation is dose dependent and it 
decreases if the dose increases above an optimal level [Takayama et al., 1997].   
1.5.5.5 Insulin like growth factors (IGFs) 
IGFs are nonglycosylated polypeptides with a molecular weight of approx 7,500 
Da. Their synthesis takes place in liver, smooth muscle, placenta and osteoblasts 
[Caffesse and Quinones, 1993].  
In vivo studies have shown that application of IGF enclosed in dextran–co-gelatin 
hydrogel microspheres to denuded root surface in beagle dogs enhanced the 
regeneration of bone and cementum [Chen et al., 2006]. IGF application showed 
increased osteoblastic collagen synthesis and bone-matrix apposition and 
increased the regeneration of bone in an in vitro study [Hock et al., 1988]. In an 
animal study 100 µg IGF was delivered entrapped in biodegradable poly (lactide-
co-glycolide) microspheres at 8-10mm defects in ovine long bones. The results 
showed that IGF application not only induced new bone formation but also 
reduced bone resorption and inflammation at the bone injury site [Meinel et al., 
2003]. IGFs have also shown to increase the adhesion and proliferation of PDL 
cells in an in vitro study [Sant'Ana et al., 2007b] 
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1.6 BIODEGRADABLE POLYMERS AND CERAMICS  
Biodegradable polymers are suitable for use in situations where an implant is 
only required to stay in the body for a limited period of time. They are currently 
used in sutures, drug delivery systems, fracture fixation devices and as scaffolds. 
Poly-ε-caprolactone (PCL), polyglycolic acid (PGA) and polylactic acid (PLA) are 
synthetic biodegradable polymers and belong to the family of aliphatic 
polyesters.  
PCL is a semicrystalline polymer with a melting temperature between 59 to 64°C 
and glass transition temperature of -60°C. It has a slow degradation rate which 
makes it suitable for use in the long term drug delivery system. Many studies 
have reported use of PCL as a drug delivery system including antibiotics and 
antihypertensive drugs. Its degradation rate and mechanical properties can be 
tailored by copolymerizing it with PLA or PGA or blending it with ceramics. It has 
also been investigated as a scaffold material for bone [Marra et al., 1999; Wan-
Ju et al., 2003; Sinha et al., 2004].  
PGA is synthesised by ring opening polymerisation of cyclic dimer of glycolic 
acid. PGA has a melting point between 224 and 228°C and a glass transition 
temperature of 36°C. In the body PGA is degraded by a hydrolytic process and 
the degradation products are metabolized by the citric acid cycle which are 
subsequently eliminated out of the body in the form of carbon dioxide and 
water. It is mainly used as a suture material, however its is being expanded by 
using it as a copolymer with PLA [Athanasiou et al., 1996a; Liu et al., 2005].  
PLA is synthesised by ring opening polymerisation of a cyclic dimer of lactic acid 
and is considered to be one of the most promising biodegradable polymers due 
to its processibility and ability to have tailored physical and biological properties 
and has been used in many biomedical applications [Rokkanen et al., 2000a; Lu 
et al., 2002; Georgiou et al., 2007; Gupta et al., 2007]. PLA is discussed in detail 
in section 1.6.1.   
Drawbacks associated with biodegradable polymers such as low mechanical 
properties, low bioactivity and unpredictable degradation pattern can be 
improved by combining them with calcium phosphates and using them as a 
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composite material [Huang et al., 2008]. In bone contacting applications calcium 
phosphate are commonly used as coatings and composite fillers and are mainly 
hydroxyapatite (Ca10(PO4)6(OH)2) and tricalcium phosphate (Ca3(PO4)2). Calcium 
phosphates are discussed in detail in section 1.6.2.  
PLA is being used as sutures, scaffolds, fracture fixation devices, bone 
regeneration and in drug delivery systems due to its favourable properties. In 
the following section PLA is discussed in detail as it was selected for the 
production of polymer- Ca P composites due to its manipulable properties. 
1.6.1 Polylactic acid (PLA) 
Polylactic acid (PLA) is a degradable polymer which has been used in many 
biomedical applications and is still a subject of extensive research to expand its 
use due to its favourable properties. It belongs to the aliphatic polyesters family 
and is prepared by ring-opening polymerisation of the cyclic dimer of lactic acid 
(HOCHCH3COOH) [Conn et al., 1995]. The chemical structure of PLA is shown in 
Figure 1.20. 
 
 
Figure 1.20: Chemical structure of PLA, where (n) denotes the central repeat unit [modified 
from Conn et al., 1995; Garlotta, 2001]. 
 
Lactic acid is converted into high molecular weight PLA by two methods. A 
solvent free route in which condensation of lactic acid produces a low molecular 
weight PLA, this is followed by controlled depolymerisation of this low molecular 
weight PLA which produces a cyclic dimer known as lactide. Lactide is purified 
by distillation. High molecular weight PLA is then produced by catalytic ring 
opening polymerisation. The second route is a solvent based azeotropic 
condensation in which lactic acid undergoes reduced pressure distillation for 2 to 
3 hours at 130°C which removes most of the condensation water. Catalyst and 
diphenyl ether are then added and after passing through a molecular sieves the 
solvent is again kept at 130 °C for further 30 to 40 hours. This process also 
produces high molecular weight PLA Lunt, 1998; Garlotta, 2001]. A schematic 
description of these two processes is shown in Figure 1.21.  
 HO       CH3         (O       CH3)n      O        CH3            OH 
O O O 
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Figure 1.21: Schematic description of PLA synthesis [ modified from Garlotta, 2001] 
 
Lactic acid is a chiral molecule and exists in two stereoisomeric forms, L and D 
enantiomers (Figure 1.22) [Garlotta, 2001]. Mechanical properties, crystallinity 
and degradation of PLA depend and can be controlled by the ratio and type of 
the enantiomers used. L enantiomer provides PLA with higher mechanical 
strength and adding D enantiomers to PLLA reduces its melting temperature and 
crystallinity [Gupta et al., 2007].     
 
 
 
 
Figure 1.22:  Structure of L and D enantiomers of PLA [adapted from Gupta et al., 2007] 
 
A more amorphous material is generally obtained when the D content is above 20 
%, whereas a highly crystalline material can be produced by keeping the D 
content below 2 % [Gupta et al., 2007]. Depending on the ratio of L to D a 
polymer with a molecular weight of thousands to millions can be produced. The 
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ratio and distribution of enantiomers play an important role in defining the 
thermal, mechanical and biological properties of PLA [Mehta et al., 2005].   
Four different morphological types of polymers with different properties can be 
prepared depending on the enantiomers; 
• PDLA: Semicrystalline and has good mechanical strength compared to 
PDLLA.  
• PLLA: It is semicrystalline and has high mechanical strength, used for 
applications needing mechanical strength like sutures and fracture 
fixation. It has a melting point temperature of 170- 180 °C and a glass 
transition temperature of 57-67 °C.  
• PDLLA: It is amorphous and racemix, used for applications such as drug 
delivery. Its properties depend on its L: D ratio. It is more susceptible to 
hydrolysis than to PLLA.   
• meso-PLA: Obtained from L and D lactides, this type of PLA is rarely used. 
A comparison of mechanical properties of PLAs containing different enantiomers 
is shown in Table 1.3. 
Table 1.3:  Effect of different enantiomers on the mechanical properties of poly lactic acid 
[modified from Garlotta, 2001]. 
PLLA                              PDLLA 
Tensile strength (MPa)                                       59                                   44 
Elongation at break (%)                                      7.0                                  5.4 
Modulus of elasticity (MPa)                                3750                                3900 
Yield strength (MPa)                                          70                                   53 
Flexural strength (MPa)                                     106                                  88 
Unnotched Izod impact (J/m)                            195                                 150 
Notched Izod impact (J/m)                                26                                   18 
Rockwell hardness                                             88                                   76 
Heat deflection temperature (°C)                      55                                   50 
Vicat penetration (°C)                                       59                                   52                  
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Degradation of PLA occurs by hydrolysis in which PLA is converted into lactic 
acid which is a metabolite present in the body. The degradation products are 
then eliminated out of the body after being converted into carbon dioxide and 
water. The mechanism of degradation involves hydrolytic cleavage of ester 
bonds on penetration of water inside the polymer, a new carboxyl end group is 
formed from the cleavage of each ester bond which in turn starts the process of 
autocatalysation [Zhang et al., 2005]. This autocatalysis speeds up the process of 
hydrolysis of the remaining ester bonds. In the beginning the degradation of PLA 
is a bulk degradation process and is homogeneous, however as oligomers are 
produced later in the process the pattern of degradation changes. The oligomers 
and carboxyl end groups produced inside the matrix cause an increase in acidity 
which in turn speeds up the degradation of the internal matrix, whereas the 
oligomers and carboxyl groups present close to the surface escape and become 
neutralised. Thus the outer surface does not degrade at the same rate as the 
internal matrix [Li, 1999]. PLA becomes more hydrophilic as the degradation 
proceeds which enhances water uptake and further accelerating degradation. 
Degradation of PLA depends on a number of factors such as its chemical 
composition, molecular weight, molecular weight distribution, processing 
condition, shape and implantation site and ranges from six months to two years. 
Degradation processes include reduction in the mass, molecular weight, 
configuration changes and reduction in the mechanical properties of an implant 
[Vert et al., 1992; Athanasiou et al., 1996b]. The ratio of L and D enantiomers 
plays an important role in determining the rate of degradation, the degradation 
rate of polymer is proportional to the D content. The degradation of high 
molecular weight polymers will be slower than that of polymers with low 
molecular weight [Li, 1999]. Glass transitional temperature (Tg) and melting 
temperature (Tm) both are directly proportional to the molecular weight, 
materials with high molecular weight have high Tg and Tm [Gupta et al., 2007]. 
The crystallinity and Tg of PLA also affect the degradation rate. PLA with high 
crystallinity has tightly packed and ordered polymer chains which make it more 
resistant to degradation and a polymer with a high Tg is more resistant to the 
penetration of water molecules which also makes it more resistant to 
degradation. In addition local pH, device morphology and size also affect the 
rate of PLA degradation [Place et al., 2009]. Factors which can play a role in the 
degradation of the biodegradable polymers are summarized in Table 1.4. 
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Table 1.4:  Factors affecting the degradation of biodegradable polymers [from Vert et al., 
1992].   
• Structure of polymer 
• Composition of polymer 
• Ionic group presence 
• Configurational structure 
• Molecular weight and its distribution  
• Presence of low molecular weight compounds like monomer, 
     oligomers, solvents, initiators, drugs, etc 
• Processing conditions 
• Shape 
• Sterilizing process 
• Amorphous or semicrystalline 
• Storage history 
• Implantation site 
• Adsorbed and absorbed compounds (water, lipids, ions, etc.) 
• Shape and size 
• Hydrolysis mechanism (enzymatic or hydrolytic) 
 
1.6.1.1 Bone contacting applications of PLA 
PLA is used in number of biomedical applications, however there are two major 
clinical areas where it comes in contact with bone. These two areas are 
orthopaedics and dentistry where PLA is used as fracture fixation devices and as 
membranes for GTR respectively. 
The use of biodegradable PLA internal fixations devices such as pins, screws, 
plates etc (Figure 1.23) instead of metallic osteofixation devices not only 
eliminates the need of second removal surgery, but can also avoid the long term 
complications associated with metallic implants such as irritation and damage of 
soft tissue and disturbance of joint movement [Waris et al., 2004]. The use of 
biodegradable polymers in orthopaedics is also favourable as it eliminates the 
problems of stress shielding associated with metal implants. Studies have shown 
that the stress shielding effect associated with metallic implants results in a 
Chapter 1 
 68 
weak, thin bone and an increase risk of fracture in mandible. Bone resorption is 
also reported in the cases of condylar fractures treated with metallic implants 
[Kennady et al., 1989; Iizuka et al., 1991]. 
 
Figure 1.23: Pins, rods , screws and plates made of SR-PLLA [from Waris et al., 2004]. 
 
In the early 1970s, Kulkarni et al. [1971] successfully used polylactic acid pins 
for the treatment of mandibular fractures in dogs and 2mm thick polylactic acid 
films for the treatment of orbital floor fractures in monkeys. The results showed 
that the pins were completely degraded by 8 months and the healing was 
comparable to the controls where stainless steel pins were used. In an in vivo 
study PLLA pins implanted in the femur of the rats were shown to have 
osteostimulatory effect around their borders and did not produce a noticeable 
inflammatory response [Nordstrom et al., 1998].  
In a clinical study self reinforced poly-L-lactide (SR-PLLA) screws were used for 
the fixation of subtalar extraarticular arthrodesis in children and the results 
showed that the cases treated with SR-PLLA screws had good fusion without any 
adverse response and that the screws maintained their strength for an adequate 
period [Partio et al., 1992]. Pihlajamaki et al. [1997] treated patients with 
displaced malleolar fractures by internal fixation using absorbable PLLA plugs 
and used magnetic resonance imaging (MRI) for postoperative assessment. The 
study showed that PLLA implants were visible in MRI and the implants did not 
produce any adverse response.  
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The use of biodegradable devices in craniofacial surgery was of great interest in 
the 1990s and extensive research is still being done to optimise the properties of 
such devices and maximise their use in order to avoid the risks and problems 
associated with metallic implants, especially in paediatric craniofacial surgery 
[Ashammakhi et al., 2001]. Moe et al. [2001] reported a study in which PLA 
implants were used for facial cosmetic and head and neck reconstructive 
surgery. PLA implants produced comparable results to metal implants with the 
advantages of ease of contouring the implants, less operative time and soft 
tissue reaction. In a clinical study a copolymer made of 82% L-lactide acid and 
18% glycolic acid was used for the treatment of zygomatic fracture in 65 
patients. The results showed good results for fracture fixation and there were no 
long term side effects associated with the degradation process of the polymers 
[Enislidis et al., 2005]. In another clinical study 80 patients with maxillary and 
mandibular fracture and reconstruction cases were treated with poly (L-lactide-
co-glycolide) (PLGA) copolymer or poly (L-lactide- co-DL-lactide) implants. Only 
6 % of the patients showed foreign body reactions, which was successfully 
controlled by conservative treatment and local curettage. All the devices were 
degraded within 24 months of implantation [Landes et al., 2006]. 
Another clinical area where, although poly-L-lactic acid (PLLA) does not come in 
direct contact with the bone, is its use for the treatment of facial asymmetry. 
When implanted in soft tissue PLA causes a foreign body reaction which results 
in fibrosis and collagen formation. This effect of PLLA is utilized for the 
treatment of facial asymmetry. In different studies the treatment has produced 
long lasting changes in dermal thickness which resulted in improved facial 
symmetry and appearance in patients. The treatment was well tolerated and the 
only adverse effect reported were non-bothersome subcutaneous papules 
[Barton et al., 2006; Burgess, 2008].   
PLA or copolymers of PLA and PGA have been used and are commercially 
available as periodontal tissue regeneration membranes with varying success. In 
a clinical study 11 patients were treated with PLA membranes (Atrisorb® Free 
FlowTM) in combination with bovine bone mineral (BBM) for intrabony defects. 
The results showed that the use of PLA-BBM produced a reduction of probing 
depth of 4.72 mm and a gain clinical attachment level of 3.71 mm in the 
patients which was better than in the patients which were treated with access 
Chapter 1 
 70 
flap procedures which showed a reduction of 2.50 mm in the probing depth and 
a clinical attachment level gain of 2.43 mm [Ioannis et al., 2004].   
In another clinical study, patients with Class II furcation defects in lower molars 
were treated with a polylactic acid membrane (Atrisorb). The results at the end 
of six weeks did not show significant difference in relative vertical clinical 
attachment level and relative horizontal clinical attachment level among the 
patients treated with Atrisorb or open flap debridement (control). However 
significant difference was found among the patients in probing depth reduction 
[Bremm et al., 2004].  
Park et al. [1997] produced PLA membranes for guided tissue regeneration with 
the ability of controlled drug delivery and tested it in vitro. Lee et al. [2001b] 
reported the fabrication of PDGF loaded PLA-TCP membrane for GTR and have 
shown that these PLA-TCP membranes loaded with PDGF produced more bone 
formation when tested in rabbits.   
With the advantages of PLA there are also some drawbacks which are associated 
with PLA, the most important being mechanical weakness and aseptic swellings 
due to accumulation of their acidic degradation products. However, this was 
mainly seen with the early implants where the method of manufacture leads to a 
high molecular weight outer layer which degraded more slowly than the core. 
After about two years the outer layer degraded enough to release the acidic 
central core degradation products producing a sudden release and consequently 
“sterile sinus” or inflammatory response. Other potential hazards, although not 
very common, associated with the use of biodegradable implants are toxicity, 
mutagenicity and infection [Bostman and Pihlajamaki, 2000].  
The formation of sterile sinuses is more likely with crystalline poly (L-lactide) 
than amorphous poly (D-lactide) due to the formation of highly crystalline 
debris, however fast degradation rate of amorphous (D-lactide) can also be a 
cause of swelling as the low pH produced can cause inflammatory tissue 
reactions. Clinical use of amorphous polylactides can be more favourable than 
crystalline polylactides where mechanical strength is not a requirement 
[Tegnander et al., 1994; Ignatius et al., 2001; Ishii et al., 2003; Maquet et al., 
2003]. In a clinical study by Bergsma et al. [1995], zygomatic bone fractures 
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were treated with high molecular weight poly lactic acid (PLLA) bone plates and 
screws. After three years of implantation swelling was reported at the 
implantation site which may be due to accumulation of degradation product and 
increase in osmotic pressure due to the degradation fragments. In vitro studies 
showed that amorphous PDLLA does not produce crystalline remnants on 
degradation [Heidemann et al., 2001].  
A survey showed that only 1 out of 491 patients (0.2 %) treated with polylactic 
acid implants showed foreign body reaction and in other studies the reaction to 
poly lactic acid implants was also found to be lower than to polyglycolic acid 
implants [Bostman and Pihlajamaki, 2000]. No adverse response was observed in 
many clinical studies where polylactic acid implants were used [Partio et al., 
1992; Pihlajamaki et al., 1997].   
Optimised combinations of mechanical properties and degradation rates can be 
achieved by using appropriate ratios of D and L enantiomer, implant size, use of 
polymer as composite with ceramics or self reinforcement. The addition of 
ceramics such as HA and TCP can enhance the bioactivity and can improve the 
biological properties and mechanical properties of PLA [Rokkanen et al., 2000b; 
Kim et al., 2006; Jeong et al., 2008]. 
1.6.2 Bioactive calcium phosphate ceramics 
Calcium phosphates (Ca P) have been used extensively in the field of 
biomaterials. Calcium phosphates of various kinds having different Ca/P ratio 
ranging from 0.5 to 2.0 can be synthesized by mixing calcium and phosphate 
solutions. However, the two calcium phosphates of major interest and which are 
widely used in biomaterials are HA and TCP. HA has a Ca/P ratio of 1.67 and its 
chemical formula is Ca10(PO4)6(OH)2. The Ca/P ratio of TCP is 1.50 and its 
chemical formula is Ca3(PO4)2.  
HA is a major component of bones and teeth and is one of the most important 
and widely used ceramic in biomaterials and tissue engineering due to its 
chemical and physical similarity to natural bone [Rossa, 1991; Kurashina et al., 
1995]. In bones HA is present in the form of nanocrystals having dimensions of 
the order of 4 Χ 20 Χ 50 nm. Synthetic and natural HA are not identical but have 
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chemical and crystallographical similarities [Damien and Parsons, 1991]. Ca/P 
ratio of natural HA is less than the 1.67 Ca/P ratio of synthetic HA. HA present in 
the bones is not stoichiometric whereas synthetic HA is mostly stoichiometric 
[LeGeros et al., 1988; Murugan and Ramakrishna, 2005]. HA and TCP are 
considered bioactive, osteoconductive and non-immunogenic which makes them 
a material of choice for biomaterial applications [Frame, 1987; Damien and 
Parsons, 1991; Murugan and Ramakrishna, 2005]. General physiochemical, 
biological and mechanical properties of synthetic HA and TCP are listed in Table 
1.5. 
Table 1.5: General properties of HA [from Kitsugi et al., 1987; LeGeros, 1993; Larry, 1998; 
Murugan and Ramakrishna, 2005] 
                                                            HA                                TCP 
Chemical composition                           Ca10(PO4)6(OH)2            Ca3(PO4)2 
Ca/P molar ratio                                   1.67                            1.50 
Crystal system                                       Hexagonal 
Young_s modulus (GPa)                          80–110 
Compressive strength (MPa)                   400–900 
Bending strength (MPa)                          115–200 
Density (Mgm-3)                                      3.16                           3.07  
Fracture toughness (MPa m1/2)                0.7–1.2 
Hardness (HV)                                        600 
Decomposition temperature (°C)            >1000 
Melting point (°C)                                  1614 
Thermal conductivity (Wcm-1 K-1)            0.013 
Biocompatibility                                     High                           
Bioactivity                                              High                          High 
Biodegradation                                       Low                           High 
Cellular-compatibility                             High                           
Osteoinduction                                       Nil                             Nil 
Osteoconduction                                     High                          High 
 
Ceramics like HA and TCP degrade to varying degrees, the degradation tendency 
of HA and TCP depends on various factors which include synthesis method, 
crystallographic structure, particle size and site of implantation [Frame, 1987].  
Biodegradation or bioresorbtion of ceramics is characterized by mechanical 
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strength loss, porosity changes, dissolution, formation of other CaP phases and 
transformation of these phases on the surface of the ceramic [LeGeros et al., 
1988]. It is assumed that there are two mechanisms of ceramic bioresorption: 
the first mechanism involves dissolution of the ceramic implant by physiological 
solutions and second mechanism involves cell mediated processes such as 
phagocytosis, which result in the reduction of pH which increases the dissolution 
of the ceramic. In addition to these two mechanism physical abrasion, fracture 
and disintegration also contribute to the ceramic resorbtion [Jarcho, 1981; 
LeGeros et al., 1988]. Resorption of HA and TCP is affected by the site of 
implantation. The close proximity of implants to the cell systems, particularly 
osteoblasts and osteoclasts, plays an important role in the degradation of the 
implant. Studies have shown that the HA implanted in bone resorbs faster than 
implants implanted subcutaneously [Dubok, 2000]. Porosity of HA also play an 
important role in the degradation, more porous implants have higher 
degradation rate [Klein et al., 1983]. Factors which affect the biodegradation of 
HA and TCP are [LeGeros et al., 1988]: 
• Porosity 
• Crystal size 
• Crystal imperfections 
• Grain size 
• pH level at the implantation site 
• Implantation site 
• Degree of bone contact      
 
 
The size and shape of bioceramic particles is important for their application. 
Small particles and more uniform shape adjust better in a defect area than the 
particles with irregular shapes which also create large voids. HA with small 
particles have higher strength and lower porosity, as they have more contact 
points than larger particles [Ginebra et al., 2004]. Particles with nanosize and 
nanostructure provide a large surface area for adhesion which increases the 
interaction of particles with the surrounding environment [Ginebra et al., 2004].  
Compared to micro HA, nano-HA promotes increased osteoblast adhesion, 
enhanced cell differentiation, proliferation and deposition of calcium containing 
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minerals by osteoblasts which can result in increased formation of new bone 
tissue [Webster et al., 2000]. 
1.6.2.1 Synthesis of Hydroxyapatite (HA) 
HA powders having different morphology, stoichiometry and level of crystallinity 
can be produced by using different preparation techniques [Suchanek et al., 
2002]. It is important to produce HA with controlled stoichiometry, crystal size, 
shape and agglomeration characteristics. All these factors play an important role 
in determining dissolution, bioactivity and mechanical properties of HA [Mostafa, 
2005]. The different methods employed for the preparation of HA include a dry 
method, a wet-chemical method, a mechano-chemical hydrothermal method, a 
mechano-chemical method, spray pyrolysis, emulsion processing and microwave 
assisted synthesis [Feng et al., 2005; Murugan and Ramakrishna, 2005].  Some of 
the commonly used methods are described below: 
• Wet-Chemical Method 
o Precipitation 
Precipitation is the common method for the synthesis of HA. It involves a wet 
chemical reaction between calcium and phosphate precursors under controlled 
pH and temperature. Nano size crystals having shapes of plates, needles and 
rods can be prepared, crystallinity and Ca/P of the particles depend on the 
preparation conditions and are mostly lower than from well-crystallised 
stoichiometric HA [Suchanek et al., 2002]. This process involves a reaction 
between ammonium phosphate and calcium nitrate at 60°C and pH is maintained 
between 9 and 10 [Bezzi et al., 2003]. The precipitate after aging and drying is 
calcined at 400 °C to 600 °C and then sintered between 1000 °C and 1200 °C. 
This process however has some disadvantages such as it is important to maintain 
the pH value above 9, as reduction in the pH below 9 leads to formation of Ca 
deficient HA and the subsequent formation of tricalcium phosphate due to the 
decomposition of hydroxyapatite as a result of sintering at high temperature 
[Jillavenkatesa and Condrate, 1998].   
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o Sol-gel 
Highly pure HA powder can be produced by sol-gel method as it provides strict 
control on the process parameters. This process does not require maintenance of 
high pH values and high sintering temperatures unlike the precipitation 
technique [Feng et al., 2005]. Improved chemical homogeneity can be achieved 
by molecular mixing of calcium and phosphorous. High reactivity of the sol-gel 
powder results in the reduction of the processing temperature and degradation 
during sintering [Bezzi et al., 2003]. However possible hydrolysis of phosphates 
and expensive raw materials are two of drawbacks of this technique [Livage et 
al., 1992].  A variant of the sol gel method was developed by Deptula et al. 
[1992] in which repetitive emulsification of calcium acetate and phosphoric acid 
mixture followed by solidification by water extraction produces hydroxyapatite 
spheres. Calcination of these spheres produces HA particles. 
Jillavenkatesa and Condrate [1998] also synthesized HA by the sol-gel method 
using relatively inexpensive calcium acetate and triethyl phosphate as 
precursors. This process also overcomes the difficulties associated with the slow 
hydrolysis of phosphate as the gel formed during the process is colloidal. 
Feng et al. [2005] reported a simple sol gel method which eliminates the 
requirements of controlling pH value, vigorous stirring and long time for 
phosphate hydrolysis associated with conventional sol gel method. In the process 
the sintering temperature and aging time determine the crystallinity and 
morphology of the resulting HA powder.  A flow chart of their process which 
produced 10-15 nm diameters HA powder is shown in Figure 1.24.  
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Figure 1.24: Synthesis of HA by a sol gel method reported by Feng et al. [2005] 
 
o Hydrothermal 
Highly crystalline and pure HA can be obtained from this process. This process 
involves application of high temperatures to aqueous solutions which facilitate 
the precipitation of crystals of larger dimensions than obtained from ordinary 
wet methods. Crystals size in the range of nanometers to millimeters can be 
obtained [Narasaraju and Phebe, 1996].  
Mixing 
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o Hydrolysis 
Micron size HA particles of needle or blade shape can be obtained by hydrolysis 
of tricalcium phosphate, monetite, brushite and octacalcium phosphate at low 
temperature. However the calcium phosphate produced by this process is mostly 
nonstoichiometric HA [Suchanek et al., 2002]. 
• Mechanochemical Method 
Mechanochemical synthesis describes a solid state method in which 
thermodynamic and kinetic reaction between solids is enhanced by pressure 
applied perturbation of surface bonded species [Suchanek et al., 2002]. This 
method of ceramic powder synthesis can be used in the industrial production of 
HA due to its simplicity and low cost.  The mechanochemical method is different 
from mechanochemical hydrothermal method as it only involves solid-state 
reaction whereas the latter process also involves an aqueous phase. Simple 
equipment such as ball mills and vibratory mills are used for mechanochemical 
synthesis. In mechanochemical synthesis the overall temperature stays close to 
room temperature whereas local zones of high pressures and temperatures (up 
to 450-700°C) are produced due to friction of slurries and adiabatic heating of 
gas bubbles [Suchanek et al., 2002].   
 
• Mechanochemical Hydrothermal Method 
The mechanochemical hydrothermal method is at the intersection of 
hydrothermal and mechanochemical processes. It incorporates an aqueous phase 
which accelerates the kinetic processes. The water participates actively in the 
processes by dissolving the reactant powders and serving as a reaction medium 
which produces highly crystalline and stoichiometric powder [Shuk et al., 2001]. 
Like the mechanochemical method this process can also be used to produce 
large quantities of HA as it requires simple equipment and is processed at room 
temperature, unlike hydrothermal method which requires high temperature. HA 
produced by mechanochemical hydrothermal method has better densification, 
uniform microstructure and mechanical properties as compared to HA produced 
by wet chemical precipitation method [Mostafa, 2005].  
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• Solid-state reaction 
Stoichiometric and well crystallized HA can be produced by solid-state reactions, 
however these reactions involve high temperatures and long duration of heat 
treatment [Lin et al., 2007].  
• Emulsion Processing 
Well crystallized and pure nano HA can be synthesized by this process, the 
morphology and size of the particles strongly depends on the reaction 
temperature [Furuzono et al., 2001].  Water in oil emulsion method can be used 
to prevent the flocculation of HA particles during the synthesis as small micro or 
nano sized water spheres act like miniature reactors which prevent particle 
flocculation and limit particles growth [Phillips et al., 2003].  
• Microwave Irradiation 
Microwave irradiation has been developed to eliminate the long sintering, time-
consuming and tedious processes associated with synthesis of HA. It involves 
performing the precipitation method of producing HA but microwave energy is 
applied to accelerate the synthesis. This process has been shown to enhance the 
production of seed crystals of hydroxyapatite [Lerner et al., 1991]. Using 
microwave technique it is possible to obtain HA much faster than conventional 
methods [Teoreanu et al., 2008; Arami et al., 2009]. Siddharthan et al. [2004] 
successfully synthesized nanosized calcium deficient HA rapidly by microwave 
irradiation whilst reacting calcium nitrate hydrate and phosphoric acid. In 
another study HA nano-rods having a diameter from 60 to 80 nm and lengths of 
about 400 nm were prepared by a one-step microwave-assisted solid-state 
reaction at room temperature in much less time than using conventional heating 
[Cao et al., 2005].  
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1.6.2.2 Biomedical applications of HA 
Owing to its biocompatibility, osteoconductivity and bioactivity HA is used in a 
wide of range of biomedical applications [Dubok, 2000]. Biomedical applications 
of HA include repair of alveolar bones through to long bones defects and 
fractures, middle ear prostheses, eye implants, spinal fusion, vertebral fusions, 
cranioplasty, craniofacial repairs, in dental restorative materials, drug and 
growth factor delivery [Damien and Parsons, 1991; Paul and Sharma, 2003; 
Murugan and Ramakrishna, 2005]. Particle size plays a key role in modifying the 
properties of HA. It is a useful parameter in order to adjust the behavior of the 
material to the specific clinical applications. The bioactivity of nanosize HA is 
higher than coarser crystals and it provides a formulation with improved 
osseointegration for use in orthopedic and dental implants [Han et al., 2004]. 
The first use of synthetic HA for treatment of bone defects was reported by Ray 
and Ward [1951] when they successfully synthesed and implanted HA in the short 
bones of cats and monkeys and long bones in dogs with positive outcomes. HA 
does not have the capacity to induce bone, however it is osteoconductive and 
provides a physical matrix which is suitable for deposition of new bone and 
allows bone growth. It is believed that the new bone formed bonds directly onto 
the implanted HA without any intermediate fibrous layer, this property is 
particularly important when used as bone graft substitute [Frame, 1987; Damien 
and Parsons, 1991]. Implantation of HA in the body is followed by an 
inflammatory process in which macrophages invade the implantation site and 
attack the surface of the HA in addition to clearing the area of dead cells and 
debris. This results in formation of a chemical apatite layer on the rough HA 
surfaces which is similar to biological apatite. Migrated osteoblasts then produce 
an osteoid layer in the surface of HA which is followed by mineralisation [Kitsugi 
et al., 1987]. 
Due to its high biocompatibility, sufficient mechanical strength and ease of use, 
HA is considered to be an ideal material for the augmentation of alveolar ridges 
[Dubok, 2000]. Treatment of alveolar bone defects such as defects created by 
periodontal diseases and surgical bone defects can be achieved by packing 
porous or dense hydroxyapatite granules in the defect area. For more than two 
decades HA has been successfully used for periodontal defect restoration and 
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correction of alveolar ridge defects. Figure 1.25 shows HA blocks and HA 
particles deposited by a syringe used for ridge augmentation. The use of HA 
eliminates the drawbacks associated with use of autologus and autogenous bone 
grafts for the treatment of these defects as discussed in section 1.4.3.1 
[Rothstein et al., 1984].  
 
 
 
 
 
Figure 1.25: Hydroxyapatite blocks and particles deposited by syringe for alveolar ridge 
augmentation [adapted from Frame, 1987]  
 
Kent et al. [1986] used HA and HA /autogenous bone grafts for alveolar ridge 
augmentations in more than 200 patients and followed the cases for five years. 
They found that all the cases either treated with HA alone or in combination 
with autogenous bone showed good alveolar ridge regeneration.  In another 
study 110 patients with deficient alveolar ridges were treated with HA implants 
and followed for 33 months, all the cases showed improvement in the height, 
bulk, contour of the ridges without any major complications associated with the 
implants [Rothstein et al., 1984].  
1.6.2.3 Use of hydroxyapatite for drug release 
HA is considered to have the ability to act as a drug carrier and attempts have 
been made to exploit HA constructs for the delivery of growth factors and drugs 
[Paul and Sharma, 2003]. In an in vitro study enhanced proliferation and 
differentiation of human osteoblasts was observed when these were exposed to 
growth factors delivered by HA [Zambonin et al., 2000; Matsumoto et al., 
2004b]. Ono et al. [1998] loaded porous HA rods (5 mm diameter, 10 mm length) 
with 1µg or 5µg rhBMP-2 and implanted them into the cranial bones of rabbits. 
They found that adding rhBMP-2 to the HA rods increased the bone formation. 
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The bone formation was higher with the higher dose of rhBMP-2. Adding rBMP-2 
to HA rods also increased the strength of the rods in the initial stages of 
implantation. Porous blocks of HA have also been tested for sustained release of 
anticancer drugs in a rat model. The results showed a slow release profile of the 
drug sustained for 3 months which was more effective in inhibiting tumour 
growth than when administered intraperitoneally [Uchida et al., 1992].  
Sustained and slow release of antibiotics from porous blocks of HA was evaluated 
by Shinto et al. [1992]. Gentamicin sulphate was placed in cylindrical cavity of 
HA blocks and implanted in rats. The release of gentamicin sulphate into the 
bone of rats was slow after maximum release within first week and sustained 
even at 12 weeks after implantation. In addition the antibacterial activity of the 
drug was not affected by the addition to HA.   
1.6.3 Hydroxyapatite-polylactic acid composite 
Drawbacks associated with degradable polymers such as low mechanical 
properties and unpredictable degradation pattern can be improved by combining 
them with other biomaterials and using them as a composite material [Huang et 
al., 2008]. The addition of stiff filler will increase the stiffness and may increase 
the strength of a polymer. In bone contacting applications calcium phosphates 
are commonly used. ß-tricalcium phosphate added to PLA was shown to slow the 
degradation rate of the polymer [Nazhat et al., 2001; Niemelä, 2005]. 
The use of ceramics such as HA in PLA, may confer a number of potential 
therapeutic advantages, including increasing mechanical properties, promoting 
cell attachment and osteoconduction, and the potential for use as a vehicle for 
slow delivery of bioactive proteins such as growth factors. HA may also provide 
mechanical reinforcement for the PLA, improving its stiffness and strength [Sui 
et al., 2007] which can enable it to maintain its shape during functional 
pressures in situ. Bleach et al. [2001] showed that adding HA increases the 
flexural modulus and yield strength of polymer composites. HA has regularly 
been proposed as a potential synthetic graft material with osteoconductive 
properties [Bonfield et al., 1981; Wang et al., 2003; Liao et al., 2005]. HA-
containing composite membrane materials may increase osteoconductivity over 
PLA or other resorbable membrane materials as cell attachment to the mineral 
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will be dependent on protein absorption to the surface of the material. HA–PLA 
composite materials have been shown to be biocompatible, resorbable with good 
mechanical properties [Shikinami and Okuno, 1999].  HA-PLA composites have 
been proposed as a substitute for autologus bone powder [Ignjatovic et al., 
2001].  
In addition to other properties, HA also has the ability to both adsorb and 
release protein; protein adsorption increases with the increase in the surface 
area of HA [Matsumoto et al., 2004a; Nakamura et al., 2006].  A number of 
mineral-based carriers have been used experimentally for controlled release of 
growth factors in tissue regeneration experiments; for example collagen-
hydroxyapatite microspheres have been successfully used as a carrier of bone 
morphogenic proteins (BMPs) for bone regeneration [Wang et al., 2003]. 
1.7 SUMMARY AND AIMS OF THESIS 
Although GTR procedures are widely used for periodontal regeneration, their 
outcomes remain clinically modest on many occasions. There is thus the need to 
develop new ways of improving clinical outcomes. Currently used membranes for 
GTR are often limited by their relatively poor mechanical properties resulting in 
poor space maintenance during healing.  In addition there is considerable 
research into the possible application of growth factors to wounds to improve 
the outcome of existing regenerative procedures.   
One possible approach to address these issues is to consider using a resorbable 
composite material made from a PLA-HA composite. This material may be able 
to address issues of mechanical properties, whilst improving osteoconductivity 
and the possibility of using as an adjunctive delivery system for growth factors 
to promote regeneration further. 
Thus the aims of these studies are to develop a degradable composite membrane 
for guided tissue regeneration and to investigate the physical, mechanical and 
biological properties of these membranes. Specific objective includes:   
1). To develop a membrane with good mechanical properties which can maintain 
a space for periodontal regeneration without collapsing under occlusal pressure. 
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2). To investigate the possibility of incorporating growth factors in the 
membrane for their controlled release at the wound site to enhance tissue 
regeneration. 
3). And to determine a membrane shape and size which can be can be used in 
most clinical situations/sites by analysing different bone resorption patterns.    
 CHAPTER 2: CHARACTERISATION OF CALCIUM 
PHOSPHATE POWDERS, POLYLACTIC ACID AND 
POLYLACTIC ACID-CALCIUM PHOSPHATE FILMS 
  
2.1 INTRODUCTION 
Calcium phosphates (Ca P) such as hydroxyapatite (HA) and tricalcium phosphate 
(TCP) have been extensively used as bone substitutes and in dental applications 
as their chemical composition closely resembles the mineral phase of bone and 
teeth [Soriano, 2000]. The drawbacks associated with Ca P such as brittleness, 
low impact resistance and low tensile strength limit their scope however these 
can be overcome by combining them with polymers such as PLA. The 
combination of Ca P and PLA enables easy fabrication of devices with good 
mechanical and biological properties [Sui et al., 2007; Jeong et al., 2008].   
Polylactic acid (PLA) is a degradable polymer which has been used in many 
biomedical applications and is still a subject of extensive research to expand its 
use due to its biodegradability. With the advantages of PLA there are also some 
drawbacks, the most important being variable degradation rate in early devices 
and aseptic swellings due to accumulation and burst release of acidic 
degradation products.  
The use of Ca P within PLA may confer a number of potential therapeutic 
advantages on this material, including increased mechanical properties, 
promotion of cell attachment and osteoconduction, and the potential for use as 
a vehicle for slow delivery of bioactive proteins such as growth factors. HA may 
also provide mechanical reinforcement for the PLA, thus improving its stiffness 
and strength.  [Sui et al., 2007; Jeong et al., 2008]  
In this study the fabrication of PLA-Ca P composite films and their 
characterisation is reported.    
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2.2 MATERIALS 
2.2.1 Polylactic acid (PLA) 
PLA with an L: DL ratio of 70/30 and an IV of ~ 3.0 dl/gr (MW 500,000-600,000) 
was obtained from PURAC Biochem, The Netherlands. It was supplied in the form 
of granules.  
2.2.2 Nano-hydroxyapatite (nHA) 
nHA with mean particle size less than 200nm was purchased from Sigma-Aldrich, 
UK. 
2.2.3 Micro-hydroxyapatite 
Two different types of micron size hydroxyapatite (HA) powders were used in 
the study. First, was spray dried HA (rHA) and the second was sintered HA (sHA), 
both having average particle size of 3.80 and 4.46 µm respectively, but with a 
factor of over 13 difference in the specific surface areas. Both the powders were 
purchased from Plasma Biotal Limited, UK. These two powders have been 
characterized previously by Zhang and Tanner [2008] and the particle size 
distribution and specific surface area are given in table 2.1.  
Table 2.1: Physical properties of rHA and sHA [from Zhang and Tanner, 2008] 
 
 
 
Powder 
 
 
Particle size (µm)            Specific surface 
d0.1      d0.5     d0.9             Area (m
2
 g
-1
)  
  
rHA 
 
sHA 
0.99    3.80    6.23              13.54 
 
0.76    4.46   11.12              0.97 
 
    
2.2.4 Beta tricalcium phosphate (ßTCP) 
ßTCP was purchased from Plasma Biotal Limited, UK. The average particle size 
was 4µm.   
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2.3 METHODS  
2.3.1 PLA and PLA-Ca P composite film fabrication 
PLA and PLA-Ca P composite films were produced by a solvent casting method. 
To produce the PLA films 25 ml of chloroform was poured into spherical flasks 
and 0.5 g of PLA was added while stirring. The solution was then left on the 
stirrer for 24 hrs at room temperature. After 24 hrs of stirring the solution was 
spread in glass Petri dishes and then left overnight to allow slow evaporation of 
the chloroform. The same size of Petri dishes was used for all the films to get 
films of the same thickness.  
For the production of PLA-Ca P composite films Ca P powders were added to the 
PLA solution dissolved in chloroform after 24 hrs of stirring in the required 
concentration to give 10, 40 and 70 weight % after the evaporation of the 
chloroform, while the same amount of PLA was used for each film. These weight 
contents are equivalent to 4.2, 20.9 and 48.0 volume % of HA using 1.250 Mgm-3 
and 3.156 Mgm-3 for the densities of PLA and HA respectively and are equivalent 
to 4.3, 21.4 and 48.7 volume % of TCP using 3.07 Mgm-3 density for TCP. PLA-Ca 
P solutions were then stirred for a further 48 hrs. The solution was spread in 
120mm glass Petri dishes which were covered to allow slow evaporation of 
chloroform. After evaporation of the chloroform, the films were peeled off the 
dishes and placed in a vacuum oven for one day. The films were then annealed 
by being pressed between the bases of two glass Petri dishes and were placed in 
the oven at 70 ◦C for one hour. The films were then allowed to cool gradually 
overnight. The heat treatment was done to relax any stresses produced in the 
films during the casting process and to prevent curling up of the films during the 
experiments. 
2.3.2 Scanning Electron Microscopy (SEM) 
The morphology and particle size of the Ca P powders and the morphology of the 
films were characterised by SEM (FEI Inspect F, EFI Company, The Netherlands) 
(Figure 2.1). For Ca P powders 20kV and for PLA and PLA-Ca P composite films 
5kV were used. All the samples were gold coated.  
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Figure 2.1: Scanning Electron Microscope. 
 
2.3.3 Transmission Electron Microscopy (TEM) 
High Resolution TEM (JEOL JEM 2010) (Figure 2.2) operated at 200 keV was used 
to analyse the morphology and particle size of the Ca P powders. Powders were 
ultrasonically dispersed in methanol and then collected on copper grids coated 
with carbon (Holey Carbon Film, 300 mesh Cu, Agar Scientific) to be analysed by 
TEM.  
 
 
Figure 2.2: Transmission Electron Microscope. 
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2.3.4 X- ray diffraction (XRD) 
XRD is a non-destructive analytical technique which enables the analysis of 
chemical composition and crystallographic structure of a material. 
Ca P powders were characterized using XRD, to find chemical composition, 
crystal state and the crystalline content. A Seimens/Bruker D5000 X-ray 
Diffractometer, with monochromatic Cu Ka radiation (k = 0.15418 nm) was used. 
Scans were obtained in the 2θ range = 20–60 and step size of 0.02° s-1.  
2.3.5 Fourier Transform Infra red spectroscopy (FTIR) 
FTIR is an analytical technique which measures the infrared radiation absorption 
by a material versus wavelength, the molecular structure of the material is 
characterised by the wavelength of the light absorbed which causes vibration of 
the molecules. FTIR is also useful for the quantitative analysis as the band 
intensities which appear in the spectrum due to vibration of molecules of a 
material are directly proportional to the concentration of that molecule [Vlachos 
et al., 2006].  
FTIR spectra of the Ca P powders and PLA and PLA-Ca P composite films were 
obtained by a Thermo-Electron Nicolet 8700 FTIR spectrometer. Dry helium gas 
was used to purge the sample chambers. The spectra were measured at 8cm-1 
resolution and a total of 256 scans were obtained. A background spectrum of a 
carbon sample was obtained before obtaining sample spectra.  
2.3.6 Raman Spectroscopy 
Nicolet Almega XR dispersive Raman spectrometer was used to obtain Raman 
spectra of the Ca P powders and films, spectra were collected by taking 256 
scans per sample and an exposure time of 2 sec was used at 8 cm-1 resolution. 
The spectra were collected between 4000-100cm-1. A background spectrum was 
obtained before obtaining sample spectra.    
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2.4 RESULTS 
2.4.1 Calcium phosphate powders 
2.4.1.1 SEM and TEM  
nHA powder 
The morphology and size of nHA particles are shown in SEM and TEM images in 
Figure 2.3. The images show that the particles are spherical in shape with 
approximate size of 20-200 nm although agglomerated. 
 
 
     
 
 
 
 
Figure 2.3: SEM images (a) lower magnification (scale bar= 5 µm) (b) higher magnification 
(scale bar= 1µm) and (c) TEM (scale bar= 100 nm) showing morphology and particle size of 
nHA.    
 
 
(a) (b) 
(c) 
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sHA powder 
The morphology and size of sHA particles are shown by SEM and TEM images in 
Figure 2.4. The images show that the particles have smooth surfaces and 
irregular shape with a mean particle size of approximately 4 µm. 
 
     
 
 
 
 
Figure 2.4: SEM images (a) lower magnification (scale bar= 5 µm) (b) higher magnification 
(scale bar= 1 µm) and (c) TEM (scale bar= 500 nm) showing morphology and particle size of 
sHA. 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c) 
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rHA powder 
SEM and TEM images showing the size and morphology of rHA particles are shown 
in Figure 2.5. The images show that the particles have rough surfaces with a 
mean particle size of approximately 4 µm and are agglomerates of needle-like 
small particles.   
 
     
 
 
 
 
Figure 2.5: SEM images (a) lower magnification (scale bar= 5 µm) (b) higher magnification 
(scale bar= 1 µm) and (c) TEM (scale bar= 50 nm) showing morphology and particle size of 
rHA. 
 
 
 
 
 
 
 
 
 
 
 
(b) (a) 
(c) 
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ßTCP powder 
The morphology and size of ß-TCP particles are shown by SEM and TEM images in 
Figure 2.6. The images show that the particles have smooth surfaces, irregular 
shapes and consist of multiple particles which are fused together. The particle 
size ranges from 4 to 20 µm.  
 
     
 
 
 
 
Figure 2.6: SEM images (a) lower magnification (scale bar= 5 µm) (b) higher magnification 
(scale bar= 1 µm) and (c) TEM (scale bar= 500 nm) showing morphology and particle size of 
ßTCP. 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c) 
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2.4.1.2 XRD 
Figure 2.7 shows the XRD patterns for (a) nHA, (b) sHA (c) rHA and (d) ßTCP. All 
three HAs show diffraction peaks at 31.8° (211), 32.2° (112) and 32.9° (300) 
which are characteristic of HA XRD pattern and confirm the purity of all three 
HAs, however the crystallinity of three HAs was significantly different. sHA 
showed narrow and intense peak followed by rHA, whereas XRD of nHA showed 
broad and less intense peaks. The XRD peaks for ßTCP show the characteristic 
pattern with strong diffraction peaks at 27.8°, 31.0° and 34.4°. 
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Figure 2.7: Comparative XRD pattern for (a) nHA (b) sHA (c) rHA and (d) ßTCP.  
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2.4.1.3 FTIR  
Figure 2.8 (a), (b), (c) and (d) show the FTIR spectra of nHA, sHA, rHA and ßTCP 
powders respectively. The spectra of all three HA powders show the typical 
peaks associated with HA. The peaks at 3571 and 631 cm-1 were assigned to the 
hydroxyl group (–OH), while the peaks at 1473 and 875 cm-1 were attributed to 
stretching mode of carbonate groups (CO3). The peaks at 1040, 946, 603 and 569 
cm-1 were assigned to phosphate groups (PO4) present in the HAs. Whereas the 
FTIR spectra of ßTCP show the characteristics phosphate peaks at 946, 603 and 
569 cm-1 and there were no peaks observed associated with OH or CO3.    
 
 
 
 
Figure 2.8: FTIR spectra of Ca P powders (a) nHA (b) sHA (c) rHA and (d) ßTCP.  
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2.4.1.4 Raman spectroscopy  
Figure 2.9 shows the Raman spectra of (a) nHA, (b) sHA, (c) rHA and (d) ßTCP 
powders. For the three HAs the main peak was observed at 960 cm -1 which is 
assigned to phosphate (PO4) stretching. The intensity of this peak was highest for 
sHA followed by rHA and nHA respectively and represents the crystallinity of HA.  
In addition a less intense peak, which is assigned to PO4 bending, was observed 
at 590 cm-1.  
 
 
 
 
Figure 2.9: Raman spectra of Ca P powders (a) nHA (b) sHA (c) rHA and (d) ßTCP 
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2.4.2 PLA and PLA- Ca P composite films 
2.4.2.1 SEM 
PLA film 
Figure 2.10 shows the SEM image of PLA films, the surface of the film appears 
very smooth. 
 
 
 
Figure 2.10: SEM image of PLA film. (Scale bar = 20 µm) 
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PLA-nHA composite films 
Figure 2.11 shows the images of PLA-nHA composite film containing (a) 10 wt % 
nHA (PLA-nHA10), (b) 40 wt % nHA (PLA-nHA40) and (c) 70 wt % nHA (PLA-
nHA70). PLA-nHA10 film appears relatively smooth and there was hardly any nHA 
present on the film surface and most of the nHA was covered by a layer of PLA. 
However as the nHA concentrations increased in PLA-nHA40 and PLA-nHA70 films 
the surfaces became rough and the films also had nHA present on the surfaces 
which was not covered by PLA. 
 
 
 
Figure 2.11: SEM images of (a) PLA-nHA10, (b) PLA-nHA40 and (c) PLA-nHA70 composite 
films. (Scale bar = 20 µm) 
   
 
 
(a) (b) 
(c) 
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PLA-sHA composite films 
Figure 2.12 shows the images of PLA-sHA composite film containing (a) 10 wt % 
sHA (PLA-sHA10), (b) 40 wt % sHA (PLA-sHA40) and (c) 70 wt % sHA (PLA-sHA70).  
The surfaces of all the films appeared rough, however most of the sHA present in 
the films appeared to be covered with PLA, except in PLA-sHA70 where some of 
the particles are visible partially out of the PLA layer. 
 
 
   
 
 
 
 
 
Figure 2.12: SEM images of (a) PLA-sHA10, (b) PLA-sHA40 and (c) PLA-sHA70 composite 
films. (Scale bar = 20 µm) 
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PLA-rHA composite films 
Figure 2.13 shows the images of PLA-rHA composite film containing (a) 10 wt % 
rHA (PLA-rHA10), (b) 40 wt % rHA (PLA-rHA40) and (c) 70 wt % rHA (PLA-rHA70). 
The surface of PLA-rHA10 was smoother than the surfaces of the PLA-rHA40 and 
PLA-rHA70 films. In addition the PLA-rHA40 and PLA-rHA70 films also showed 
some micropores.  
 
 
    
 
Figure 2.13: SEM images of (a) PLA-rHA10, (b) PLA-rHA40 and (c) PLA-rHA70 composite 
films. (Scale bar = 20 µm) 
 
 
 
(a) (b) 
(c) 
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PLA- ßTCP composite films 
Figure 2.14 shows the images of PLA-ßTCP composite film containing (a) 10 wt % 
ßTCP (PLA-ßTCP10), (b) 40 wt % ßTCP (PLA- ßTCP40) and (c) 70 wt % ßTCP (PLA-
ßTCP70). In PLA-ßTCP10 films the ßTCP appeared to be homogenously dispersed, 
whereas PLA-ßTCP40 and PLA-ßTCP70 films with higher concentrations of ßTCP 
showed some agglomeration of the particles.  
 
 
     
 
Figure 2.14: SEM images of (a) PLA-ßTCP 10, (b) PLA-ßTCP40 and (c) PLA-ßTCP70 
composite films. (Scale bar = 20 µm) 
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2.4.2.2 FTIR  
PLA film 
Figure 2.15 shows the characteristic PLA FTIR peaks. The peaks at 2995 and 2945 
cm-1 are assigned to C-H stretching of the methyl group (CH3). The intense peak 
at 1760 cm-1 was assigned to C=O (carbonyl) stretching, while the peaks at 
1130,1382 and 1453 cm-1 were assigned to C-H bending of CH3.   
 
 
 
 
 
Figure 2.15: FTIR spectrum of PLA. 
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PLA-nHA composite films 
Figure 2.16 shows the comparative FTIR spectra of (a) PLA, (b) nHA, (c) PLA-
nHA10, (d) PLA-nHA40 and (e) PLA-nHA70. The spectra of PLA-nHA10, PLA-nHA40 
and PLA-nHA70 composites films show the characteristic peaks of both HA and 
PLA. As the concentration of nHA increased the intensities of PO4 peaks at 603 
and 569 cm-1, which were attributed to phosphate from HA, increased relative to 
the intensities of PLA characteristic peaks at 1760, 870 and 756 cm-1.  
 
 
 
 
Figure 2.16: Comparative FTIR spectra of (a) PLA, (b) nHA, (c) PLA-nHA10, (d) PLA-nHA40 
and (e) PLA-nHA70. 
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PLA-sHA composite films 
Figure 2.17 shows the comparative FTIR spectra of (a) PLA, (b) sHA, (c) PLA-
sHA10, (d) PLA-sHA40 and (e) PLA-sHA70. The spectra of PLA-sHA10, PLA-sHA40 
and PLA-sHA70 composites films show the characteristic peaks of both HA and 
PLA. As the concentration of sHA increased the intensities of PO4 peaks at 603 
and 569 cm-1 which were attributed to phosphate from HA increased relative to 
the intensities of PLA characteristic peaks at 1760, 870 and 756 cm-1.  
 
 
 
 
 
Figure 2.17: Comparative FTIR spectra of (a) PLA, (b) sHA, (c) PLA-sHA10, (d) PLA-sHA40 
and (e) PLA-sHA70.  
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PLA-rHA composite films 
Figure 2.18 shows the comparative FTIR spectra of (a) PLA, (b) rHA, (c) PLA-
rHA10, (d) PLA-rHA40 and (e) PLA-rHA70. The spectra of PLA-rHA10, PLA-rHA40 
and PLA-rHA70 composites films show the characteristic peaks of both HA and 
PLA. As the concentration of rHA increased the intensities of PO4 peaks at 603 
and 569 cm-1, which were attributed to phosphate from HA, increased relative to 
the intensities of PLA characteristic peaks at 1760, 870 and 756 cm-1. 
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Figure 2.18: Comparative FTIR spectra of (a) PLA, (b) rHA, (c) PLA-rHA10, (d) PLA-rHA40 
and (e) PLA-rHA70. 
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PLA- ßTCP composite films 
Figure 2.19 shows the comparative FTIR spectra of (a) PLA, (b) ßTCP, (c) PLA- 
ßTCP10, (d) PLA-ßTCP40 and (e) PLA-ßTCP70. The spectra of PLA-ßTCP10, PLA- 
ßTCP40 and PLA-ßTCP70 composites films show the characteristic peaks of both 
HA and PLA. As the concentration of ßTCP increased the intensities of PO4 peaks 
at 603 and 569 cm-1, which were attributed to phosphate from HA, increased 
relative to the intensities of PLA characteristic peaks at 1760, 870 and 756 cm-1. 
 
 
 
 
 
Figure 2.19: Comparative FTIR spectra of (a) PLA, (b) ßTCP, (c) PLA-ßTCP10, (d) PLA-
ßTCP40 and (e) PLA-ßTCP70. 
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2.4.2.3 Raman spectroscopy  
PLA film 
Figure 2.20 shows the Raman spectra of PLA film. The spectra show 
characteristic peaks for PLA, the peak at 875 cm-1 is characteristic of carbon, 
carbonyl bond (C-COO) stretching. The peak at 1040 cm-1 corresponds to C-CH3 
stretching while the peak at 1766 cm-1 corresponds to C=O stretching. The peak 
at 1452 cm-1 corresponds to methyl group (CH3) symmetric bending and at 1315 
cm-1 to CH bending. 
 
 
Figure 2.20: Raman spectra of PLA film.  
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PLA-nHA composite films 
Figure 2.21 shows the comparative Raman spectra of (a) PLA, (b) nHA, (c) PLA-
nHA10, (d) PLA-nHA40 and (e) PLA-nHA70. The spectra of PLA-nHA10, PLA-nHA40 
and PLA-nHA70 composites films show the characteristic peaks of both HA and 
PLA. The PO4 peak corresponding to nHA is low in PLA-nHA10, however as the 
concentration of nHA increased in the films from 10 wt % to 70 wt % the PO4 
peak became more intense and its height relative to the C-COO (PLA) peak 
increased.  
 
 
 
 
Figure 2.21: Comparative Raman spectra of (a) PLA, (b) nHA, (c) PLA-nHA10, (d) PLA-nHA40 
and (e) PLA-nHA70.  
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PLA-sHA composite films 
Figure 2.22 shows the comparative Raman spectra of (a) PLA, (b) sHA, (c) PLA-
sHA10, (d) PLA-sHA40 and (e) PLA-sHA70. The spectra of PLA-sHA10, PLA-sHA40 
and PLA-sHA70 composites films show the characteristic peaks of both HA and 
PLA. The PO4 peak corresponding to sHA is low in PLA-sHA10, however as the 
concentration of sHA increased in the films from 10 wt % to 70 wt % the PO4 peak 
became more intense and its height relative to the C-COO (PLA) peak increased. 
 
 
 
Figure 2.22: Comparative Raman spectra of (a) PLA, (b) sHA, (c) PLA-sHA10, (d) PLA-sHA40 
and (e) PLA-sHA70. 
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PLA-rHA composite films 
Figure 2.23 shows the comparative Raman spectra of (a) PLA, (b) rHA, (c) PLA-
rHA10, (d) PLA-rHA40 and (e) PLA-rHA70. The spectra of PLA-rHA10, PLA-rHA40 
and PLA-rHA70 composite films show the characteristic peaks of both HA and 
PLA. The PO4 peak corresponding to sHA is low in PLA-rHA10, however as the 
concentration of rHA increased in the films from 10 wt % to 70 wt % the PO4 peak 
became more intense and its height relative to the C-COO (PLA) peak increased. 
 
 
 
 
Figure 2.23: Comparative Raman spectra of (a) PLA, (b) rHA, (c) PLA-rHA10, (d) PLA-rHA40 
and (e) PLA-rHA70. 
 
 
 
 
 
 
 
 
 
 
 
(e) 
(d) 
(c) 
(b) 
(a) 
C-COO 
875 cm-1 
 PO4  
960 cm
-1
 
Chapter 2 
 111 
PLA- ßTCP composite films 
Figure 2.24 shows the comparative Raman spectra of (a) PLA, (b) ßTCP, (c) PLA-
ßTCP10, (d) PLA-ßTCP40 and (e) PLA-ßTCP70. The spectra of PLA-ßTCP10, PLA-
ßTCP40 and PLA-ßTCP70 composites films show the characteristic peaks of both 
ßTCP and PLA. The PO4 peak corresponding to ßTCP is low in PLA- ßTCP10 
whereas the intensity of C-COO (PLA) peaks is high, however as the 
concentration of ßTCP increased in the films from 10 wt % to 70 wt % the PO4 
peak became more intense and its height relative to the C-COO (PLA) peak 
increased. 
 
 
 
Figure 2.24: Comparative Raman spectra of (a) PLA, (b) ßTCP, (c) PLA-ßTCP10, (d) PLA-
ßTCP40 and (e) PLA-ßTCP70. 
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2.5 DISCUSSION 
The use of composites in biomedical applications has attracted a huge interest 
over the last few decades as the properties of composites can be tailored to suit 
a specific application. Addition of a Ca P such as HA and TCP to the polymer 
improves its bioactivity, osteoconductivity and mechanical properties. 
Crystalline HA is stable and non soluble, but can be resorbed by osteoclasts, 
whereas TCP is soluble. The rate of dissolution of different Ca P decreases as 
follows [Niemelä, 2005; Velayudhan et al., 2005; Rezwan et al., 2006]: 
Amorphous HA > α – TCP > ß – TCP > crystalline HA. 
In this study PLA Ca P composite films containing nHA, sHA, rHA and TCP at 10, 
40 and 70 wt % concentrations were produced. The concentration, size and 
shape of the Ca P particles play an important role in determining the properties 
of the composite. It is reported that composites with higher HA contents have 
higher bioactivity and that nano size HA as compared to micro HA has shown to 
have better biological properties and promote attachment, proliferation and 
differentiation of cells [Di Silvio et al., 2002; Murugan and Ramakrishna, 2005; 
Sun et al., 2007].  The solvent casting technique used in this study enabled the 
production of films where HA or TCP particles were present on the surface 
without or with a thin coating of PLA with different degrees of surface 
roughness, this is beneficial as osteogenic cells or body fluid will make contact 
with the bioactive Ca P particles on implantation and it is also suggested that 
the cells adhesion and differentiation is more pronounced on rough surfaces [Ball 
et al., 2008].   
SEM and TEM images of the Ca P powders showed that the HAs and TCP had 
different shapes and sizes. Images showed that nHA was spherical in shape with 
size in the range between 20 to 200nm. sHA has irregular shapes with smooth 
surfaces and an average particle size of 4 µm. Images of rHA showed that 
although the average particle size was 4 µm, each particle consisted of 
agglomerate of small needle like particles and had a rough surface agreeing with 
observation of Zhang and Tanner [2008]. TCP particles were fused together and 
had irregular, but smooth surfaces.   
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XRD of HA powders showed the purity of these powders as all showed the major 
characteristics HA diffraction peaks corresponding to (211), (112) and (300) 
planes at 31.8°, 32.2° and 32.9° respectively and did not show a peak at 31.0° 
(0210) which confirms that there was no secondary TCP phase present [Huang et 
al., 2007]. The XRD pattern of nHA powder showed that its crystallinity was 
lower than the other two HAs used in the study as the nHA peaks were broader 
and less intense. Sintered sHA showed very intense and narrow peaks, indicative 
of high crystallinity as would be expected after sintering. The crystallinity of HA 
is dependent on the temperature at which it is synthesised, HAs which are 
synthesised at higher temperature have higher crystallinity. The crystallinity of 
HA in turn affects the solubility of HA, HA with lower crystallinity have higher 
solubility [Matsumoto et al., 2004a; Zhu et al., 2006]. The XRD pattern of ßTCP 
also showed its purity as it showed the characteristics peaks corresponding to 
(214), (0210) and (220) planes at 27.8°, 31.0° and 34.4° respectively and did not 
show any peak at 30.7°(034), which is attributed to α-TCP [dos Santos et al., 
2008].     
FTIR of all the three HAs used in the study showed the OH peaks at 3571 and 631 
cm-1, the peak at 3571 cm-1 is assigned to stretching mode (vs) while at 631 cm
-1 
is assigned to the librational mode (vL) of OH group. The peak at 1040 cm
-1 is 
assigned to P-O bond vibration of the PO4 while the peak at 960 cm
-1 is 
attributed to symmetric stretching of P-O bond of PO4. The peaks at 603 and 569 
cm-1 are assigned to bending mode of O-P-O bond of phosphate group [Rey et al., 
1991; Koutsopoulos, 2002]. The absence of OH group in the spectra of TCP can 
be used to establish the difference between HA and TCP [de Aza et al., 1997]. 
Raman spectra of HAs showed a characteristic very strong peak at 960 cm-1 which 
is assigned to the P-O bond symmetric stretching of PO4. Two peaks of medium 
intensities were also found at 590 and 450 cm-1 which are assigned to O-P-O 
bending mode of PO4 [de Aza et al., 1997; Koutsopoulos, 2002]. 
SEM images of PLA and PLA/Ca P composite films showed the surface texture of 
these films.  PLA films appeared smooth, whereas the composite films showed 
different degrees of surface roughness. Among the PLA-nHA films the films 
containing 10 wt % nHA appeared smooth as compared to films containing 40 and 
70 wt % nHA. Additionally the films containing 40 and 70 wt % nHA had more nHA 
present on the film surfaces, whereas in films containing 10 wt % nHA most of 
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the nHA was embedded within the PLA matrix. Similarly in PLA-sHA composite 
films the surface roughness of films which had 40 and 70 wt% sHA was more than 
films with 10 wt % sHA content. The difference of roughness among the films 
containing 40 and 70 wt% sHA was not very pronounced, this can be due to more 
particle agglomeration in films containing 70 wt % sHA which resulted in less 
spread of particles in the matrix. The same roughness pattern was observed in 
PLA-rHA films, however the PLA-rHA films surface appear rougher as compared 
to PLA-sHA films which can be attributed to rougher rHA particles used in PLA-
rHA films. With the greater specific surface area for the rHA more of the PLA 
will be involved. Among the PLA-TCP composite films, the films containing 10 wt 
% TCP had the most homogenous particle spread, while the films containing 40 
and 70 wt % TCP showed some agglomeration of powders on their surfaces.     
FTIR spectra of PLA-HA and PLA-TCP composite films showed the presence of 
characteristic PLA, TCP and HA peaks. The intensities of the peaks associated 
with PO4 at 1040, 603 and 569 cm
-1 increased with increase in the concentration 
of HA or TCP in the films from 10 to 70 wt %. This finding is in confirmation with 
the SEM images that more HA or TCP particles were present on the surfaces of 
the films containing higher concentrations of HA or TCP. 
Raman spectra for PLA show the characteristic peaks. The peak at 875 cm-1 is 
characteristic of carbon-carbonyl bond (C-COO) stretching, while the peak at 
1040 cm-1 corresponds to C-CH3 stretching and the peak at 1766 cm
-1 corresponds 
to C=O stretching. The peak at 1452 cm-1 corresponds to methyl group (CH3) 
symmetric bending and at 1315 cm-1 to CH bending. The Raman spectra of PLA-
HA and PLA-TCP composite films showed the characteristic strong peak PO4 peak 
at 960 cm-1 in addition to PLA characteristics peaks. As the concentration of HA 
increased in the films the ratio of PO4 peak also increased relative to PLA 
carbonyl bond (C-COO) peak at 875 cm-1. As the spectra of composite films show 
the presence of both PLA and HA peak, it suggests that no chemical reaction 
took place during the mixing and the mixing was physical.  
The presence of HA or TCP particles in higher quantities on the surface of the 
composite films may affect the biological and physical properties of the films. 
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2.6 CONCLUSIONS 
Ca P powders and PLA-Ca P composite films were analysed using SEM, TEM, XRD, 
FTIR and Raman. The powders had different sizes and shapes. XRD, FTIR and 
Raman of Ca P confirmed the purity of these powders. The surface roughness of 
the films were influenced by the concentration and type of the powder used. 
 CHAPTER 3: BIOACTIVITY OF POLYLACTIC ACID-
CALCIUM PHOSPHATE COMPOSITES 
  
3.1 INTRODUCTION 
Biodegradable polymers such as PLA are increasingly used in the treatment and 
fixation of skeletal defects due to their degradability in the body [Rokkanen et 
al., 2000a]. The advantages of using biodegradable polymers over non-
resorbable implants are that they do not need a second surgical procedure for 
their removal and stress shielding effects can also be avoided. However one 
drawback associated with most of these polymers is their lack of bioactivity. 
Calcium phosphates such as HA and TCP, because of their osteoconductive and 
osteoinductive properties, are extensively studied and are widely used in various 
dental and orthopaedic application as they can accelerate the healing of bone 
tissue [Xin et al., 2005]. 
By using PLA with HA or TCP in a composite, the biodegradability and bioactivity 
of these materials can be combined to produce a material with enhanced 
properties. The bioactivity of materials is usually analysed by the ability of 
bone-like apatite to form on these materials when soaked in simulated body 
fluid (SBF). Ion concentrations in SBF closely match those present in human 
blood plasma (Table 3.1) [Kokubo et al., 1990].   
Table 3.1: Comparison of ion concentrations in human blood plasma and SBF [adapted from 
Kokubo and Takadama, 2006].   
Ion concentrations (mM) 
                      Na
+
         K
+
       Mg
2+
      Ca
2+
      Cl
-   
       HCO
-
3      HPO
2
4
-
    SO4
2-
 
Blood plasma 
SBF 
  142.0          5.0          1.5             2.5          103.0          27.0              1.0            0.5   
  142.0          5.0          1.5             2.5          147.8          4.2                1.0            0.5   
 
The aim of this study is to investigate the bioactivity of PLA-HA and PLA-TCP 
composite films by assessing the ability of an apatite layer to form on their 
surface when immersed in SBF.  
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3.2 MATERIALS  
The materials used were PLA (PURAC Biochem, The Netherlands), nHA (Sigma- 
Aldrich, UK), sHA and rHA (Plasma Biotal Limited, UK) and TCP (Plasma Biotal 
Limited, UK) as described in detail in section 2.2.  
3.3 METHODS 
3.3.1 Preparation of Simulated Body Fluid 
Simulated body fluid (SBF) was prepared as described by [Kokubo and Takadama, 
2006] by dissolving reagents in deionised water. The reagents, their quantities 
and the order in which they were dissolved in the deionised water for the 
preparation of 1000 ml SBF are shown in Table 3.2. All the reagents were 
purchased from Sigma Aldrich, UK.  
Table 3.2:  Order, reagents and their quantities used for the preparation of 1000 ml SBF 
solution [ adapted from Kokubo and Takadama, 2006].   
Order Reagent Quantity 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
NaCl 
NaHCO3 
KCl 
K2HPO4.3H2O 
MgCl2.6H2O 
1.0M-HCl 
CaCl2 
Na2SO4 
Tris 
1.0M-HCl 
8.035g 
0.355g 
0.225g 
0.231g 
0.311g 
39ml 
0.292g 
0.072g 
6.118g 
0-5ml 
 
For the preparation of 1000ml SBF initially 700ml of deionised water was placed 
in a glass beaker with a stirring bar and was heated up to 36.5 + 1.5 °C on a 
magnetic stirrer. The reagents were dissolved in the water one by one at 36.5 + 
1.5 °C in the order of 1 to 8 as listed in Table 1. The next reagent was only 
added after the previous reagent was completely dissolved.  Before the addition 
of 9th and 10th reagent, the solution volume was adjusted to 900ml. After volume 
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adjustment Tris was added to the solution little by little to gradually raise the 
pH of the solution to 7.45+0.01. Addition of Tris was stopped once the pH of the 
solution reached 7.45+0.01, as a next step HCl was added to the solution to 
lower the pH to 7.42+0.01 taking care not to lower the pH below 7.40. Again, 
the remaining Tris was added until the pH of the solution reached 7.45+0.01. 
The procedure of alternate addition of Tris and HCl was repeated to maintain 
the pH between 7.42 and 7.45 until all the Tris had dissolved. Finally after 
dissolving the total Tris the pH of the solution was adjusted to 7.40 by adding a 
small amount of HCl at 36.5°C.  After cooling the solution to 20°C, deionised 
water was added to the solution to adjust the solution volume to 1000ml.     
3.3.2 Sample Preparation  
The films were prepared as described in section 2.3.1. The resultant films were 
then cut into 12 mm diameter discs and 5 samples for each time point and 
composite were used. The samples were sterilised by soaking in 70% ethanol for 
1 minute and then dried at 50°C. The samples were immersed into 20 ml SBF in 
polystyrene bottles for 1, 7, 14, 21 and 28 days at 37 °C.  The SBF in bottles was 
replaced by fresh SBF after 14 days. At given time points the samples were 
removed from the solution and rinsed with distilled water and dried at 50°C.  
3.3.3 Sample characterisation 
The samples were characterised by scanning electron microscopy (SEM) with 
energy dispersive spectroscopy (EDS) and Raman Spectroscopy. 
3.3.3.1 SEM  
The samples were carbon coated for SEM.  SEM images and EDS spectra were 
obtained by using FEI Inspect F, EFI Company, The Netherlands.  
3.3.3.2 Raman Spectroscopy 
Nicolet Almega XR dispersive Raman spectrometer was used to obtain Raman 
spectra of the samples, spectra were collected by taking 128 numbers of scans/ 
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sample and an exposure time of 2 sec was used at 8 cm-1 resolution. The spectra 
were collected between 4000-100cm-1.  
3.4 RESULTS 
3.4.1 SEM 
3.4.1.1 PLA 
SEM images of PLA samples at 1, 7, 14, 21 and 28 days after immersion in SBF 
are shown in Figure 3.1. There was no apatite formation observed on PLA films 
immersed in SBF, even after 28 days.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: SEM images of PLA at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF. (Scale bar=10 µm) 
 
(a) (b) 
(c) (d) 
(e) 
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EDS analysis of PLA samples in SBF are showed in Figure 3.2. The spectra showed 
C and O peaks corresponding to carbon and oxygen present in the polymer and 
there were no Ca or P peaks corresponding to an apatite layer. However, at 28th 
day of immersion in SBF the spectra of the PLA sample showed small Na and Cl 
peaks which are probably due to deposition of these elements from SBF. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: EDS spectra of PLA films at (a) 1, (b) 14 and (c) 28 days after immersion in SBF. 
 
(a) 
(c) 
(b) 
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3.4.1.2 PLA-nHA composite films 
Figures 3.3, 3.4 and 3.5 shows the SEM images of PLA-nHA10, PLA-nHA40 and 
PLA-nHA70 samples respectively at (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days 
after immersion in SBF. As the figure shows, there was no apatite formation on 
day 1 on PLA-nHA10 and PLA-nHA40 films, however apatite formation was 
observed on these films on day 7. Whereas PLA-nHA70 film showed apatite 
formation on day 1 and by day 7 the sample was fully covered with the apatite 
layer. The apatite layer subsequently increased with time on PLA-nHA10 and 
PLA-nHA40 samples and by 21 days, it had started to become dense and packed. 
The apatite layers produced on the films containing 40 and 70 wt% nHA present 
finer microstructure as compared to the layer on film containing 10 wt% HA 
which has a globular appearance, this difference in morphology of the apatite 
layer is probably due to the presence of more crystallisation nuclei. By 28 days, 
the apatite layer was covering most of the samples surface. Whereas PLA-nHA70 
film was fully covered by apatite layer on 7th day and at 28th day the apatite 
layer had considerably increased in thickness and had become very dense.  
                
 
                
 
(c) 
(b) (a) 
(d) 
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Figure 3.3: SEM images of PLA-nHA10 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm).  
 
        
 
                                                      
 
                        
 
Figure 3.4: SEM images of PLA-nHA40 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm).  
 
(e) 
(c) 
(b) (a) 
(e) 
(d) 
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Figure 3.5: SEM images of PLA-nHA70 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm) . 
 
 
 
 
 
 
 
 
 
 
(c) 
(b) (a) 
(d) 
(e) 
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Figures 3.6, 3.7 and 3.8 shows the respective EDS spectra for PLA-nHA10, PLA-
nHA40 and PLA-nHA70 samples at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF.  Although the spectra for PLA-nHA10 and PLA-nHA40 shows the presence of 
Ca and P peaks even at day 1, these peaks do not correspond to apatite layer 
formation but to HA present in the films. However, the intensity of Ca and P 
peaks increased with the increase of immersion time in SBF that represent the 
formation of apatite layer. The EDS spectra for PLA-nHA70 showed high Ca and P 
peaks even on day 1 and the intensity of these peaks did not change much over 
time especially after day 14th. 
 
Figure 3.6: EDS spectra of PLA-nHA10 at (a) 1, (b) 14 and (c) 28 days after immersion in SBF 
(a) 
(b) 
(c) 
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Figure 3.7: EDS spectra of PLA-nHA40 at (a) 1, (b) 14 (c) 28 days after immersion in SBF. 
 
 
(a) 
(b) 
(c) 
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Figure 3.8: EDS spectra of PLA-nHA70 at (a) 1, (b) 14 (c) 28 days after immersion in SBF. 
(a) 
(b) 
(c) 
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3.4.1.3 PLA-rHA composite films 
Figures 3.9, 3.10 and 3.11 show the surface morphologies of PLA-rHA10, PLA-
rHA40 and PLA-rHA70 samples respectively at (a) 1, (b) 7, (c) 14, (d) 21 and (e) 
28 days after immersion in SBF. There was no apatite formation on any film at 
day 1. However all the films have apatite crystals formed at day 7. With 
increases in the soaking time the quantity and size of these crystals increased. 
More nucleation centres were present on films containing higher amounts of HA 
and these films showed increased apatite layer formation. Although by 21 days 
all the films were fully covered with the apatite layer, this layer was dense and 
more tightly packed on the film containing 70 wt% HA.  
       
 
      
 
(a) 
(d) (c) 
(b) 
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Figure 3.9: SEM images of PLA-rHA10 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
     
 
     
 
      
Figure 3.10: SEM images of PLA-rHA40 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm) . 
(e) 
(a) 
(e) 
(d) (c) 
(b) 
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Figure 3.11: SEM images of PLA-rHA70 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm) . 
 
 
Figures 3.12, 3.13 and 3.14 show the EDS spectra for PLA-rHA10, PLA-rHA40 and 
PLA-rHA70 samples respectively at (a) 1, (b) 14 and (c) 28 days after immersion 
in SBF.  At day 1 the spectra of all the films showed Ca and P peaks which are 
due to the presence of HA in the films and the intensity of these peaks were high 
in film containing higher amounts of HA.  
However, the intensity of these peaks subsequently increased for all the films 
after immersion in the SBF due to the formation of apatite layer. 
 
(a) 
(e) 
(d) 
(b) 
(c) 
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Figure 3.12: EDS spectra for PLA-rHA10 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
 
(b) 
(a) 
(c) 
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Figure 3.13: EDS spectra for PLA-rHA40 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
(c)  
(b)  
(a)  
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Figure 3.14: EDS spectra of PLA-rHA70 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
(a) 
(b) 
(c) 
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3.4.1.4 PLA-sHA composite films 
Figures 3.15, 3.16 and 3.17 show the SEM images of PLA-sHA10, PLA-sHA40 and 
PLA-sHA70 samples respectively at (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days 
after immersion in SBF. There was no apatite formation on any film at day 1. At 
day 7 apatite formation has already started on all the films, with the highest 
amount formed on films containing 70 wt% sHA. Apatite formation started at 
individual sites and then grew in size and subsequently united to form a layer. 
The apatite layer subsequently increases with increase in immersion time on all 
films and by 21 days the all the films were fully covered with the apatite layer. 
 
      
 
      
 
 
 
(a) 
(d) (c) 
(b) 
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Figure 3.15: SEM images of PLA-sHA10 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
 
      
 
      
 
      
 
Figure 3.16: SEM images of PLA-sHA40 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
(e) 
(a) 
(e) 
(d) (c) 
(b) 
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Figure 3.17: SEM images of PLA-sHA70 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
Figures 3.18, 3.19 and 3.20 show the EDS spectra for PLA-sHA10, PLA-sHA40 and 
PLA-sHA70 samples respectively at (a) 1, (b) 14, and (c) 28 days after immersion 
in SBF.  Ca and P peaks present at day 1 correspond to the sHA present in the 
films and the intensity of these peaks is directly proportional to the amount of 
sHA present.   
(a) 
(d) (c) 
(b) 
(e) 
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The intensity of these peaks subsequently increased for all the films after 
immersion in the SBF, which representing formation of an apatite layer on these 
films.  
 
  
     
Figure 3.18: EDS spectra of PLA-sHA10 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
(a) 
(b) 
(c) 
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Figure 3.19: EDS spectra of PLA-sHA40 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
 
(a) 
(c) 
(b) 
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Figure 3.20: EDS spectra of PLA-sHA70 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
(a) 
(c) 
(b) 
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3.4.1.5 PLA-TCP composite films 
Figures 3.21, 3.22 and 3.23 show the SEM images of PLA-TCP10, PLA-TCP40 and 
PLA-TCP 70 samples respectively at (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days 
after immersion in SBF. There was no apatite formation on films containing 10 
and 40% TCP at day 1, however the film containing 70% TCP had apatite particles 
on its surface. All the films have apatite layer formation at day 7.  The number 
of apatite particles increased on the films with increases in soaking time and the 
number of apatite crystals were directly proportional to the amount TCP present 
in the films. The apatite layer subsequently increases with time on all films, 
however, the film containing 70% TCP showed highest apatite formation. 
 
     
 
                                                        
 
(c) 
(b) (a) 
(d) 
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Figure 3.21: SEM images of PLA-TCP10 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
 
      
 
     
 
 
Figure 3.22: SEM images of PLA-TCP40 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
 
(e) 
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Figure 3.23: SEM images of PLA-TCP70 at day (a) 1, (b) 7, (c) 14, (d) 21 and (e) 28 days after 
immersion in SBF (all scale bars =10 µm). 
 
 
  
Figures 3.24, 3.25 and 3.26 show the EDS spectra for PLA-TCP10, PLA-TCP40 and 
PLA-TCP70 samples respectively at (a) 1, (b) 14, and (c) 28 days after immersion 
in SBF.  At day 1 the spectra of all the films showed Ca and P peaks which are 
due to the presence of TCP in the films and the intensity of these peaks were 
high in film containing higher amounts of TCP.  
The intensity of these peaks subsequently increased for all the films with the 
formation of apatite layer after immersion in the SBF. 
 
(d) 
(a) 
(c) 
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Figure 3.24: EDS spectra of PLA-TCP10 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF 
(a) 
(c) 
(b) 
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Figure 3.25: EDS spectra of PLA-TCP40 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF. 
(a) 
(c) 
(b) 
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Figure 3.26: EDS spectra of PLA-TCP70 at (a) 1, (b) 14 and (c) 28 days after immersion in 
SBF 
 
(a) 
(b) 
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3.4.2 Raman spectroscopy 
3.4.2.1 PLA 
Figure 3.27 shows the Raman spectra of PLA films before immersion in SBF (a) 
and after immersion in SBF at day 1 (b), 14th (c) and 28th (d). The spectra show 
characteristic peaks for PLA and no phosphate peaks are visible even at 28 days. 
The peak at 1040 cm-1 corresponds to C-CH3 stretching while the peak at 1766 
cm-1 corresponds to C=O stretching. The peak at 1452 cm-1 corresponds to methyl 
group (CH3) symmetric bending and at 1315 cm
-1 to CH bending.  
 
 
 
 
 
 
 
 
Figure 3.27: Comparative Raman spectra of PLA films at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF showing that the peaks do not change with soaking time. 
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3.4.2.2 PLA-HA composite films 
Raman spectra of PLA-nHA, PLA-rHA and PLA-sHA composite films are shown in 
Figures 3.27-3.29, 3.30-3.32 and 3.33-3.35 respectively. The figures show Raman 
spectra of films before immersion in SBF (a) and after immersion in SBF at day 1 
(b) day 14th (c) and at day 28th (d).  The peak at 960 cm-1 is attributed to 
phosphate (P-O stretching). The presence of this peak at 960 cm-1 in the samples 
before immersion in the SBF can be attributed to phosphate present in the HA 
and after immersion in the SBF to phosphate present in the apatite layer 
formed. The intensity of this peak increased for all the samples with increase in 
immersion time in the SBF which can be ascribed to apatite layer formation. The 
increase was more prominent in PLA-HA samples containing 40 and 70 wt % HA 
than samples containing 10 % HA. This is due to greater apatite layer formation 
on samples containing higher quantity of nHA in PLA-HA samples. Characteristic 
peaks of PLA are also present. The peak at 1766 cm-1 corresponds to C=O 
stretching and the peak at 875 cm-1 which is characteristic of carbon, carbonyl 
bond (C-COO) stretching. The peak at 1040 cm-1 is assigned to C-CH3 stretching.  
The peaks at 1388 cm-1 and 1452 cm-1 correspond to methyl group (CH3) 
symmetric bending and at 1315 cm-1 to CH bending. 
Figure 3.28: Comparative Raman spectra of PLA-nHA 10 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
(a) 
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Figure 3.29: Comparative Raman spectra of PLA-nHA 40 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF. 
 
 
Figure 3.30: Comparative Raman spectra of PLA-nHA 70 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF. 
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Figure 3.31:  Comparative Raman spectra of PLA-rHA 10 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
 
 
Figure 3.32: Comparative Raman spectra of PLA-rHA 10 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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Figure 3.33: Comparative Raman spectra of PLA-rHA 70 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
 
 
Figure 3.34: Comparative Raman spectra of PLA-sHA 10 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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Figure 3.35: Comparative Raman spectra of PLA-sHA 40 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
 
 
 
Figure 3.36: Comparative Raman spectra of PLA-sHA 70 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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3.4.2.3 PLA-TCP composite films 
Raman spectra of PLA-TCP10, PLA-TCP40 and PLA-TCP70 composite films are 
shown in Figures 3.36, 3.37 and 3.38 respectively. The peak intensity of peak at 
1388 cm-1 and 1315 cm-1 is very high as compared to intensities of the peaks at 
960 cm-1 which is attributed to phosphate (P-O stretching) and at 875 cm-1 which 
is characteristic of carbon, carbonyl bond (C-COO) stretching. To make the 
changes in the intensities of these two peaks at 960 cm-1 and 875 cm-1 more 
appreciable, the selected area for these two peaks in the spectrum is shown in 
the box above the figures. The intensity of PO4
3- peak at 960 cm-1 for all films 
increased with increase in the SBF immersion time, however the maximum 
change was observed in film containing 70 wt% TCP. 
 
 
 
 
 
 
Figure 3.37: Comparative Raman spectra of PLA-TCP 10 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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Figure 3.38: Comparative Raman spectra of PLA-TCP 40 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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Figure 3.39: Comparative Raman spectra of PLA-TCP 70 at (a) 0 (b) 1, (c) 14 and (d) 28 days 
after soaking in SBF 
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3.5 DISCUSSION 
When implanted a bioactive material produces a specific biological response and 
a biologically active apatite layer is formed on its surface. Bone bioactive 
implant materials are proposed to be categorised as; Class A, osteoinductive 
materials and class B, osteoconductive materials. Osteoinductive materials elicit 
both extracellular and intracellular responses in the host environment, whereas, 
osteoconductive materials only elicit an extracellular response [Hench, 1994; 
Cao and Hench, 1996]. The formation of an apatite layer on the implant surface 
also affects the topographic configuration of the material which in turn affects 
the cellular behaviour and tissue response to the implant. Bioactive material 
surfaces favour the proliferation of osteoblasts over fibroblast proliferation 
[Seitz, 1982]. The apatite which is formed on the surface of the bioactive 
material is carbonate-containing hydroxyapatite with small crystallites and 
resembles the bone apatite in composition and structure. These properties 
enable bone producing cells (osteoblasts) to proliferate and differentiate 
preferentially on this apatite layer and produce apatite and collagen [Kokubo, 
1998].  
Kokubo et al. [1990] proposed that the “essential requirement for an artificial 
material to bond to living bone is the formation of bonelike apatite on its 
surface when implanted in the living body, and that this in vivo apatite 
formation can be reproduced in a simulated body fluid (SBF) with ion 
concentrations nearly equal to those of human blood plasma”. The process of 
apatite layer deposition on the surface of the material involves formation of 
apatite nuclei which subsequently grow, consuming calcium and phosphate ions 
from the SBF. Various studies have shown that as the apatite layer deposition 
increases the concentrations of calcium and phosphorous in SBF decreases 
[Jaakkola et al., 2004; Me et al., 2006]. SBF is supersaturated with calcium and 
phosphate ions and becomes stable by apatite crystal formation and the rate of 
formation of apatite nuclei is affected by the number of calcium ions released 
from the material. It is also proposed that the rate of formation of apatite on a 
material surface when soaked in SBF is predictive of the degree of in vivo 
bioactivity of that material [Kokubo, 1998; Kokubo and Takadama, 2006]. Thus 
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the bioactivity of a material can be evaluated by soaking it in SBF and analysing 
the rate of apatite formation.  
Calcium phosphates are well documented bioactive materials and form bonelike 
apatite on their surface in SBF [Gu et al., 2004; Sun et al., 2006]. The formation 
of an apatite layer is thought to involve surface structural changes when soaked 
in SBF. The first structural change involves formation of a Ca rich amorphous 
calcium phosphate (ACP) as a result of specific interaction of HA surface with 
calcium ions in the SBF. The second surface structural change is the formation of 
a Ca poor ACP due the interaction of Ca rich ACP with the phosphate ions in the 
SBF. The third change is the gradual crystallisation of Ca poor ACP into bonelike 
apatite. Subsequently this apatite grows by consuming calcium and phosphate 
ions from SBF. HA has negative surface charge when immersed into SBF due to 
exposure of its hydroxyl and phosphate units. This negative charge HA interacts 
specifically with positive Ca ions in SBF thus forming a Ca rich ACP. Formation of 
Ca rich ACP changes the surface charge to positive which then facilitates the 
interaction of Ca rich ACP specifically with negative phosphate ions in the SBF 
and to form a Ca poor ACP which in turn crystallizes into bonelike apatite. The 
apatite which is formed then acts as nucleation centres for apatite deposition 
[Bell et al., 1972; Neo et al., 1993; Duan et al., 2004; Kim et al., 2005; Me et 
al., 2006].   
In this study the bioactivity of PLA/Ca P composite films containing different 
types of HA and TCP in different concentration was evaluated by assessing the 
ability of an apatite layer to form on their surfaces in SBF. Among the PLA/HA 
and PLA/TCP composite films the formation of an apatite layer was highest and 
most rapid on films containing 70 wt % nHA followed by film containing 70 wt % 
TCP. In contrast there was no apatite layer formation on plain PLA films even 
after 28 days of immersion in SBF. Increased apatite formation on PLA-nHA films 
can be attributed to more nucleation centres present on the film in addition to 
its larger surface area. Previous studies have also shown that materials with 
large specific surface area produce earlier apatite formation as compared to 
materials with lower surface area [Jaakkola et al., 2004; Murugan and 
Ramakrishna, 2005; Bohner and Lemaitre, 2009]. PLA-TCP composite film which 
has similar sized particles as PLA-sHA and PLA-rHA composite films showed 
increased and faster formation of the apatite on its surface as compared to PLA-
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sHA and PLA-rHA composite films. Among the PLA-TCP films the maximum 
apatite formation was on films containing the highest concentration i.e. 70 wt % 
TCP. This increased apatite formation can be attributed to the fact that the 
dissolution rate of TCP is higher than HA [Ducheyne et al., 1993] and the 
dissolution increases the Ca2+ concentration in the SBF around the area of 
dissolution. This increased Ca2+ concentration causes more ion attachment to the 
material surface, which then act as nucleation centres and an apatite layer is 
produced [Khor et al., 2003].    
The morphology of the apatite layer formed on PLA-nHA films containing 40 and 
70 wt % nHA showed a fine needle like structure as compared to globular 
morphology of apatite formed on the films containing 10 wt% nHA. This 
difference can be attributed to the presence of more nucleation centres which 
are more closely present on the films with a higher nHA concentration. The 
morphology of the apatite layers formed on composite films containing sHA, rHA 
and TCP is globular and the SEM images show individual globules at the site of 
nucleation. The apatite formation increased with the passage of time and the 
globules became tightly packed and gave the apatite layer a cauliflower like 
morphology. 
Raman spectra of all the PLA-HA and PLA-TCP composite films show a 960cm-1 
peak which corresponds to symmetric stretching vibration of P-O [Zhou et al., 
2007] in apatite crystals, the intensity of this peak increased with increasing SBF 
immersion time which is indicative of apatite formation. In addition the change 
in the intensity of this peak was high in films containing higher amount of HA or 
TCP which is due to formation of more apatite on these films. The strong peak in 
PLA-HA films at 875 cm-1 is characteristic of carbon, carbonyl bond (C-COO) 
stretching in the polymer chain [Patrick, 2001; Taddei et al., 2002]. Raman 
spectra of plain PLA films did not show emergence of phosphate peak at 960cm-
1.  
3.6 CONCLUSIONS 
Higher calcium phosphates content in the composite results in a higher rate of 
apatite formation.  Additionally particle sizes of the calcium phosphates used in 
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the composite also play an important role in determining the rate of apatite 
layer formation. Increased apatite formation was observed with nano particles 
used in this study. The formation of an apatite layer on TCP was more compared 
to HA of the same content. 
 CHAPTER 4: DEGRADATION OF POLYLACTIC ACID-
CALCIUM PHOSPHATE COMPOSITES 
  
4.1 INTRODUCTION 
Polylactic acid (PLA) has been used in many biomedical applications such as 
tissue engineering, drug delivery, orthopaedics and maxillofacial reconstruction 
due to its biocompatibility and biodegradability.  The ability of PLA to be used in 
many different applications is due to the possibility of tailoring its physical, 
chemical and degradation properties to individual needs. The rate at which PLA 
degrades is very important and should match the rate at which the new tissue 
forms at its implantation site. Degradability of PLA depends on various factors 
which include its molecular weight, crystallinity, L and D isomer ratio, 
configuration, implant size and implant site [Grizzi et al., 1995; Middleton and 
Tipton, 2000; Ural et al., 2000].  
Combining calcium phosphates such as hydroxyapatite (HA) and tri-calcium 
phosphate (TCP) with PLA not only improves bioactivity and mechanical 
properties of PLA but also affects its degradation rate [Takayama et al., 2009]. 
The aim of this study is to investigate the effect of HA and TCP addition on the 
degradation of PLA and also to examine the effect of different HA and TCP 
concentrations used.      
4.2 MATERIALS 
The materials used were PLA (PURAC Biochem, The Netherlands), nHA (Sigma- 
Aldrich, UK), sHA and rHA (Plasma Biotal Limited, UK) and TCP (Plasma Biotal 
Limited, UK) as described in detail in section 2.2.  
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4.3 METHODS 
4.3.1 Composite films preparation 
PLA-HA and PLA-TCP composite films were prepared as described in detail in 
section 2.3.1, namely dissolving the PLA in chloroform and once dissolved adding 
the Ca P powder, continue to stir and finally cast the film.  
4.3.2 Degradation protocol 
Degradation of the composite films in vitro was analysed by incubating 
composite film samples in phosphate buffered saline (PBS) at 37°C. Circular 
samples 12 mm diameter were cut using a hole puncher and sterilized by soaking 
in 70% ethanol for a 5 minutes and then dried at 50°C. Three samples for each 
composite film and time point were weighted (Wo) before immersion in the PBS 
and were placed in polypropylene bottles for 1 day, 1, 3, 6, 9 and 12 weeks. 
Each bottle containing a single sample was filled with 20 ml PBS which was 
replaced with fresh 20 ml PBS after every 3 weeks.  At each time point the 
samples were removed from the bottles and weighted after gently wiping the 
sample surface with a tissue to give wet weight (Ww). The samples were then 
washed with deionised water to remove any soluble salt from their surfaces. 
After washing the samples were dried in an oven at 37 °C for 24 hours and then 
in a vacuum oven for 2 hours before weighing to give dry weight (Wd). The 
difference between Wo and Ww was taken as wet weight gain (WG) and the 
difference between Wo and Wd was taken as weight loss (WL). These two were 
calculated according to Equations 4.1 and 4.2 respectively. 
WG (%) = 100 (Ww-Wo)/ Wo     Equation 4. 1 
WL (%) = 100 (Wo-Wd)/ Wo      Equation 4. 2 
4.3.3 Data Analysis 
Statistical analyses were done by 1- way ANOVA with Bonferroni’s post-test with 
P < 0.05. 
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4.4 RESULTS 
4.4.1 PLA 
Figure 4.1 shows the percentage wet weight gain by PLA films after immersion in 
PBS for up to 12 weeks. PLA films gained weight for up to 6 weeks, which 
increased gradually from day 1 up to the 6th week and reached a maximum of 
0.59 %. After the 6th week the weight decreased and dropped until the end of 
testing.  
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Figure 4.1:  Percentage wet weight gain by PLA films versus incubation time in PBS at 37 
°C. The first data point is at day 1 showing weight gain in the 1
st
 24 hours. Mean + SD, n=3 
for each time point.  
 
Figure 4.2 shows the percentage dry weight loss by PLA films after immersion in 
PBS for up to 12 weeks. PLA films lost weight over the entire duration of 
immersion in SBF and reached 5 % at the end of the 12th week.  
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Figure 4.2:  Percentage dry weight loss of PLA films versus incubation time in PBS at 37 °C. 
The first data point is at day 1 showing weight loss in the 1
st
 24 hours. Mean + SD, n=3 at 
each time point. 
 
4.4.2 PLA-nHA composite films 
Figure 4.3 shows the percentage wet weight gain by PLA-nHA composite films 
containing 10, 40 and 70 wt % nHA after immersion in PBS for up to 12 weeks in 
comparison with the non-filled PLA film (results shown in figure 4.1.). PLA-nHA 
composite film containing 40 wt % nHA showed more weight gain than films 
containing 10 and 70 wt % nHA. At day 1 PLA-nHA70 films showed more weight 
gain than PLA-nHA10 films, however after the first day the weight gain by PLA-
nHA70 film decreased and remained less than PLA-nHA10 throughout the 
incubation period. Weight gain by PLA-nHA70 films was 4 % on day 1 which 
decreased to 1.19 % at the 12th week. PLA-nHA40 films showed 4.3 % weight gain 
on day 1 which reached maximum at the 12th week i.e. 8.33 %. PLA-nHA10 films 
showed minimum weight gain among all the films on day 1 i.e. 1.89 %, the 
weight gain reached its maximum at 1 week and than gradually decreased to 
reach 3.33 % at the 12th week. All the composite films showed more weight gain 
than the non-filled PLA.   
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Figure 4.3: Percentage wet weight gain by PLA-nHA composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight gain in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. * Significantly greater than PLA, p<0.05, one way ANOVA 
and Bonferroni post test. 
 
Figure 4.4 shows the percentage dry weight loss by PLA-nHA composite films 
containing 10, 40 and 70 wt % nHA after immersion in PBS for up to 12 weeks in 
comparison with the non-filled PLA film (result shown in figure 4.2). For all the 
films the weight loss increased with PBS immersion time and the maximum 
weight loss was shown by films containing maximum nHA i.e. 70 wt % nHA 
followed by films containing 40 and 10 wt % nHA respectively. Film containing 40 
and 70 wt % nHA showed a sharp weight loss between day 1 and the 1st week 
which was followed by a plateau until the 3rd week.  The weight for these two 
types of films then again decreased until the 12th week reaching 5.6 and 4.5 % 
for films containing 70 and 40 wt % nHA respectively. The films containing 10 wt 
% nHA lost weight gradually and reached 3 % at the end of 12 weeks. Only the 70 
wt % nHA film lost more weight than the non-filled PLA film.    
 
 
* 
* 
* 
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Figure 4.4: Percentage dry weight loss of PLA-nHA composite films versus incubation time 
in PBS at 37 °C. The first data point is at day 1 showing weight loss in the 1
st
 24 hours. Mean 
+ SD, n=3 at each time point. * Significantly less than PLA, p<0.05, one way ANOVA and 
Bonferroni post test. 
 
 
4.4.3 PLA-rHA composite films 
Figure 4.5 shows the percentage wet weight gain by PLA-rHA composite films 
containing 10, 40 and 70 wt % rHA after immersion in PBS for up to 12 weeks in 
comparison with non-filled PLA film (results shown in figure 4.1). On day 1 films 
containing 70 wt % rHA showed slight weight gain i.e. 0.48 %, the remaining two 
types of films containing 40 and 10 wt % did not show any weight gain. However 
after day 1 all PLA-rHA composite films showed negative values for weight gain 
up to the 12th week, except PLA-rHA composite film containing 70 wt % rHA 
which showed slight weight gain at the 12th week i.e. 0.67 %. Unlike PLA all 
composite films showed a reduction in weight. 
 
* 
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Figure 4.5: Percentage wet weight gain of PLA-rHA composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight gain in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. * Significantly greater than PLA, p<0.05, one way ANOVA 
and Bonferroni post test. 
 
 
Figure 4.6 shows the percentage dry weight loss by PLA-rHA composite films 
containing 10, 40 and 70 wt % rHA after immersion in PBS for up to the 12 weeks 
in comparison with the non-filled PLA film (results shown in figure 4.2). All the 
composite films showed weight loss throughout immersion in the PBS up to 12th 
week. The greatest weight lost was shown by films containing 10 wt % rHA 
followed by films containing 70 and 40 wt % rHA respectively. The final weight 
loss at the end of the 12th week was 6.3, 3.8 and 5 % for films containing 10, 40 
and 70 wt % rHA. The weight loss of film containing 10 wt % rHA was greater and 
of film containing 40 wt % rHA was less than non-filled PLA film.   
* 
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Figure 4.6:  Percentage dry weight loss of PLA-rHA composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight loss in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. 
 
4.4.4 PLA-sHA composite films 
Figure 4.7 shows the percentage wet weight gain by PLA-sHA composite films 
containing 10, 40 and 70 wt % sHA after immersion in PBS for up to 12 weeks in 
comparison with non-filled PLA film (results showed in figure 4.1). At day 1 
highest weight gain was shown by film containing 70 wt % sHA. After the 1st day 
the weight gain by film containing 70 wt % sHA decreased sharply and at week 1 
it was less than weight gain by films containing 10 and 40 wt % sHA. However 
after the 1st week the weight gain by film containing 70 wt % sHA again 
increased upto 6th weeks, before again decreasing up to the 12th week. After 
increased weight gain at week 1 by both PLA-sHA10 and PLA-sHA40 films showed 
decrease in weight gain. At the end of the 12th week the weight gains were -1.3, 
-1.29, 0 % for PLA-sHA10, PLA-sHA40 and PLA-sHA70 composite films 
respectively.   
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Figure 4.7: Percentage wet weight gain by PLA-sHA composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight gain in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. * Significantly greater than PLA, p<0.05, one way ANOVA 
and Bonferroni post test. 
 
 
Figure 4.8 shows the percentage dry weight loss by PLA-sHA composite films 
containing 10, 40 and 70 wt % sHA after immersion in PBS for up to 12 weeks in 
comparison with non-filled PLA film (results shown in figure 4.2). All PLA-sHA 
composite films showed increasing weight loss with PBS immersion time. Until 
week 1 the maximum weight loss was shown by films containing 10 wt % sHA 
followed by films containing 40 and 70 wt % sHA respectively. However at week 
3 the films containing 70 wt % sHA showed more weight loss compared to films 
containing 40 wt % sHA. At the end of the 12th week the weight losses were 5.4, 
3.8 and 4.4 % for PLA-sHA10, PLA-sHA40 and PLA-sHA70 films respectively.  
* 
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Figure 4.8: Percentage dry weight loss of PLA-sHA composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight loss in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. 
 
4.4.5 PLA-TCP composite films 
Figure 4.9 shows the percentage wet weight gain by PLA-TCP composite films 
containing 10, 40 and 70 wt % TCP after immersion in PBS for up to 12 weeks in 
comparison with non-filled PLA film (results shown in figure 4.1). On day 1 the 
maximum weight gain was shown by films containing 70 wt % TCP i.e. 1.6 %, 
whereas the films containing 10 and 40 wt % did not show any weight gain. 
However the weight gain by films containing 70 wt % TCP went negative after 
day 1. The films containing 10 and 40 wt % TCP showed an increase in weight 
gain between day 1 and 1st week after which the weight gain for these two types 
of films also decreased and went into weight loss.  
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Figure 4.9: Percentage wet weight gain by PLA-TCP composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight gain in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. 
 
Figure 4.10 shows the percentage dry weight loss by PLA-TCP composite films 
containing 10, 40 and 70 wt % TCP after immersion in PBS for up to 12 weeks in 
comparison with non-filled PLA film (results shown in figure 4.2). All PLA-TCP 
composite films showed an increasing weight loss with PBS immersion time. Until 
week 1 the maximum weight loss was shown by films containing 10 wt % TCP 
followed by films containing 40 and 70 wt % TCP respectively. However after 
week 1 the weight loss was more for films containing 70 wt % TCP as compared 
to films containing 40 wt % TCP. At the end of the 12th week the weight losses 
were 6.9, 5.3 and 6 % for films containing 10, 40 and 70 wt % TCP respectively. 
The weight loss by all composite films was greater than non-filled PLA film. 
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Figure 4.10: Percentage dry weight loss of PLA-TCP composite films versus incubation time 
in PBS at 37 °C. The first data points are at day 1 showing weight loss in the 1
st
 24 hours. 
Mean + SD, n=3 at each time point. * Significantly greater than PLA, p<0.05, one way ANOVA 
and Bonferroni post test. 
 
4.5 DISCUSSION 
The degradation rate of an implant plays an important role in defining the 
success or failure of a resorbable implant. The rate at which an implant 
degrades affects its mechanical properties, cell growth and the body’s response. 
Ideally an implant should maintain its strength until the strength of new bone is 
adequate and then should degrade at the same rate as the new bone 
regenerates [Liao and Cui, 2004].    
Hydrolytic degradation of PLA is heterogeneous and involves surface and bulk 
erosion mechanisms. Surface erosion occurs at the polymer-liquid interface, 
whereas bulk erosion involves uniform degradation throughout the polymer. 
Depending on the manufacturing process the degradation of PLA devices can be 
faster in the centre than on the surface. The first event which takes place on 
immersion of a PLA device in the aqueous solution or when implanted is water 
uptake. These water molecules then produce hydrolytic decomposition of the 
polymer chain. During the degradation, oligomers are produced; the oligomers 
which are present close to the surface escape the matrix into the surrounding 
* 
Chapter 4 
 170 
medium. However those which are present inside the matrix diffuse out very 
slowly and mainly remain entrapped thus contributing to the autocatalytic effect 
and increasing the degradation rate in the centre of the device [Vasanthan and 
Ly, ; Grizzi et al., 1995].        
The PLA degradation produces lactic acid and burst release of this lactic acid 
can produce tissue inflammation. Addition of TCP or HA can help in lowering the 
acidity thus controlling the degradation rate. However, in PLA-Ca P composites 
the acid breakdown is chemically buffered by the Ca P. Water absorption 
increases as the degradation progresses due to accumulation of hydrophilic 
degradation products inside the polymer matrix. However on reaching a certain 
level, it reduces due to release of degradation products [Yang et al., 2008]. 
In the present study, the in vitro degradation kinetics of PLA/Ca P composite 
films containing HA or TCP in different concentrations was analysed by 
incubating samples in PBS at 37 °C. To understand the results obtained in this 
study it should be considered that in composite films two mechanisms are 
occurring simultaneously, i.e. degradation of PLA and dissolution of particles 
from the surface and the matrix, while the presence of the interface between 
the PLA and Ca P filler allows liquid to accumulate at this interface. 
Among the non-filled PLA and PLA/Ca P films the least weight gain was shown by 
non-filled PLA and PLA-TCP films containing 40 wt % TCP at the end of 12 weeks. 
However, in the case of PLA-TCP40 films the possible reason for this low value is 
the dissolution of TCP particles from the sample in addition to polymer 
degradation. Whereas the low liquid absorption by non-filled PLA is expected as 
PLA is hydrophobic and the non-filled PLA samples also lack any interfaces which 
are present in the composite films and liquid can ingress the matrix through 
these interfaces in the composite films. One thing to note is that at day 1 in all 
the composite films, maximum liquid absorption was observed with samples 
which had the highest filler concentrations i.e. 70 wt %, so it can be seen that 
the water absorption increases with increase in the filler content. Similar results 
of of more liquid absorption with increase filler content were shown by 
Suwanprateeb et al. [1997] who investigated 0, 20 and 40 vol % of a spray dried 
HA, similar to the rHA used in this study, in a high density polyethylene. 
However, after the first day the values for liquid absorption decreased for 
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samples which had 70 wt % filler which can be attributed to the dissolution of 
particles from the samples. As the incubation proceeded, the liquid absorption 
by the films did not follow a set pattern which can be due to multiple factors 
that were occurring simultaneously.  These factors include dissolution of the 
particles from the films, degradation of PLA and exposure of the particle 
surfaces which were embedded in the matrix due to the degradation of PLA 
matrix and which then caused increase in liquid absorption.  
The degradation of non-filled PLA and PLA composite films used in this study was 
slow and the maximum weight loss was 7% in 12 weeks observed with PLA-TCP 
films containing 10 wt % TCP. As the thickness of the samples used in the study 
was between 0.04 to 0.07 mm, it is expected that the oligomers produced in the 
matrix were able to escape in the surrounding aqueous medium easily thus their 
effect of contributing to the autocatalysis is lost and did not increase the 
degradation rate.  A study by Grizzi et al. [1995] also showed similar results, in 
that the PLA films lost only 5-7 % weight in 25 weeks. 
Among the composite films which contained rHA, sHA and TCP the maximum 
weight lost was observed in films containing lower filler content i.e. 10 wt % 
filler. This result is in keeping with other studies that HA and TCP incorporation 
into the composite slows the degradation rate by hindering the autocatalytic 
degradation of polymer [Agrawal and Kyriacos, 1997; Imai et al., 1999; Ara et 
al., 2002]. The reason for higher degradation of some composite films than non-
filled PLA films can be due to the dissolution of particles from the composite 
films which also added to the total degradation. Initially films containing 40 wt % 
filler showed more weight loss than from the films containing 70 wt % filler, 
however after 3rd week of incubation more weight loss was shown by films 
containing 70 wt % filler. This is probably due to more filler dissolution from the 
films containing 70 wt % filler which resulted in increased overall weight loss. 
Ural et al. [2000] has also suggested that the addition of HA in a polymer 
composite reduces the degradation rate and further that the composites with 
higher filler content degrade at a slower rate compared to those with lower 
filler contents. This may be due to the ability of HA or TCP particles present in 
the composite to absorb water molecules which penetrate the polymer matrix 
and are responsible for the hydrolytic decomposition of polymer chains.   
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Interestingly among PLA-nHA composite films the maximum weight loss was 
observed in films containing 70 wt % nHA followed by films containing 40 and 10 
wt % nHA respectively. The degradation of composite films containing 10 and 40 
% nHA was less than neat PLA films, which is in agreement with a study 
conducted by Ural et al. [2000] which showed that adding HA to the polymer 
composite reduces the degradation rate. Higher weight loss in films containing 
70 wt % filler can be attributed to faster dissolution of filler particles from the 
surface of the samples and as the PLA-nHA70 had more particles present on the 
surface than PLA-nHA40 and PLA-nHA10 the weight loss was more pronounced.  
The maximum weight loss at day 1 and at the end of 12 weeks was shown by 
PLA-TCP composite films which is also in agreement with other studies, that TCP 
dissolves faster than HA [Paul et al., 1993; Kwon et al., 2003].  
4.6 CONCLUSIONS 
Water absorption increases with the filler content in the composite. Dissolution 
of TCP particles from PLA-TCP composite was higher than the dissolution of HA 
particles from PLA-HA composite. Incorporation of Ca P in the composite slows 
the degradation rate. Although in this study, the degradation of composite films 
was not always lower than neat PLA films, however in samples where it was 
higher this can be attributed to dissolution of particles from the composite. Thus 
by varying the concentration of Ca P the degradation rate of PLA can be tailored 
to suit individual need of clinical applications.  
 CHAPTER 5: EFFECTS OF nHA AND PDGF 
CONCENTRATIONS ON OSTEOBLAST AND PDL CELLS 
GROWTH IN PLA-nHA COMPOSITE 
  
5.1 INTRODUCTION 
The use of a ceramic such as HA within a degradable PLA may confer a number 
of potential therapeutic advantages on this material, including increased 
mechanical properties, promotion of cell attachment and osteoconduction and 
the potential for use as a vehicle for slow delivery of bioactive proteins such as 
growth factors. PLA-HA composite material has been shown to be biocompatible, 
resorbable and have good mechanical properties [Shikinami and Okuno, 1999]. 
The incorporation of a suitable growth factor into a GTR membrane could 
enhance significantly the outcome of GTR procedures.   
The aim of the study reported here was to investigate the proliferation and 
differentiation of osteoblast cells on PLA-nHA composite with different 
concentrations of nHA and assessing the potential of this material to act as a 
carrier system for growth factors delivery. In addition the nHA and the PLA-nHA 
composite films produced for the experiments were characterized by Scanning 
Electron Microscopy (SEM), Fourier Transform Infra Red spectroscopy (FTIR) and 
X- Ray Diffraction (XRD).  
5.2 MATERIALS  
5.2.1 Polylactic acid 
PLA (PURAC Biochem, The Netherlands) as described in section 2.2 was used for 
the fabrication of the films. 
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5.2.2 Nano-Hydroxyapatite  
nHA was produced in the lab for this experiment. For nHA production, calcium 
nitrate tetrahydrate [Ca(NO3)2.4H2O] was used as the calcium precursor 
dissolved in ethanol, both obtained from Sigma Aldrich (UK). Sodium hydrogen 
phosphate [(NH4)2HPO4] also purchased from Sigma Aldrich (UK) was used as a 
phosphate precursor in the reactions dissolved in deionised water. The 
production method is described in section 5.3.2.  
5.2.3 Cells 
Primary rat calvarial osteoblasts isolated by collagenase digestion and rat 
periodontal ligament (PDL) cells isolated by explant culture were used in the 
experiments. Osteoblasts and PDL cells were donated by Dr C Wellman and Dr M 
Al-Masri respectively (Barts & The London School of Medicine & Dentistry). The 
cells were cultured and maintained in Minimal Essential Medium (MEM) Alpha 
medium (Invitrogen, UK) which was supplemented with 10% fetal calf serum 
(FCS) (Sigma Aldrich, UK), 0.3µg/ml fungizone (Invitrogen, UK) and 50u/ml 
penicillin- 50ug/ml streptomycin (Invitrogen, UK). The cells were grown in a 
humidified incubator at 37◦C with 5% CO2. The medium was replaced twice a 
week. 
5.2.4  Platelet Derived Growth Factor 
Recombinant rat Platelet Derived Growth Factor – BB (PDGF-BB) purchased from 
Sigma Aldrich (UK) was used in the experiments. 
5.2.5 CASY cell counter 
Cells cultured on the films were counted using a CASY electronic cell counter 
(Model TTC, Sedna Scientific Ltd). CASY measures the cells suspended in the 
solution by aspirating through a precision measuring pore. On passing through 
the aperture these cells are scanned at a frequency of 1 MHz in a low voltage 
field (Figure 5.1). The signal data is then accumulated to give the total number 
of cells. 
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Figure 5.1: A schematic presentation of CASY cell counter working [adapted from 
sednascientific.com]. 
 
5.2.6 CellTiter 96® AQueous non-radioactive cell proliferation Assay 
(MTS)  
Cell proliferation on the films was assessed by an MTS assay. A solution of MTS 
(Promega UK Ltd) and phenazine methosulfate (PMS) (Sigma Aldrich, UK) was 
used to determine the number of viable cells on the films.  
5.2.7 Alkaline phosphatase (ALP) 
ALP assay was prepared by dissolving 2 × 15 mg tablets of p-nitrophenyl 
phosphate in 8.36ml of distal water in addition to 6µl MgCl2  (2M) and 2.35ml of 
alkaline buffer solution (1.5 M) (Sigma, A9226).  
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5.3 METHODS 
5.3.1 Film fabrication 
The films were fabricated as described in detail in section 2.3.1. That is the PLA 
was dissolved in chloroform and once fully dissolved the nHA was added to give 
PLA-nHA composite films containing 10 wt % nHA (PLA-nHA10), 40 wt % nHA 
(PLA-nHA40) and 70 wt % nHA (PLA-nHA70). The suspension was further stirred 
and then the films were cast. The films were cut into 12mm circular samples and 
were sterilized by ultraviolet (UV) irradiation. 
5.3.2 Nano-hydroxyapatite synthesis 
An Ethanol-based sol–gel method was used for the synthesis of nHA as reported 
by Feng et al. [2005].   
Calcium nitrate tetrahydrate [Ca (NO3)2.4H2O] (0.083M) in ethanol and amonium 
hydrogen phosphate [(NH4)2HPO4] (0.05M) in water were mixed and the ratio of 
calcium and phosphate precursors was maintained at 1.66. Ca(NO3)2.4H2O was 
mixed in 50ml of ethanol and the solution was stirred and heated upto 85°C. On 
reaching 85°C, (NH4)2HPO4 dissolved in 50 ml of water was added drop by drop 
by means of a glass-dropping funnel. Amonium hydroxide (NH4OH) was added 
into the solution to maintain the pH value above pH 10. The solution was stirred 
for 5-6 hrs as gel formation occurred (Equation 5.1). The final gel was then aged 
in an oven for 24 hrs at 40°C.  
The sample was then heat treated in a Carbolite furnance (Sheffield, UK) in air. 
The temperature was increased at the rate of 10°C min-1 and on reaching 700°C 
the sample was held for 60 minutes and then cooled down to 20°C at the same 
rate. The powder was then ball milled for 12 hrs.  
10Ca (NO3)2 4H2O         +     6(NH4)2HPO4  + 8NH4OH  
       →    Equation: 5.1  
          Ca10 (PO4)6(OH)2            +       20NH4NO3      + 6H2O 
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5.3.3 Films and nHA characterisation 
5.3.3.1 FTIR 
FTIR spectra of the PLA and PLA-nHA composite films were collected using a 
Thermo-Electron Nicolet 8700 FTIR spectrometer. The spectra were obtained at 
8cm-1 resolution and a total of 256 scans were collected. 
5.3.3.2 SEM 
The morphology and the size of synthesised n-HA particles and the films were 
characterised by SEM (FEI Inspect F, EFI Company, The Netherlands) using the 
field emission technique. For nHA samples 20kV was used and for PLA and nHA-
PLA composite films 5kV was used. 
5.3.3.3 XRD 
The nHA powder produced was characterized using XRD, to find chemical 
composition, crystal state and the crystalline content. A Simens/Bruker D5000 
Diffractometer, with monochromatic Cu Ka radiation (k = 0.15418 nm) was used 
to obtain the nHA powder XRD. Scans were obtained in the 2θ range = 20–60, 
with a step size of 0.02 s-1. Commercial nHA (Sigma, UK) was scanned to provide 
a comparative XRD pattern. 
5.3.4 Cell culture 
To evaluate osteoblast proliferation on different films, cells were seeded on PLA 
films and 10, 40, 70 wt % PLA-nHA composite films. Osteoblasts of 7-9th passage 
were used for the tests. 90% confluent cells were trypsinized and cell density 
was adjusted to 3×104 cells/ml. UV sterilised films were transferred into 24 well 
plates, a small dot of silicon was used to stick the films to the base of the wells.  
The films were seeded with 3×104 cells/ml / well for 1, 2, 4, 7, 10 and 14 days in 
triplicates.  Wells with no films were used as controls. 
For experiments in which platelet derived growth factor was added, the cell 
density was decreased to 1×104 cells/ml/well and the medium was 
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supplemented with 1% fetal calf serum instead of 10% fetal calf serum. The well 
plates were placed in a humidified incubator at 37◦C with 5% CO2. Cell 
proliferation was analyzed at day three. 
PDL cell proliferation was analysed on 10 and 70 wt % PLA-nHA composite films. 
PDL cells of 11-13th passage number were used. For cell seeding on films the 
same protocol was used for PDL cells as was used for osteoblasts.   
5.3.5 PDGF addition 
The effect of PDGF added to the films on the proliferation of cells was 
evaluated. To pre-adsorb PDGF to films for testing, 100ng recombinant rat 
platelet-derived growth factor – BB (PDGF-BB) (Sigma) in 100 µl phosphate 
buffered saline (PBS) was added to the surface of specimens placed in 24 well 
plates. The films were then incubated for three hrs at 37◦C. After three hrs the 
PBS solution was carefully removed from the surface of the films and cells at 
density 1×104 cell ml-1 were seeded on to the films.  
In a second set of films, rather than adding PDGF directly on the films, PDGF was 
added to the medium in solution at the same time as adding the cells as above. 
The final concentration of PDGF in the medium was 100ng ml-1 so that the same 
total amount of PDGF was added to the well as when films were pre-adsorbed 
with PDGF. 1ml of PDGF containing medium was then added to each film placed 
in 24 well plates. Cells in medium without PDGF with 1 and 10% FCS supplement 
were used as negative and positive controls respectively. 
5.3.6 CASY cell counting protocol 
In order to measure the cells on the films, films were removed from the medium 
at days 1, 2, and 5 and were placed in new 24 well plates. The films were then 
washed with PBS, after which 500µl trypsin was added to each well and the 
plates were placed in the incubator for 10 minutes. After that 1.5ml of cell 
medium was added to each well and mixed with trypsin containing cells. From 
this cell containing medium/trypsin solution 500µl was removed and added into 
4.5ml of CASY diluting solution. The cell numbers were then analysed using CASY 
counter. 
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5.3.7 MTS Assay protocol 
MTS changes colour on reacting with cells. The amount of colour change is 
directly proportional to the number of living cells. In order to measure cell 
proliferation films were taken from the medium at day 1, 2, 4, 7, 10 and 14 and 
were placed in new 24 well plates. PMS and MTS solution were mixed at a 
concentration of 50µl/ml just before addition to the medium. MTS/PMS solution 
was then added to the medium at a concentration of 200 µl/ ml, then 500 µl of 
MTS/PMS solution containing medium was added to the wells containing films. 
The well plates were incubated for 3 hrs, then three samples of 100µl each were 
taken out from each of the wells and transferred to 96 well plates. The 
colorimetric measurement was then performed using a spectrophotometer at 
490 nm (FLUOstar Optima, BMG Labtech). 
5.3.8 ALP activity 
ALP activity of cells was evaluated by adding 500µl ALP solution to each film in 
24 well plates. ALP solution was added to the same films after taking out MTS 
solution. 
The films were then incubated for at 37°C for one hour. After one hour three 
samples of 100µl each were taken from each film and absorbance was measured 
at 405nm in a photospectrometer.  
5.3.9 Cell morphology 
SEM was used for morphological analysis of cells. At the 14th day of incubation 
the films containing cells were washed with PBS twice before fixing the cells in 4 
% formaldehyde for 15 minutes. The cells were then dehydrated by suspending in 
successive 50, 70, 80, 90 and 100% ethanol solutions for 5 minutes each.  The 
films containing cells were finally transferred to hexamethyldisilazane and were 
allowed to dry at room temperature. The films samples were then gold coated 
and analyzed under SEM at 5kV. 
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5.3.10 Data Analysis 
Statistical analyses of cell culture data were calculated by 1- way ANOVA with 
Bonferroni’s post-test with P < 0.05.  Analysis was carried out using GraphPad 
Prism software. 
5.4 RESULTS 
5.4.1 nHA characterisation  
5.4.1.1 SEM  
Figure 5.2 shows the morphology and size of nHA synthesized. The particles were 
agglomerates of spherical nodules with the nodules being 40-60nm across and 
the agglomerates being 0.5 – 1mm across. High temperature during synthesis, 
low temperature during ageing and then an increase in temperature during heat 
treatment causes variations in the size of the particles. 
 
 
Figure 5.2 SEM of nHA showing individual nodule size and morphology within the 
agglomerated granules (scale bar= 500nm). 
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5.4.1.2 FTIR 
FTIR spectrum of nHA powder is shown in Figure 5.3. The peaks at 3571 cm-1 and 
631cm-1 represent OH group. The peaks at 1040, 603 and 569 cm-1 represent the 
P-O absorption band. CO3 group is represented by the peak at 1473 cm
-1. 
 
Figure 5.3: FTIR spectrum of synthesized nHA powder. 
 
5.4.1.3 X-ray Diffraction  
X-ray diffraction (XRD) of commercial (Plasma Biotal, UK) and experimental nHA 
are shown in Figure 5.4. A strong diffraction peak at 31.9° with lesser peaks at 
32.2, 32.9 and 25.9 and 39.8, 46.7 and 49.5 confirm the presence of 
hydroxyapatite. The diffraction patterns correspond to hydroxyapatite and 
confirmed the phase purity and high crystallinity of the materials produced. The 
slight broadening of the peaks shows that the nHA has slightly lower crystallinity 
than the commercial HA.    
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Figure 5.4 XRD pattern of commercial and experimental nHA 
 
5.4.2 Film characterisation 
5.4.2.1 SEM  
Figures 5.5, 5.6 and 5.7 respectively show the morphology of 10, 40 and 70 wt % 
PLA-nHA composite films. The surface of PLA-nHA70 film showed more nHA on 
the surface as compared to PLA-nHA10 and PLA-nHA40 composite films. The 
surface of PLA-nHA10 film appears smooth, whereas the surface of PLA-nHA70 
film is rougher, irregular and shows micropores due to presence of nHA. It is 
interesting to see that at 10 wt %, a few nHA agglomerates can be seen and that 
these are all covered in a visible PLA layer. However as the nHA content 
increases, the amount of visible nHA increases and at 70 wt % nHA substantial 
areas of the film surface appear nHA exposed from the PLA matrix. It is likely 
that a very thin layer of PLA is covering these particles but that the layer is too 
thin and thus too electron-lucent to be visible on the SEM image. All these 
images are of the “top” surface that is the air contacting surface as the films 
dried.  
Commercial nHA 
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Figure 5.5: SEM image of PLA-nHA10 film (scale bar 4 µm). 
 
 
 
Figure 5.6 SEM image of PLA-nHA40 film (scale bar 4 µm). 
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Figure 5.7 SEM image of PLA-nHA70 film (scale bar 4 µm). 
 
5.4.2.2 FTIR 
FTIR spectra of PLA film and PLA-nHA10, PLA-nHA40 and PLA-nHA70 composite 
films are shown in Figure 5.8. The peak at 1760cm-1 represents the carbonyl 
group of PLA which is present in all films and showed no drift even in PLA-nHA70 
films.  HA peak at 3571cm-1 is more pronounced in PLA-nHA composite film, 
whereas it decreases as the nHA content decreases in PLA-nHA40 and PLA-nHA10 
films. The peaks between 538cm-1 and 638cm-1 represent bending peaks of 
phosphate from the nHA in PLA-nHA composite films.  
 
Figure 5.8 FTIR spectra of (a) PLA-nHA70 film (b) PLA-nHA40 film (c) PLA-nHA10 and (d) 
PLA film.  
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5.4.3 Cell proliferation assessed by CASY cell counter 
Figure 5.9 shows the number of cells on PLA film, PLA-nHA10 and PLA-nHA70 
composite films at day 1, 2 and 5 after culture. Although the cell numbers were 
greater at day 5 than at day 1 and 2, the cell number on different films showed 
no specific trend with high variations.  
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Figure 5.9: Osteoblast cell numbers on different films at day 1, 2 and 5 (n=3 per material and 
time). 
 
5.4.4 Cell proliferation assessed by MTS assay  
5.4.4.1 Osteoblast proliferation on PLA and PLA-nHA films 
Osteoblasts cell proliferation on different films is shown in Figure 5.10. Among 
the films, cells showed highest proliferation on PLA-nHA10 films. The rate of 
proliferation of cells decreased with the increase of nHA content in the films. 
Cells reached confluence at 10 days on PLA and PLA-nHA10 films, whereas the 
cells were still proliferating on PLA-nHA40 and PLA-nHA70 composite films at day 
14. PLA-nHA70 films showed less cell growth when compared to the other films. 
The experiment was repeated three times with similar results.  
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Figure 5.10:  Proliferation of osteoblasts on PLA and PLA-nHA films containing different 
amount of nHA (n=3 per material and time) 
5.4.4.2 PDL cells proliferation on PLA-nHA films 
PDL cells showed similar responses on films with different nHA content. Cells 
proliferated less on films with higher HA content. Figure 5.11 shows more cell 
proliferation on PLA-nHA10 composite film than on PLA-nHA70 composite film. 
The experiment was repeated three times with similar results. 
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Figure 5.11: Proliferation of PDL cells on films containing different amount of nHA 
compared to tissue culture plastic as the control (n=3 per material and time) 
   
Chapter 5 
 187 
5.4.4.3 Osteoblast proliferation with PDGF added on the films and in 
the medium 
Figure 5.12 shows the proliferation of cells at day 3 on different films loaded 
with PDGF and on films in which PDGF was added in the cell medium. The films 
on which PDGF was directly added showed more cell proliferation compared to 
films in which PDGF was added to the cell medium. There was no difference 
between cell proliferation on positive control films with 10% FCS and films with 
PDGF in the medium, whereas PDGF adsorbed to films caused the greatest 
proliferation. The lowest cell proliferation was seen on negative control films 
with 1% FCS and no PDGF added. The experiment was repeated three times with 
similar results. 
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Figure 5.12: Osteoblast cell proliferation in response to PDGF adsorbed to films or in 
solution in the medium.  Mean ± SD n=3 per material and serum condition.  *Significantly 
less than other groups.  **Significantly greater than other groups, p<0.05 1–way ANOVA and 
Bonferroni Post test.  
 
 
 
** ** 
* * * * 
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5.4.4.4 Alkaline phosphatase activity 
Figure 5.13 shows alkaline phosphatase activity of osteoblasts cells at the 14th 
day after culturing on different films. The data was normalized by cell number. 
The cells on PLA-nHA films containing 70 wt % nHA showed the highest alkaline 
activity, whereas the lowest cell activity was observed on control and PLA films.  
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Figure 5.13: ALP activity of osteoblasts cells seeded on different films. The data was 
normalized by cell numbers. (n=3 per material). Mean ± SD.  *Significantly greater than other 
groups, p<0.05 1–way ANOVA and Bonferroni Post test.   
 
5.4.4.5 Cell morphology 
SEM images of cells at day 14 after culturing on PLA, PLA-nHA10, PLA-nHA40 and 
PLA-nHA70 composite films are shown in Figure 5.14. The cells on the films are 
well spread and fully cover the films. The cells on PLA and PLA-nHA10 films are 
densely packed and forming layers. On the films containing 40 and 70 wt % nHA 
the cells are bridging over the surface depressions and pores formed by the nHA 
particles. 
 
 
a b 
* 
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Figure 5.14: SEM images of cells cultures at day 14 on (a) PLA (b) PLA-nHA10, (c) PLA-
nHA40 and (d) PLA-nHA70 composite films (All scale bars= 2µm). 
 
5.5 DISCUSSION 
Different materials are currently being used as barrier membranes for guided 
tissue regeneration (GTR), however with limited regeneration potential. 
Consequently there is considerable interest in further developments in 
regenerative techniques to improve outcomes and predictability. One possible 
development is to use growth factors incorporated in the membranes for their 
release at the site to enhance tissue growth. 
In this study nHA-PLA composite films have been analyzed as potential materials 
for GTR membranes. In order to assess biocompatibility, the effect of these films 
on growth of osteoblasts and PDL cells was tested. The aim was to develop a 
membrane which can enhance regeneration by combining the properties of 
resorbable PLA and bioactive nHA and also has the ability to deliver bioactive 
proteins such as growth factors at the defect site, thus further enhancing 
regeneration. 
2 µm 2 µm 
2 µm 2 µm (a) (b) 
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Hydroxyapatite is a known biocompatible and osteoconductive material and has 
the ability to absorb and release proteins [Matsumoto et al., 2004]. nHA with 
particle size between 40-60 nm was produced and the SEM image (Figure 5.2) of 
nHA shows the nano and spherical structure of the particles. Nano and spherical 
structured HA is advantageous, as it provides more surface area and binding sites 
for both, cell attachment and protein absorption. The crystallinity and purity of 
nHA was confirmed by XRD which only showed the reflection peaks associated 
with HA and no peaks related to tricalcium phosphate or calcium oxide were 
present. Similarly, the nHA FTIR spectra showed the typical characteristics of HA 
[Khan et al., 2008].  
SEM images of films with different nHA content showed that as the nHA content 
increases, the surface of film becomes rougher which could provide more 
surface area for cell attachment [Teng et al., 2009]. In FTIR spectra of films, 
there was no shift of PLA carbonyl group peak at 1760cm-1, which shows that the 
mixing of PLA and nHA is physical and no chemical reaction took place. Bending 
peaks of phosphate from HA between 538cm-1 and 638cm-1 become more 
pronounced as the nHA content increases from 10 to 70 wt %. The OH group peak 
at 3571cm-1 is only visible in PLA-nHA containing 70 wt % nHA.  
The effect of nHA-PLA films on proliferation and differentiation of osteoblasts 
were tested. Both cell proliferation and differentiation were assessed on the 
same sample so that the results can be correlated. It is known that the initial 
cell adhesion to a material is important, because it greatly influences the 
succeeding processes of cell proliferation and differentiation [Dalby et al., 2002; 
Verrier et al., 2004].  
CASY cell counter results showed that cell number increased at 5 day compared 
to 1 and 3 days. However, the results did not show any specific pattern of cells 
growth on different films or the effect of different films on the cells 
proliferation. This high variation can be either due to ineffectiveness of 
trysinisation to completely remove cells from films or due to CASY counter 
reading errors resulting from the presence of nHA particles in the solution. 
Longer than usual incubation after trysinisation and cleaning of CASY counter 
(cleaning was done with running a cycle of CASY solution) after every reading 
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was tried to overcome this problem, but with little success. Thus the CASY 
technique was rejected in this application. 
The MTS assay showed less variable results and a constant pattern of cell growth 
on different film, so after initial tests all the experiments were carried out using 
the MTS assay. Both osteoblasts and PDL cells showed high proliferation on films 
with lower nHA content and low proliferation on films with high nHA content.  
PDL cells showed more proliferation on films containing 10 wt % nHA than films 
which contained 70 wt % nHA. Similar results were shown by osteoblasts, with 
the highest cell proliferation being shown by cells on films containing 10 wt % 
nHA followed by films containing 40 and 70 wt % nHA respectively. There was 
minimal difference between the number of cells on PLA and PLA-nHA10 films at 
day 10 and 14; this may be because the cells had already reached confluence on 
these films at day 10, whereas the cells on PLA-nHA40 and PLA-nHA70 films were 
still proliferating at days 10 and 14 and showed an increase in number between 
days 10 and 14. 
ALP levels can be attributed to the degree of cell differentiation [Matsuyama et 
al., 1990]. In this study, high ALP expression showing differentiation of 
osteoblasts cells on films containing high concentrations of nHA may explain the 
low number of proliferating cells on PLA-nHA40 and PLA-nHA70 film, and high 
number of cells on PLA and PLA-nHA10 films.  The highest ALP activity was seen 
in the cells on PLA-nHA70 films, which is probably due to the differentiation 
promoting effect of nHA on cells. Low levels of ALP in cells on PLA and PLA-
nHA10 films suggest no or low differentiation of these cells. Theses results are in 
support of various studies that nHA encourage bone cells to differentiate [Hott 
et al., 1997; Matsumura et al., 2004; Zhang et al., 2008].  
PDGF is a heparin-binding polypeptide and has mitogenic, proliferative and 
chemotactic effects on connective tissue cells [Nevins et al., 2003]. PDGF 
adsorption in the composite films and its subsequent effect on the proliferation 
of osteoblasts was analyzed. The cells which were treated with PDGF, either by 
adding PDGF in the serum or by absorption in the films, showed more 
proliferation on  day 3 as compared to 1% serum control samples. Cell 
proliferation on samples where soluble PDGF was added to the medium and on 
control samples containing 10% serum in the medium were similar. However the 
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highest cell proliferation was seen on films where PDGF had been pre-adsorbed.  
This result shows that the effect of PDGF on cells was highest where a carrier 
was used and also establishes that these films can be used as a carrier for 
growth factor delivery. 
5.6 CONCLUSIONS 
The highest proliferation of PDL cells and osteoblasts was achieved on PLA-
nHA10 films, whereas highest ALP activity was shown by cells cultured on 
composite films containing 70 wt % nHA. PDGF enhanced the proliferation of 
osteoblasts. The highest proliferation was shown by cells on films pre-adsorbed 
with PDGF which shows the suitability of these composites as a carrier system 
for growth factor delivery. A composite material containing high concentration 
of nHA may be a very useful material for application as a GTR membrane. 
 CHAPTER 6: DETERMINATION OF THE FLEXURAL 
STRENGTH OF POLYLACTIC ACID-HYDROXYAPATITE 
COMPOSITE MEMBRANES 
6.1 INTRODUCTION 
Collapse of GTR membranes is one of the major causes of their failure which 
results in compromised clinical outcomes. An ideal membrane should be stiff 
enough to withstand overlying tissue and masticatory pressure. This requirement 
is more important when the GTR membrane is used without graft to cover a 
large bone defect. Although a stiff membrane will be able to withstand the 
occlusal forces, it may not be easy to adapt a stiff membrane over the bone 
defects and may require substantial chair side preparation. Additionally a stiff 
membrane may also damage the soft tissue.  
The strength and stiffness of a membrane can be improved by using a fibre 
reinforced composite material, also the limitations of using a stiff membrane 
can be avoided by using a prefabricated membrane. This prefabrication can 
minimize the chair side preparation and will also improve membrane adaptation. 
As has been investigated in chapter 8, few membranes shapes can fit most of the 
alveolar bone defects it may be possible to use prefabricated membranes with 
adequate strength and stiffness to withstand the occlusal pressures.  
The aim of study reported in this section is to investigate the effect of fibre 
orientation on the flexural strength of the proposed PLA-HA-PLA fibre composite 
membrane.   
6.2 MATERIALS 
6.2.1 PLA 
The PLA used as the matrix polymer was obtained from PURAC Biochem (The 
Netherlands) and is described in section 2.2.1.  
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6.2.2 PLA fibres 
Drawn PLLA fibres were obtained from Degradable Solutions Ltd, Switzerland. 
They had mean fibre diameter of 50 – 80 µm.  
6.2.3 HA 
Sintered HA (sHA) was used as filler in the composite and is described in section 
2.2.3.  
6.3 METHODS 
6.3.1 Prepregging 
PLA-HA-PLA fibre composite sheets were prepared using a prepregging machine. 
To prepare the prepreg, PLA fibres were pulled through a PLA-HA matrix solution 
and then collected on a rotating drum as shown in Figure 6.1.   
 
 
Figure 6.1: PLA fibre being collected on a drum after passing through PLA-HA matrix (image 
from Prof Liz Tanner). 
 
 
PLA fibre Bath 
Prepreg 
collected on 
the drum 
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The PLA-HA matrix solution was prepared by dissolving PLA in acetone, in which 
sHA was added to obtain a final 70 % wt concentration. 10 g PLA was added to 
500 ml acetone in a flask and stirred for 6 hours at room temperature. Once the 
PLA was completely dissolved, 7 g sHA was added to the solution and stirred for 
a further 72 hours to ensure a homogenous mix. The matrix solution was then 
transferred into the bath on the prepregging machine. Next two fibre spools 
were mounted at the opposite side of the collection drum and the fibres were 
unwounded and passed through the matrix bath and wounded onto the drum 
which was covered with a wax paper. The machine was started to rotate the 
drum which also moved transversely. After the rotating drum was covered with a 
layer of prepreg the machine was stopped. The prepreg was left on the drum to 
dry overnight. Once completely dried the sheet was cut off from the drum and 
heat treated. For heat treatment, the prepreg was cut into smaller pieces 
(Figure 6.2) which were then pressed between two metal plates and placed in 
the oven at 70 °C for 1 hour. After one hour the oven was turned off and the 
specimens were allowed to cool gradually over night. An optical microscope 
image of the prepreg sheet is shown in Figure 6.3.     
 
 
Figure 6.2: Prepreg containing PLA fibres in a PLA-HA matrix. 
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Figure 6.3: An optical microscope image of prepreg sheet showing PLA fibres embedded in 
the PLA-HA matrix. (Image from Dr Wojciech Chrzanowski )   
 
  
6.3.2 PLA-HA-PLA fibre composite membrane fabrication 
PLA-HA-PLA fibre composite membranes were fabrication by hot pressing 7 
layers of prepreg in a stainless steel mould with three different lay ups. The 
prepreg lay up used were 0°/0°/0°/90°/0°/0°/0°, 0°/0°/90°/0°/90°/0°/0° 
and 0°/90°/0°/90°/0°/90°/0° as shown in Figure 6.4 (a) Group 1, (b) Group 2 
and (c) Group 3 respectively.  
 
 
 
 
 
 
 
 
Figure 6.4: Prepreg lay up used for membranes fabrication (a) 0°/0°/0°/90°/0°/0°/0°, (b) 
0°/0°/90°/0°/90°/0°/0° and (c) 0°/90°/0°/90°/0°/90°/0°.  
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The mould was placed in the hot press (Mackey Bowley, Kent, UK) and the 
pressure was applied. The temperature was gradually increased to a maximum of 
140 °C. The pressure was increased with increase in the temperature, thus final 
pressure at 140 °C was 10 MPa. On reaching 140°C the mould was kept at this 
temperature for 3 minutes before the heating was turned off and the mould was 
allowed to cool under pressure. Once the temperature dropped to 40°C the 
mould was removed from the hot press and the membrane was taken out (Figure 
6.5). The thickness of all the membranes produced was nominally 0.9mm. The 
samples were then cut parallel to long axis of the mould to get the fibre 
orientation shown in Figure 6.4.   
  
  
Figure 6.5: (a) Mould used to hot press the prepreg, and (b) a seven layer PLA-HA-PLA fibre 
composite membrane produced using the prepreg.  
 
Additionally the membranes of Group 1,2 and 3 were cut across the long axis, 
which gave the samples having fibre orientation 90°/90°/90°/0°/90°/90°/90°, 
0°/90°/0°/90°/0°/90°/90°and 90°/0°/90°/0°/90°/0°/90° respectively and are 
shown in Figure 6.6 (a) Group 4, (b) Group 5 and (c) Group 6. 
(a) 
(b) 
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Figure 6.6: Membranes of Group 1, 2 and 3  were cut across and resulted in samples with 
fibre orientations (a) Group 4, 90°/90°/90°/0°/90°/90°/90°, (b) Group 5, 90°/90°/0°/90°/0°/90°/90° 
and (c) Group 6, 90°/0°/90°/0°/90°/0°/90° respectively. 
 
6.3.3 Four point bending test 
The tests were carried out using a MTS machine (858 MiniBionix® II). Figure 6.7 
(a) shows sample setup for four point bending test and (b) a sample being tested 
under the applied displacement. 
    
Figure 6.7: (a) Sample setup for four point test and (b) a sample being tested.  
A force displacement curve was recorded for each sample. From the curve 
maximum force and displacement were extracted for calculating flexural 
strength and flexural modulus using equation 6.1 and 6.2 respectively.  
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where σ is the flexural strength, F is the load (force) at any given point, L is the 
length of the support span, b is the sample width, d is the sample thickness and 
m is the slope.  
The load was applied at the rate of 5 mm.min-1. The length and width of each 
samples were measured and an average of three readings was obtained. Five 
samples were tested from each group for a maximum displacement of 8 mm.  
6.3.4 Data Analysis 
Statistical analyses were done by 1- way ANOVA with Bonferroni’s post-test with 
P < 0.05.   
6.4 RESULTS 
Figure 6.8 show a force displacement curve used to calculate flexural strength 
and flexural modulus.  
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Figure 6.8: A force displacement curve used to calculate maximum force and displacement.  
Equation 6.1 
Equation 6.2 
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Figure 6.9 show the flexural strength of the membranes with different prepreg 
lay ups. The graph shows the mean value and standard deviation of 5 samples 
from each group. The highest flexural strength was shown by membranes of 
groups 2 which had the maximum numbers of prepreg sheets laid at 0°, although 
the difference was not significant from the membranes other groups, except the 
membranes of group 4 and 5. The membranes of group 4 and 5 which had the 
maximum numbers of prepreg sheets laid at 90° showed significantly low 
flexural strength. 
0
50
100
150
200
250
 0
°/0
°/
0°
/9
0°
/0
°/0
°/
0°
0°
/0
°/9
0°
/0
°/9
0°
/0
°/
0°
 0
°/
90
°/
0°
/9
0°
/0
°/
90
°/0
°
90
°/9
0°
/9
0°
/0
°/9
0°
/9
0°
/9
0°
90
°/9
0°
/0
°/9
0°
/0
°/9
0°
/9
0°
90
°/0
°/9
0°
/0
°/
90
°/0
°/
90
°
Prepreg lay up
F
le
x
u
ra
l 
s
tr
e
n
g
th
 (
M
P
a
)
 
Figure 6.9: Flexural strength of PLA-HA-PLA fibre membranes having different prepreg lay 
ups. Mean + SD n=5 per group. * Significantly less than other groups, p<0.05, one way 
ANOVA and Bonferroni post test.  
 
Figure 6.10 show the flexural moduli of the membranes with different prepreg 
lay ups. The graph shows the mean value and standard deviation of 5 samples 
from each group. The membranes of group 4 which had the maximum numbers 
of prepreg sheets laid at 90° showed significantly lower flexural modulus than 
membranes of all other groups except from the membranes of group 5. Whereas, 
the highest flexural modulus was shown by membranes of groups 2 which had 5 
prepreg sheets laid at 0°, however it was not significantly higher than 
membranes of group 1 and 3.  
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Figure 6.10: Flexural modulus of PLA-HA-PLA fibre membranes having different prepreg lay 
ups. Mean + SD n=5 per group. * Significantly different than group 4, 5 and 6, ** significantly 
different than group 4 and 5, *** significantly different than group 1, 2, 3 and 6, **** 
significantly different than group 1, 2 and 3, ***** significantly different than group 1,2 and 4, 
p<0.05, one way ANOVA and Bonferroni post test.  
 
6.5 DISCUSSION 
In an attempt to produce a periodontal membrane with improved physical and 
biological properties we have investigated PLA-HA-PLA fibre composites as 
potential membrane materials. The use of fibres has been established to 
increase the properties of the material. Additionally the use of the fibres of 
same material as matrix results in a chemical bonding between the fibres and 
matrix which eliminate the possibility of a weak interface between the fibre and 
the matrix.  
The mechanical properties of a fibre reinforced composite depends on number 
of factors which includes [Behr et al., 2000]: 
• orientation of fibres:  
Unidirectional fibres= produce anisotropic mechanical properties 
Multidirectional fibres= produce orthotropic mechanical properties 
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Group2 
Group 4 
Group 5 
Group 6 
Group3 
***** 
*** 
* 
**** 
** 
* 
Chapter 6 
 202 
 
• adhesion of fibres to the matrix polymer: 
Proper adhesion between fibres and the matrix is important for the 
transfer of load from matrix to the fibres. Additionally proper adhesion 
between the fibre and the matrix reduces the chances of voids and 
cracks.   
In this pilot study flexural strength and flexural modulus of the PLA-HA-PLA fibre 
membranes were analyzed by a four point bending test.  
As shown in Figure 6.9 and 6.10 the flexural strength and the flexural modulus of 
the PLA-HA-PLA fibre composite membranes were affected by the fibre 
orientation in the prepreg lay up. The highest flexural strength and modulus was 
shown by membranes of Group 2 which had the maximum number of prepreg 
layers laid at 0° reinforced transversally with two prepreg layers laid at 90°. The 
possible explanation for this pattern of high flexural strength for membranes 
having more prepreg laid up at 0° if the force is applied perpendicular to the 
long axis of the fibres then the fibres contribute to the resistance against the 
force and provide strength to the material. Whereas if the force applied is 
parallel to the fibre long axis, it results in the production of the failure at the 
matrix-fibre interface and the fibres do not contribute to the resistance against 
the force applied [Dyer et al., 2004]. The membranes of group 4 which had the 
maximum numbers of prepregs laid at 90° showed the lowest flexural strength 
and modulus. This result can be because the positions of maximum numbers of 
fibre present in these membranes were parallel to the applied force, which can 
result in more chances of a material failure at the fibre-matrix interface.   
6.6 CONCLUSIONS 
This study showed that the flexural strength of a PLA-HA-PLA fibre composite 
membranes depend on the orientation of fibres in the prepreg. Hence the 
strength of the membrane can be optimised by laying up most of the prepreg at 
0° reinforced transversally by one or two layers laid at 90°.   
 CHAPTER 7: RELEASE OF PROTEIN FROM POLYLACTIC 
ACID-HYDROXYAPATITE COMPOSITE MEMBRANES. 
  
7.1 INTRODUCTION 
The ideal membrane for GTR is resorbable and has sufficient mechanical 
stiffness to prevent intrusion of the soft tissues into the defect, yet be 
sufficiently flexible for the dental surgeon to be able to fit around the defect. 
However, the additional potential benefits of secondary biological activities of 
membranes including osteoconduction and the potential to release bioactive 
proteins to accelerate the healing process remain to be investigated. In these 
cases, release of bone bioactive proteins might ideally be directed in a 
unidirectional manner, resulting in release to the bone contacting surface, with 
limited release towards the gingival contacting surface. 
In this study the interaction of proteins with PLA-HA composite membrane 
material has been investigated. Specifically, the aims of the study are to 
investigate the protein release kinetics of the material, its permeability and the 
effects of alterations in membrane composition on these properties. As this was 
a release study only three layers of pre-preg was used in each specimen. 
7.2 MATERIALS 
7.2.1 PLA-HA Composite Membranes 
Composite sheets consisting of PLA fibres in a PLA matrix with and without 
hydroxyapatite were used. The PLA drawn fibres had an L: D ratio of 96:4 (wt %) 
and a diameter between 70 to 90µm (supplied by Tampere University of 
Technology Finland). Matrix PLA had an L: D, L ratio of 70:30 (wt %) (Boehringer 
Ingelheim, Germany). 
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For the HA reinforced sheets the PLA matrix solution contained HA (Mean 
particle size=2.99, Specific surface areas 16.3 m2g-1) (Plasma Biotal Ltd, 
Tideswell, UK) giving PLA-HA-PLA fibres composite. Thus in the HA-PLA-PLA fibre 
composite the PLA fibres were held in an HA-PLA matrix while in the PLA-PLA 
fibre composite the PLA fibres were in an unfilled PLA matrix. In the HA-PLA-PLA 
fibre composite the HA content was 20 wt % of the whole specimen. 
7.2.2 PLA-nHA Composite Films 
For the production of PLA-nHA composite films, PLA and nHA were used as 
described in detail in sections 5.2.1 and 5.2.2 respectively.  
7.2.3 Other materials 
Bovine serum albumin, minimum 98% (Sigma, batch # 025K0598) was used to 
evaluate the protein release pattern of the membranes.  
Bio-Rad protein assay reagents A and B (Catalog # 500113 and 500114) were used 
to determine the quantity of protein released.  
FLUOstar Optima (BMG Labtech) microplate reader was used to read the protein 
concentrations. 
7.3 METHODS 
7.3.1 PLA-HA-PLA fibre composite membrane fabrication 
The trilayer membranes were produced using a hand lay-up procedure in a 
stainless steel mould using a hot press (Palamine, Haverhill, UK) (Figure 7.1). 
The PLA fibres of the top and bottom layers were parallel, while the fibres of 
the middle layer were perpendicular to the other two layers (0/90/0). The 
membranes were produced at different pressures and temperatures. The 
temperatures used were 140 °C and 150 °C while the pressures used were 2.72 
MPa and 3.14 MPa which gave membrane thickness of 0.25mm and 0.2mm 
respectively. 
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Figure 7.1 Hot press [Palamine, Haverhill, UK] 
 
 
7.3.2 Film fabrication 
The PLA and PLA-nHA composite films were fabricated as described in detail in 
section 2.3.1. The films were then cut into 6mm circular samples. 
7.3.3 Measurement of Protein Concentrations 
Protein concentrations of solutions were measured using the BioRad protein 
assay based on the method of Bradford [Bradford, 1976].  BioRad reagent was 
added to solutions as described below and optical density measured by 
spectrophotometery at 595 nm wavelength.  Optical density readings were 
converted to true protein concentrations from a standard curve constructed 
using a series of albumin concentrations from 0 µg ml-1 to 500 µg ml-1. 
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7.3.4 Measurement of Protein Release 
For each experiment, PLA-HA-PLA fibres composite membrane pieces of 
nominally equal weight were placed in 24 well plates and 1 mg bovine serum 
albumin (BSA) dissolved in distilled water was added on to the surface of the 
membranes as a drop. Plain PLA-PLA fibre membranes were used as controls. 
The membranes were kept at room temperature and allowed to dry overnight. 
Specimens where the drop did not remain on them were discarded. Next, 
membranes were placed in new well plates and 1ml of PBS was added to each 
well. A sample solution of 50µl each was taken out at 0.25, 1, 2, 4, 24, 48, 72 
and 96 hours. 50 µl Bio-Rad with an additional 50µl PBS was added to the sample 
solutions and the readings were obtained as before. The remaining PBS solution 
in the wells was completely replaced by fresh 1 ml of solution after each 
sampling time point. Three samples were measured for each material and each 
time point.  
7.3.5 Permeability of films  
Tests were conducted to check the permeability of PLA films and PLA-nHA 
composite films with different concentrations of nHA.  To conduct these tests, 
films were placed in a 48 well micro-chemotaxis chamber (NeuroProbe Inc, 
CabinJohn, MD USA) (Figure 7.2). For diffusion control, films were deliberately 
pierced using a small gauge hypodermic needle to allow free diffusion between 
the upper and lower chambers. Chambers in the lower plate were filled with 
26µl of solution and in the upper plate all the chambers were filled with 50µl 
PBS, except the positive control which was filled with 50µl albumin as shown in 
Table 7.1. Thus the negative control had PBS on both sides of the film and the 
positive control had albumin on both sides of the film, while the active 
chambers had PBS in the upper chamber and albumin in the lower chamber. The 
films tested were non-filled PLA and PLA-nHA composite films containing 25 wt % 
nHA (PLA-nHA25) and 75 wt % nHA (PLA-nHA75). 25µl of sample solution was 
obtained from the upper chambers at 0.5, 2, 4 and 24 hours.  25µl of PBS and 
50µl of Bio-Rad was added to the 25µl sample solution and readings were 
obtained using a spectrophotometer at 595nm wavelength as before 
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Figure 7.2: 48 well micro chemotasis chamber used to measure the permeability of PLA and 
PLA-nHA composite films. 
 
Table 7.1: Set-ups for PLA-nHA composite film permeability test (n = 3 for each group) 
showng solutions placed in upper and lower chambers of test kit.  
 Lower Chamber Upper Chamber 
-ve control 
Test 
Diff control* 
+ve control 
PBS 
BSA 
BSA 
BSA 
PBS 
PBS 
PBS 
BSA 
* Pierced Membrane 
7.3.6 Statistical analysis 
Where appropriate, protein concentrations were calculated from optical density 
readings using standard curves of known concentrations of BSA.  Means and 
standard deviations were calculated, and statistical differences were tested by 
1-way ANOVA with Bonferroni’s post test. Statistical significance was assumed if 
the P-value was less than or equal to P < 0.01 
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7.4 RESULTS 
7.4.1 Optical density values for different BSA concentrations 
Figure 7.3 shows the optical density values obtained with different 
concentrations of BSA. This standard curve was used to convert the optical 
density readings obtained in the experiments into protein concentration values. 
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Figure 7.3 Measurement of different proteins concentrations 
 
 
7.4.2 Protein release from the membranes 
During the first hour the PLA-PLA fibre composite membrane released more BSA 
than the PLA-HA-PLA fibre composite membranes (Figure 7.4). The PLA-PLA fibre 
membrane released most of the BSA during the first two hours and the release 
reduced subsequently, by the end of 24 hours the release was negligible. 
However release from PLA-HA-PLA fibres composite membrane was gradual and 
persistent with small amounts released even at 96 hours. 
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Figure 7.4 Amount of BSA released from PLA-PLA fibre and HA-PLA-PLA fibres composite 
membrane in 96 hours showing means and standard deviations. n=3 
 
7.4.3 Protein release from PLA-HA-PLA fibre composite 
membranes produced at different temperatures and pressures 
Different patterns of BSA release were observed from the PLA-HA-PLA fibres 
composite membranes produced at different temperatures and pressures (Figure 
7.5). During the first hour the membranes produced at higher temperature and 
pressure i.e. 150 °C and 3.14 MPa showed greater BSA release than the 
membranes produced at lower temperatures and pressures i.e. 140 °C and 2.72 
MPa. However, the release of BSA from the membranes produced at higher 
temperatures and pressures decreased to negligible amounts after four hours. In 
contrast release from the membranes produced at low temperatures and 
pressures were initially lower, and their release was more prolonged and was 
still detectable at 48 hours. 
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Figure 7.5 Release of BSA from PLA-HA-PLA fibres composite membranes produced at 
150°C and 3.14 MPa or 140°C and 2.72 MPa upto 48 hours showing means and standard 
deviations. n=3 
 
7.4.4 Permeability of membranes with different concentrations of 
HA 
Figure 7.6(a) shows the permeability of PLA films. The diffusion through PLA film 
was negligible even at the end of 24 hours. Figure 7.6 (b) shows the permeability 
of films containing 25 and 75 wt % nHA.  During the initial four hours the 
diffusion of protein from the two membranes was low and did not differ greatly.  
However at the end of 24 hours the diffusion through the PLA-nHA75 film was 
substantially higher than through the PLA-nHA25 film.  Figure 7.6 (c) shows the 
results of control experiments when albumin was added to both upper and lower 
chambers. Albumin concentration for PLA-nHA25 film at half an hour was very 
high when compared to PLA-nHA75 film. Albumin concentration for PLA-nHA25 
film decreased subsequently with time, whereas for PLA-nHA75 film the 
concentration remained low throughout. Figure 7.6 (d) shows the results of 
“diffusion control” experiments where albumin was placed in the lower chamber 
and the membrane was deliberately pierced to allow free diffusion. In these 
experiments, the albumin concentration for the PLA-nHA75 film was higher than 
PLA-nHA25 film at 0.5, 2 and 4 hours, whereas at 24 hours the albumin 
concentration for both the films was similar.  
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Figure 7.6: Permeability tests: 
(a) Amount of protein diffused through PLA film up to 24 hours, (b) Amount of protein diffused 
through PLA-nHA25 and PLA-nHA75 composite films up to 24 hours, (c) Positive control. Readings 
obtained at different time points for PLA-nHA25 and PLA-nHA75 composite films when albumin 
was added to both upper and lower chambers of the micro-chemotaxis chamber and (d) Diffusion 
(d)  
 
 (c)  
* 
* 
* * 
* * 
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control. Readings obtained at different time points for PLA-nHA25 and PLA-nHA75 composite 
films when films were deliberately pierced. Mean ± SD  n = 3 replicate samples at each time 
point.  * indicates significantly different between tests at specified time point (P < 0.01) by 1-
way ANOVA and Bonferroni post test. 
 
7.5 DISCUSSION 
As noted previously, although a range of different materials have been used for 
GTR procedures, none of these have ideal properties. The construction of 
composite membranes using HA-filled PLA-PLA fibre laminar structures is a novel 
approach to this problem, which may have advantages over current materials.  
The material is expected to have superior mechanical properties compared to 
conventional membranes due to the presence of PLA fibres [Yair, 2006] even in 
thin sections, whilst retaining its resorbable properties. Whilst a full 
characterisation of the mechanical properties of these membranes is planned for 
further investigations, empirically these composite membranes are both stiff and 
strong.     
Protein release patterns from PLA-HA-PLA fibre composite membranes were 
more sustained than protein release from PLA-PLA fibre membranes. Both 
membrane types released high levels of BSA during the first hour, which may be 
the result of the release of BSA present on the surface of the membranes and 
which occurred quickly. However for PLA-PLA fibre membranes there was 
minimal sustained protein release, whereas release from PLA-HA-PLA fibres 
composite membranes was more sustained with measurable release still being 
detectable after 48 hours.  Mizushima et al. [2006] have reported the sustained 
release of the drug interferon alpha from porous hydroxyapatite particles, which 
would support these observations.  
Similarly, PLA-HA-PLA fibres composite membranes produced at lower 
temperatures and pressures had more sustained protein release kinetics than 
membranes produced at comparatively higher pressures and temperatures. 
Membranes produced at lower temperature and pressure showed the same 
pattern of more sustained release for longer times, whereas for membranes 
produced at high temperature and pressure most of the total BSA was released 
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during the initial few hours. This difference is probably due to greater 
compaction of the membrane produced at higher temperature and pressure, 
allowing less space for the ingress of BSA inside the membrane.  This results in 
the BSA being absorbed or adsorbed only onto the surface of the membrane and 
subsequently released quickly.   
It appears that when there is space either between the pre-peg sheets or 
between the HA particles and the PLA matrix within a membrane or film, they 
are able to absorb more protein and subsequently release the protein more 
slowly.  
PLA-nHA composite films showed much greater permeability for protein when 
compared to PLA films.  The permeability of films increased with the increase of 
nHA content in the films.  These results suggest that permeability is related to 
porosity due to nHA incorporation.  PLA films without nHA were essentially non 
permeable.  
In these experiments, a “positive control” was used to validate the assay 
process, whereby equal concentrations of the protein were placed in the upper 
chamber of the diffusion test apparatus. This experiment was carried out to 
determine if there were changes in protein concentration with time, due to 
absorption of protein to the film and the diffusion chamber. Data from these 
controls showed a decrease in albumin for PLA-nHA75 film as compared to PLA-
nHA25 film at 30 minutes. This may be due to the fact that albumin is being 
absorbed at a greater rate with the higher concentrations of nHA in PLA-nHA75 
film. In addition “diffusion control” was also used where films were deliberately 
pierced to allow free diffusion between chambers of the apparatus. The high 
albumin diffusion through PLA-nHA75 composite film seen in these tests during 
the initial four hours may be due to larger holes produced on piercing as that 
material is more highly filled, and therefore has more interfaces through which 
the protein can track. The results demonstrate that the incorporation of the nHA 
into the membrane substantially alters the diffusion of protein through the films 
and suggest the possibility that an unfilled PLA coating on one side of the GTR 
membrane could be readily used to direct protein release unidirectionally as 
required clinically.   
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Overall, the data demonstrates that the protein release kinetics of these 
composite materials can be controlled by a combination of altering membrane 
composition, and the temperature and pressures used for their production. 
7.6 CONCLUSIONS 
The protein release kinetics of PLA-HA-PLA fibre composite membranes 
demonstrate a more sustained release of protein when compared to PLA-PLA 
fibre membranes. Thus these composite membranes could be useful 
therapeutically as a delivery system for bioactive proteins. The diffusion of 
protein through PLA-nHA composite film increases with increased nHA content. 
This property may be beneficial in order to obtain directional release of proteins 
by differential coating of membrane surfaces with unfilled and filled PLA films.
 CHAPTER 8: ANALYSIS OF ALVEOLAR BONE 
RESORPTION PROFILE 
  
8.1 INTRODUCTION 
Guided tissue regeneration (GTR) membranes are used for the regeneration of 
alveolar bone lost during periodontal diseases or resorbed after the loss of tooth.  
Periodontal diseases affect the periodontium which is the supporting structure 
for the tooth and in severe cases of periodontal disease the supporting structure 
in the jaw gets destroyed which ultimately results in tooth loss. The treatment 
aim in such cases is not only to stop the disease process but to also regenerate 
the lost periodontal tissues. Different methods are being used for the treatment 
and regeneration of periodontal tissues (section 1.4).  
Extraction of teeth which are damaged due to caries or trauma also results in 
the resorption of alveolar bone not only in the buccolingual direction but also in 
the vertical direction (Figure 8.1). In order to restore the alveolar ridge shape to 
be suitable for dental implants, different methods of bone regeneration are 
employed, including the use of GTR membranes.      
 
Figure 8.1:  The progression of maxilla and mandible alveolar ridge resorption, from (A) 
shortly after extraction of tooth through to subsequent gross atrophy (E) [modified from 
[Floyd et al., 1999].   
Different types of GTR membrane are currently used. Ease of use and 
adaptability are two of the major requirements of GTR membranes for successful 
results. However, additionally the stiffness of the GTR membrane needs to be 
A   B      C      D        E
  
Maxilla 
 
 
 
 
 
 
Mandible 
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high enough to prevent the collapse under the soft tissue or occlusal pressure 
under mastication.  
As a part of the study to develop a composite membrane with enhanced 
regeneration potential, an analysis of the alveolar bone resorption pattern was 
performed to define a membrane shape which is suitable for most of the cases. 
The PLA/PLA fibre/HA composite material described in previous chapters 
potentially has good mechanical properties for maintenance of space under 
periodontal wounds, compared to existing membranes. However existing 
membranes are highly flexible and can be adapted to the required shape over 
the bone. In contrast our PLA/ HA membranes show increased stiffness and 
therefore are likely to require a degree of pre-shaping during the manufacturing 
process.  Thus it is envisaged that a clinician might select one of a number of 
preformed membrane shapes for each specific defect and then trim it 
accordingly.  In order to test the feasibility of this idea it was decided to carry 
out a pilot study to determine the cross sectional profiles of membranes 
required and to determine the extent of variability of membrane profiles 
required.  
8.2 MATERIALS AND METHODS 
To determine the alveolar bone loss pattern following protocol was devised: 
 
8.2.1 Selection of cases 
To determine the profile of alveolar bone resorption seven partially and 
completely edentulous patients aged between 25 and 60 which were already 
under clinical assessment for placement of dental implants were selected. 39 
computerised tomography (CT scan) slices from different edentulous areas of 
mandibular alveolar ridges were obtained, in collaboration with Dr Jimmy 
Makdissi, Consultant Radiologist, Barts and the London Dental Hospital. Figures 
8.2 and 8.3 respectively show cross sectional slices of alveolar ridges of anterior 
and posterior mandibles of two different patients. The cross sectional scan slices 
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were obtained parallel to occlusal plane of the mandible. These scans were then 
used to draw possible shapes for GTR membranes.  
Figure 8.2: Cross sectional scan images of an anterior mandible, the distance between each 
scan slice was 2mm. Cortical thickness and trabeculation density can also assessed from 
the scan slices. 
 
Figure 8.3: Cross sectional scan images of posterior mandible, the distance between each 
scan slice was 2mm. Cortical thickness and trabeculation density can also assessed from 
the scan slices.  
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8.2.2 Determination of GTR membrane shape 
Cross sections of edentulous alveolar ridges obtained from CT scans were printed 
and a suitable GTR membrane shape was hand drawn over the alveolar ridges by 
an experienced periodontologist (Prof Francis Hughes). Figure 8.4 shows the 
profile of GTR membranes drawn over the anterior and posterior mandibular 
ridges of 8 different patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4: Membrane shapes, hand drawn over the alveolar ridges of anterior and posterior 
mandible.  
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8.2.3 Digitizing of membrane shapes 
The hand drawn membrane contours were digitized using AccuTab digitizer 
(GTCO Corporation, USA) (Figure 8.5).  A program was developed to convert the 
drawn membrane contours into mathematical XY contours. The XY contours were 
then exported to an Excel® spread sheet and subsequently graphs were drawn 
using the data obtained.  
 
Figure 8.5: AccuTab digitizer used for digitizing membrane profiles.  
 
8.2.4 Analysis of digitized shapes 
The curves obtained by digitizing the hand drawn membrane contours were then 
arbitrarily aligned by hand to align them as closely as possible. Having done this 
the curves were analysed to describe mathematically the lines of best of fit and 
95% range. This data was analysed by Pengwei Hao (Dept of computer science, 
QMUL) and Yanlin Geng (State Key Lab of Machine Perception, Beijing University, 
China) to define a suitable membrane shape.  
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8.3 RESULTS 
Various curves were obtained from digitizing the membranes shapes which were 
hand drawn over the alveolar ridges scans from mandible of different patients. 
Some of the obtained curves are shown in Figure 8.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6:  Curves obtained form digitized contours of membrane profiles hand drawn over 
the alveolar ridges.  
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The curves when superimposed were broadly divided into two main groups (A) 
and (B) depending on their shapes. Figure 8.7 (a) and (b) show Group A and B 
curves respectively and a curve which best fits most of the curves in each group 
was drawn and is shown by a red line. The parabolic best fit curves of two 
groups are represented by (a) y=-0.1204x2+1.8867x-0.7491 and (b) y=-
0.1542x2+2.0290x+0.9172. 
 
 
Figure 8.7 (a) and (b): Two groups of superimposed curves with respective best fit curves.   
(a) Group A 
(b) Group B 
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As a next step inner and outer boundaries curves for the best fit curves in both 
the groups were drawn as shown in Figure 8.8 (a) and (b). These outer and inner 
boundaries curve of both best fit curves enclosed 95% of the curves in that 
particular group. It can be seen from the equations that the shape of the curves 
has not been altered it is just the offset from the zero axis that has been 
changed. Thus for Group A the offset is -0.7491 with the values of -0.1220 and -
1.4339 for inner and outer boundaries, while for Group B the values for inner 
and outer boundaries are -0.1101 and + 1.9314 about the mean value of 0.9712. 
Thus if the curves  -0.1204 x2 +1.8867x and -0.1542x2 + 2.0920x are used to 
manufacture the mould profiles they should provide an acceptably good fit to 
the required shape for most patient. 
 
 
 
 
 
(a) Group A 
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Figure 8.8 (a) and (b):  Best fit curves drawn with inner and outer boundaries which include 
most of the digitised curves in the respective group.   
 
In a previous study which was conducted by a group member (Dr Amber Fareed, 
Queen Mary University of London), bone resorption profiles of alveolar ridges 
were analysed using ScanOra of six patients which were under assessment for 
dental implant placement. Figure 8.9 below shows (a) one of the ScanOra 
showing edentulous area of alveolar ridge used in the study (b) hand drawn 
alveolar bone profile on the ScanOra and (c) membrane shape hand drawn by an 
experienced periodontologist (Prof Francis Hughes) on the outline of the alveolar 
bone profile traced on a paper. Similarly membrane shapes were drawn on the 
alveolar bone outline of six different patients (Figure 8.10). 
 
(b) Group B 
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(a)                                     (b)                                    (c) 
Figure 8.9: (a) ScanOra of edentulous alveolar ridges, (b) alveolar bone profile tracing on the 
ScanOra and (c) outline of alveolar bone profile traced on acetate paper with hand-drawn 
membrane shape [from Dr Amber Fareed].  
 
 
 
 
 
 
 
Figure 8.10: Membrane shapes hand drawn on alveolar bone outline of six different patients 
[from Dr Amber Fareed]. 
 
The membrane shapes shown in Figure 8.10 were then digitized using the same 
protocol described in section 8.2.3.  
Figure 8.11 (a) shows the digitized shapes of the various hand drawn membrane 
shapes obtained from sketching on the ScanOra of six different patients in the 
previous study. These membrane shapes surprisingly closely fit within the inner 
and outer boundaries of Group B in our study as shown in figure 8.11 (b).   
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Figure 8.11: (a) Membrane shapes obtained by using ScanOra in a previous study, and (b) 
enclosed by thick black lines representing inner and outer boundaries of group B of the 
present study.     
 
8.4 DISCUSSION 
Periodontal regeneration is based on the concept of maintaining a space 
between soft tissue and alveolar bone by use of a GTR membrane which creates 
a protected environment and allows osteogenic cells to migrate to the area 
[Cortellini and Tonetti, 2000; Park et al., 2000a].  Different types of membranes 
are currently used with varying success. Some of the pre-requisites for successful 
periodontal bone regeneration are the ability of the GTR membranes to adapt to 
the bone defect, full coverage of the defected area and ability to maintain a 
space without collapsing under pressure by overlying flaps due to tissue tension, 
mastication or other physiological forces which are transmitted through the flap 
[Tatakis et al., 1999b; Lee et al., 2001a]. The importance of space maintenance 
by the GTR membrane in periodontal regeneration is well documented and had 
been reported in various studies. GTR membrane collapse or failure of 
maintaining space between the soft tissue and defect area by the membrane due 
(a) 
(b) 
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to inadequate or improper placement results in compromised periodontal 
regeneration [Polimeni, 2004].     
The objective of this study was to analyse profiles of mandibular alveolar ridges 
of different patients and define a shape for GTR membranes which can be used 
for the vast majority of periodontal defects. A suitable sized and shaped 
membrane will not only reduce the time needed to complete the clinical 
procedure but will also enable the clinician to place the membrane properly 
with reduced risk of failure. This can be achieved by defining a shape of the 
membrane which can fit most of the defects. 
CT imaging was used for the evaluation of alveolar ridges. It is one of the most 
commonly employed imaging tools in implant dentistry for alveolar bone 
assessment. Cross-sectional and 3-dimensional images can be obtained by using 
CT scans [Garg and Vicari, 1995]. CT scans not only provide information about 
the quantity of the bone available but it is also possible to asses its quality, 
including thickness of cortical bone and cancellous bone density. Three 
dimensional images of the jaw bone can be constructed and stereolithographic 
models can be fabricated using data obtained by CT scans [Floyd et al., 1999; 
BouSerhal et al., 2002].  
CT scans of 7 patients were selected and 39 cross sectional slices from different 
areas of mandibular alveolar ridges were obtained. These cross sectional slices 
of alveolar ridges were then used to draw a suitable shape GTR membrane. The 
digitized profiles of these membrane shapes were superimposed to define a 
membrane shape which can fit most of the profiles. Interestingly it was found 
that the obtained curves can be broadly divided into two groups. To define a 
shape for the membrane a curve was then drawn which best fit all the curves in 
both the group. Further inner and outer boundaries curves for the best fit curves 
were drawn and it was found that the boundary curves enclosed 95% of the 
curves in a particular group.  
In addition, when comparing the present study with an additional pilot study in 
our group, the total number of patients evaluated for defining the membrane 
shape was 13. It can be seen that most of the alveolar ridge patterns closely 
resemble each other.   
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Thus it can be considered that the alveolar ridge resorption patterns do not 
differ a lot from each other and that most alveolar ridge resorption defects 
could be treated with few pre-formed shapes of GTR membranes. As this study 
shows that the selected curve from each group after minimal chair side trimming 
should be able to fit most of the alveolar ridges in that group.  
Although the CT scans analysed in this study were obtained for potential implant 
cases rather than periodontology involved cases, as the radiographic 
examination for implant assessment typically requires tomographic or CT cross 
sections through the jaws, it was felt that this was an appropriate compromise. 
Firstly because these membranes may have application for GBR in implant 
therapy as well as for periodontal regeneration.  Secondly it is expected that 
buccal-lingual profiles obtained from these data are likely to be similar to those 
required for periodontal defects also. Further larger studies would be useful to 
confirm further the universality of this observation.  In addition the study has so 
far restricted itself to analysis of mandibular profiles only, and requires to be 
extended to maxillary profiles in future studies. 
8.5 CONCLUSIONS 
Although a wider study is required to validate fully the findings of this study, it 
can be suggested that relatively few number of pre-moulded membranes can be 
employed for the regeneration of maximum number of periodontal defects. 
 CHAPTER 9: GENERAL DISCUSSION, FUTURE WORK 
AND CONCLUSIONS 
9.1 GENERAL DISCUSSION 
Over the last two decades GTR has evolved as a technique to treat periodontal 
defects [Becker and Becker, 1993; Caffesse et al., 1997]. Various studies have 
shown its superiority over flap debridement procedures for its ability to promote 
periodontal regeneration [Needleman et al., 2002; Maurizio et al., 2004]. 
However, the fact remains that the overall outcomes for periodontal 
regeneration using GTR are relatively modest [Michael and Ulf, 2001] and when 
compared to results obtained with other regeneration techniques such as grafts, 
the differences were not substantial.  
Both resorbable and nonresorbable membranes are used for GTR procedures. 
However all the membranes used have limitations which affect the overall 
outcome of this technique. Resorbable membranes do not require removal with 
a second surgical procedure. However, most of them either lack adequate 
stiffness or collapse under pressure due to too early loss of strength, so the 
essential requirement of space maintenance is lost and the results are 
compromised [McAllister and Haghighat, 2007].  Non-resorbable membranes have 
comparatively better strength, but are generally difficult to adapt due to their 
stiffness and can also damage the soft tissues. To overcome the limitations of 
GTR membranes and to obtain better results, GTR membranes are typically used 
in combination with other regenerative techniques such as grafts. However, the 
use of graft materials may have disadvantages according to the type of graft 
used. For example autologus bone causes considerable donor site morbidity, and 
allograft or xenograft materials increase the risk of disease transfer [Sogal and 
Tofe, 1999].  
Thus there is a need to develop a membrane with better physical and biological 
properties. Ideally it should have good clinical manageability, have sufficient 
strength to resist pressures from the overlying flap and those exerted during 
mastication, should not only maintain a space and act as a barrier between the 
defect and soft tissue, but also facilitate the regeneration of bone by virtue of 
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having osteoconductive properties and finally resorb without side effects. 
Furthermore, there may be additional advantages for a material to have the 
ability to carry growth factors or be seeded by autogenous stem or progenitor 
cells.  
PLA-Ca P composites have been investigated as potential GTR membrane 
materials with improved physical and biological properties. The aim of the study 
presented here was to develop a membrane which would fulfil most if not all the 
requirements of an ideal membrane. 
One of the major problems associated with the currently available materials 
which results in their failure is that they are difficult to adapt to the defect and 
there is a possibility that they will not properly cover the defect or collapse into 
the defect space. To improve the clinical manageability and to improve the 
adaption, it would be ideal to have high strength prefabricated membranes 
which will require minimum chair side preparation and still cover the defect 
appropriately. In a pilot study the profiles of mandibular alveolar bone has been 
investigated among different patients to define shapes for GTR membranes. 
Interestingly, it was found that a low number of different membrane shapes can 
fit most of the mandibular alveolar bone profiles analyzed in this study. The 
limitations of this study were that firstly, only the mandibular ridges were 
analysed and secondly, the CT images studied were of the patients under 
treatment for dental implants rather than for periodontal diseases. Although 
further investigations are required to validate these findings, it is proposed that 
a few shapes of prefabricated GTR membranes will be suitable to be employed 
for most defects. This development would enable the use of stiffer membranes 
with high strength. Additionally these membranes will require minimum 
chairside preparation. Thus the membrane material investigated will have good 
clinical manageability if used as pre-fabricated membranes. 
Another limitation of currently used membranes is the inability to withstand 
occlusal pressures and their collapse into the defect area. This collapse is either 
due to lack of strength or too early loss of stiffness, before sufficient tissue 
regeneration has occurred. When collapsed, a membrane loses its barrier 
function of preventing migration of the faster growing epithelial and connective 
tissue cells to the bone defect and does not maintain a space for repopulation of 
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the defect area by osteogenic cells. A fibre reinforced PLA-HA composite has 
been investigated as a membrane material. Fibre reinforcement in addition to 
HA will increase the strength and stiffness and will enable the fabrication of 
membranes with better mechanical properties [Bleach et al., 2001]. From the 
study carried out to test the flexural strength of the membranes, it can be 
concluded that by changing the orientation of fibres in a multiple layer 
membrane the mechanical properties can be manipulated and further improved 
to optimise the membrane stiffness and strength. Additionally the use of high 
strength fibre reinforced composite materials for the fabrication of pre-shaped 
membranes will eliminate the drawbacks associated with the manageability and 
adaptation of the stiffer membrane materials. Although the optimal thickness of 
membranes and hence the number of layers within a membrane, has not been 
determined here, it is recognised that it is probably desirable to keep such a 
membrane as thin as possible and further studies on thinner membranes would 
be useful in future.  
Tissue regeneration may be enhanced and clinical outcomes can be improved if a 
barrier membrane also possesses bioactive and osteoconductive properties.  
Tests were carried out to analyse the bioactivity and osteoconductivity of the 
proposed composite membrane materials. The results showed that adding HA 
increased the bioactivity and osteoconductivity of the material. A membrane 
fabricated using this composite material may thus not only act as a barrier but 
might also have increased bioactivity and osteoconductivity to enhance its 
regenerative potential.  
In various studies growth factors have shown the potential to induce and 
enhance the regeneration of periodontal tissues [Cho et al., 1995; Nevins et al., 
2003]. Therefore, there is a considerable interest in the therapeutic application 
of growth factors for periodontal regeneration. An ideal GTR membrane might 
therefore be able to carry and release growth factors in a sustained manner. In a 
preliminary study, albumin and serum proteins were used to analyse the kinetics 
of protein interactions with fibre reinforced PLA-HA composite. The results 
showed that the ability of these composites to absorb and release the proteins in 
a sustained manner were dependent on the manufacturing parameters used for 
the membranes. These parameters can be manipulated to optimise the potential 
of these composite materials as growth factor carrier. Furthermore, the ability 
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of PLA-HA composite films to absorb and release PDGF and its effect on the 
proliferation of osteoblast cells was tested. The results showed that the PDGF 
added to the composite materials retained its activity and enhanced the 
proliferation of osteoblasts when seeded onto these composite materials. 
Growth factors lost or released into the wrong tissue may limit their clinical 
effectiveness. To address this issue it is proposed to achieve a unidirectional 
release of growth factors by coating the two sides of the membrane with thin 
films of different materials. The permeability of PLA and PLA-HA composite films 
was tested and from the results it was concluded that the PLA films were 
relatively impermeable and the permeability increased with increase in the 
quantity of HA in the films. So the surface of the membrane towards the soft 
tissue could be coated with an impermeable PLA film to prevent the release of 
growth factors on that side, while the bone side could be composite film, thus 
achieving a unidirectional release of growth factor to the appropriate target. As 
basic protein interaction kinetics with the fibre reinforced PLA-HA composite 
were investigated, further studies involving growth factors (PDGF and BMPs) are 
needed to validate the ability of these composite materials to carry and release 
growth factors.   
One of the issues related with early resorbable materials was their unpredictable 
degradation behaviour and the accumulation of their degradation products due 
to too rapid degradation [Bostman and Pihlajamaki, 2000]. The degradation 
pattern of PLA-Ca P composites was investigated. The results showed that the 
addition of Ca P to the polymer slowed the degradation rate of PLA. Addition of 
Ca P to the polymer may also neutralize the acidic aspect of PLA degradation 
[Niemelä, 2005]. Although this study analyzed the effect of Ca P on the 
degradation of PLA, it did not take into consideration the effect of fibre-matrix 
interfaces in the proposed multilayer fibre reinforced PLA-HA composite 
membrane on the degradation rate, therefore a study is needed to analyse the 
degradation rate of fibre reinforced membranes. The degradation rate of a fibre 
reinforced PLA-HA composite can be tailored to suite the application by altering 
the quantity of L and D isomers in the PLA and concentration of HA.     
From the investigations carried out in this project it can be proposed that a fibre 
reinforced PLA-HA composite material will be a suitable material to develop for 
use as a GTR membrane and may offer significant advantages over existing 
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materials for this application.  Although the materials investigated in this study 
have shown favourable properties to be used as a GTR membrane material, all 
the tests have been performed in vitro. To be sure about the properties of these 
materials and to ascertain how these materials will perform clinically, in vivo 
tests are required including full clinical evaluation.   
9.2 FUTURE WORK 
Although overall results of the studies described are very encouraging, there are 
a number of studies required to further develop these composite materials for 
possible clinical use. These include various aspects of in vitro testing.  However, 
ultimately the potential application can really only be tested adequately in 
human clinical trials. Some specific further studies which would be valuable are 
considered below: 
1) Work is required to improve the reliability of membrane manufacture; in 
particular to test the parameters which can be used to produce the 
membranes without any defect. Studies are required to optimise the 
processing of prepreg and the fabrication of fibre reinforced PLA-HA 
composite membranes. Use of different prepreg lay ups in the composite 
membrane and their effect on the mechanical properties of the membrane 
need to be investigated to optimise the stiffness and strength of the 
membranes. 
2) Long term degradation studies should be carried out. Additionally, tests 
should be done to analyze the effects of moulding temperature and 
pressure on the degradation of the membranes.  
3) The ability of these membranes to carry and release antibiotics and other 
growth factors such as BMPs needs to be investigated. Fabrication of 
multilayered membranes consisting of different surface layers be carried 
out to test the directional release of growth factors and proteins.    
4) Further analysis is required of bone profiles of maxillary and mandibular 
alveolar ridges in both edentulous patients and patients with periodontal 
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diseases to broaden and validate the findings of mandibular ridge 
resorption profiles done in the present study.  
5) Ultimately, the suitability of these membranes for GTR procedures needs to 
be evaluated in vivo.  This might involve animal studies, although as these 
materials have all been used extensively in alternative applications in 
humans, this might not be necessary or particularly informative. Human 
clinical studies are required firstly to demonstrate safety and basic efficacy 
of the membranes in the first instance.  In the longer term, membranes 
may have a variety of different applications requiring slightly different 
preparations, for example with supplemented growth factors, seeded stem 
cells and for antibiotic delivery. 
9.3 CONCLUSIONS 
1) PLA-Ca P composites containing three different types HAs and one TCP 
were produced. The production process of the films was optimised and the 
Ca P powders and PLA-Ca P films produced were characterised. Three 
different concentrations of the fillers were used for the manufacturing of 
PLA-Ca P films and their effect on the film’s character was evaluated. 
Increasing the concentration of the filler increased its amount on the 
surface, which affected the roughness of the films.  
2) The bioactivity of the PLA-Ca P composite films was dependent on the type 
and concentration of the HA and TCP used. The bioactivity of the 
composite films increased with increases in the HA or TCP concentration.  
3) The degradation of PLA decreased with the addition of Ca P. The highest 
weight gain was shown by films containing highest HA or TCP 
concentrations. In addition to PLA degradation, Ca P dissolution from the 
composite films also added to the overall weight loss. 
4) The proliferation of osteoblast and PDL cells was highest on films 
containing 10 wt % nHA, whereas the highest ALP activity was shown by 
cells on films containing 70 wt % nHA. The addition of PDGF to the films 
increased the proliferation of osteoblasts. 
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5) The fibre reinforced PLA-HA composite membranes produced at low 
temperature and pressure showed more sustained protein release than the 
membranes produced at higher temperature and pressure.  Non-filled PLA 
films did not show any permeability, whereas the permeability of the 
composite films increased with increase in the nHA content. 
6) Analysis of mandibular alveolar bone profiles showed that there was not 
much difference between them and only two specific shapes of membranes 
can fit most patients. 
7) The flexural strength of the fibre reinforced PLA-HA composite membranes 
was dependent on prepreg sheet lay up. The flexural strength was highest 
for the membranes containing the maximum number of prepreg at 0°, 
although transverse fibres are needed for lateral strength.  
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